Transcription Factors
The Practical Approach Series SERIES EDITOR B. D. HAMES Department of Biochemistry and Molecula...
91 downloads
2457 Views
16MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Transcription Factors
The Practical Approach Series SERIES EDITOR B. D. HAMES Department of Biochemistry and Molecular Biology University of Leeds, Leeds LS2 9JT, UK
See also the Practical Approach web site at http://www.oup.co.uk/PAS * indicates new and forthcoming titles
Affinity Chromatography Affinity Separations Anaerobic Microbiology Animal Cell Culture (2nd edition) Animal Virus Pathogenesis Antibodies I and II Antibody Engineering * Antisense Technology Applied Microbial Physiology Basic Cell Culture Behavioural Neuroscience Bioenergetics Biological Data Analysis Biomechanics - Materials Biomechanics - Structures and Systems Biosensors Carbohydrate Analysis (2nd edition) Cell-Cell Interactions The Cell Cycle Cell Growth and Apoptosis if Cell Separation
Cellular Calcium Cellular Interactions in Development Cellular Neurobiology * Chromatin if Chromosome Structural Analysis Clinical Immunology Complement * Crystallization of Nucleic Acids and Proteins (2nd edition) Cytokines (2nd edition) The Cytoskeleton Diagnostic Molecular Pathology I and II DNA and Protein Sequence Analysis DNA Cloning 1: Core Techniques (2nd edition) DNA Cloning 2: Expression Systems (2nd edition) DNA Cloning 3: Complex Genomes (2nd edition) DNA Cloning 4: Mammalian Systems (2nd edition)
* Drosophila (2nd edition) Electron Microscopy in Biology Electron Microscopy in Molecular Biology Electrophysiology Enzyme Assays Epithelial Cell Culture Essential Developmental Biology Essential Molecular Biology I and I * Eukaryotic DNA Replication Experimental Neuroanatomy Extracellular Matrix Flow Cytometry (2nd edition) Free Radicals Gas Chromatography Gel Electrophoresis of Nucleic Acids (2nd edition) if Gel Electrophoresis of Proteins (3rd edition) Gene Probes 1 and 2 Gene Targeting Gene Transcription if Genome Mapping Glycobiology if Growth Factors and Receptors Haemopoiesis * High Resolution Chromotography Histocompatibility Testing HIV Volumes land 2 * HPLC of Macromolecules (2nd edition) Human Cytogenetics I and II (2nd edition)
Human Genetic Disease Analysis * Immobilized Biomolecules in Analysis Immunochemistry 1 Immunochemistry 2 Immunocytochemistry if In Situ Hybridization (2nd edition) lodinated Density Gradient Media Ion Channels if Light Microscopy (2nd edition) Lipid Modification of Proteins Lipoprotein Analysis Liposomes Mammalian Cell Biotechnology Medical Parasitology Medical Virology MHC Volumes 1 and 2 if Molecular Genetic Analysis of Populations (2nd edition) Molecular Genetics of Yeast Molecular Imaging in Neuroscience Molecular Neurobiology Molecular Plant Pathology I and II Molecular Virology Monitoring Neuronal Activity Mutagenicity Testing * Mutation Detection Neural Cell Culture Neural Transplantation Neurochemistry (2nd edition) Neuronal Cell Lines
NMR of Biological Macromolecules Non-isotopic Methods in Molecular Biology Nucleic Acid Hybridisation Oligonucleotides and Analogues Oligonucleotide Synthesis PCR 1 PCR 2 *PCR3:PCR In Situ Hybridization Peptide Antigens Photosynthesis: Energy Trans duction Plant Cell Biology Plant Cell Culture (2nd edition) Plant Molecular Biology Plasmids (2nd edition) Platelets Postimplantation Mammalian Embryos if Post-Translational Modification Preparative Centrifugation
Protein Blotting if Protein Expression Protein Engineering Protein Function (2nd edition) Protein Phosphorylation Protein Purification Applications Protein Purification Methods Protein Sequencing Protein Structure (2nd edition) Protein Structure Prediction Protein Targeting Proteolytic Enzymes Pulsed Field Gel Electrophoresis RNA Processing I and II if RNA-Protein Interactions Signalling by Inositides Subcellular Fractionation Signal Transduction * Transcription Factors (2nd edition) Tumour Immunobiology
Transcription Factors A Practical Approach Second Edition Edited by
DAVID S. LATCHMAN Professor of Molecular Pathology, and Director, Windeyer Institute of Medical Sciences, University College London Medical School, London, UK
OXPORD UNIVERSITY PRESS
1999
OXFORD UNIVERSITY PRESS
Great Clarendon Street, Oxford OX2 6DP Oxford University Press is a department of the University of Oxford and furthers the University's aim of excellence in research, scholarship, and education by publishing worldwide in Oxford New York Athens Auckland Bangkok Bogota Buenos Aires Calcutta Cape Town Chennai Dar es Salaam Delhi Florence Hong Kong Istanbul Karachi Kuala Lumpur Madrid Melbourne Mexico City Mumbai Nairobi Paris Sao Paulo Singapore Taipei Tokyo Toronto Warsaw and associated companies in Berlin Ibadan Oxford is a registered trade mark of Oxford University Press Published in the United States by Oxford University Press Inc., New York © Oxford University Press 1999 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press. Within the UK, exceptions are allowed in respect of any fair dealing for the purpose of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, or in the case of reprographic reproduction in accordance with the terms of licenses issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms and in other countries should be sent to the Rights Department, Oxford University Press, at the address above. This book is sold subject to the condition that it shall not, by way of trade or otherwise, be lent, re-sold, hired out, or otherwise circulated without the publisher's prior consent in any form of binding or cover other than that in which it is published and without a similar condition including this condition being imposed on the subsequent purchaser Users of books in the Practical Approach Series are advised that prudent laboratory safety procedures should be followed at all times. Oxford University Press makes no representation, express or implied, in respect of the accuracy of the material set forth in books in this series and cannot accept any legal responsibility or liability for any errors or omissions that may be made. A catalogue record for this book is available from the British Library Library of Congress Cataloging in Publication Data (Data available) ISBN 0-19-963697-4 (Hbk) 0-19-963696-6 (Pbk) Typeset by Footnote Graphics, Warminster, Wilts Printed in Great Britain by Information Press, Ltd, Eynsham, Oxon.
Preface In the five years since the first edition of this work was published, the number of groups studying transcription factors has dramatically increased. Thus, those studying the regulation of individual genes are increasingly occupied with the study of the transcription factors which regulate such genes, whilst numerous sequences isolated as expressed sequence tags or as part of genome projects have been shown to encode transcription factors. Similarly, a wide range of new methodologies have been developed to facilitate the study of these factors whether isolated as part of studies on the regulation of an individual gene or as part of genome screening procedures. A new edition of this book is therefore necessary to allow it to continue to provide a full description of the methods required to fully characterize the function and activity of an individual transcription factor. The opportunity has been taken of updating the material in the original edition, all the original chapters having either been comprehensively updated by the original authors or completely rewritten by new authors. Most importantly, however, four new chapters have been added, both widening the scope of the original edition and adding specific methods that have become of particular importance since it was first published. As before, the book begins with an initial series of chapters aimed at characterizing the proteins binding to a specific DNA sequence. In particular, the initial chapter on the DNA mobility shift assay (Chapter 1) is now followed by a completely rewritten chapter by new authors dealing with a wide range of methods for characterizing the DNA-protein interaction in more detail (Chapter 2). As before, methods for characterizing the transcription factor protein in more detail are described in the next chapter (Chapter 3). Such a characterizing of the factor paves the way for the isolationg of cDNA clones encoding it, either by the use of oligonucleotides predicted from its protein sequence (Chapter 4) or by screening of a cDNA expression library with its DNA binding site (Chapter 5). However, an increasing number of factors are now identified on the basis of their homologies to other known factors as determined either by experimental screening procedures or by database searches (Chapter 6). In this situation, little or no information will be available about the targets for these transcription factors and for this reason an additional chapter has been added which describes the methods available for identifying the target genes of a previously uncharacterized factor (Chapter 7). Evidently, once a transcription factor has been cloned and its target genes characterized, a range of methods are available to analyse its function further. As in the previous edition, a specific chapter thus deals with many of the methods available for doing this (Chapter 8). This chapter is now supplemented, however, by additional chapters which deal with specific specialized
Preface aspects such as analysing transcription factor function by carrying out in vitro transcription assays using transcriptionally active nuclear extracts derived from rat brain (Chapter 9) and for similarly analysing the effects of these factors on chromatin structure (Chapter 10). In addition, since the activity of many transcription factors in these and other assays is affected by their posttranslational modification, a final chapter describes the methods for analysing the phosphorylation or glycosylation state of transcription factors (Chapter 11). It is hoped that the general updating of existing chapters and the provision of additional chapters will allow this work to build on the success of its predecessor and to continue to provide a comprehensive guide for those who wish to apply the appropriate methods for studying these critical factors. As before, I would like to thank all the contributors for the efforts they have made which have rendered their methods accessible for use by others and to thank the staff of Oxford University Press for deciding to commission this new edition and for their skills in producing it. London April 1998
D.S.L.
VIII
Preface to the First Edition As well as being the essential first step in the conversion of the genetic information in the DNA into protein, the process of transcription is also the major point at which gene expression is regulated. Thus, whilst some cases of post-transcriptional control do exist, in most cases gene regulation is achieved by activating (or repressing) the transcription of particular genes in specific cell types or in response to a specific signal. Once this has occurred, all the other stages of gene expression (RNA processing, translation etc.) follow and the appropriate protein is produced in a cell-type specific or inducible manner. Both the basal process of transcription itself and its regulation are controlled by specific short DNA sequences in the gene promoters or enhancers. These sequences act by binding specific proteins known as transcription factors, which then influence the rate of transcription of the gene. The study of these transcription factors is, therefore, a critical aspect of gene regulation. In general, however, the characterization of these factors involves a distinct set of methods for studying the proteins themselves and their interaction with DNA, which may not be available even in a laboratory skilled in the standard molecular biology techniques for studying DNA and RNA. The aim of this book is to provide such a set of methods which will allow the user who has identified specific regulatory regions in the gene of interest to completely characterize the protein(s) which bind to them. Initially, this study will involve identifying the proteins binding to a specific DNA sequence within the regulatory region by the DNA mobility shift assay (Chapter 1) as well as characterizing the DNA-protein interaction in more detail using DNasel footprinting and methylation interference techniques (Chapter 2). Subsequently, the biochemical characteristics of the protein can be studied, allowing determination of its size and its ability to form complexes as well as to stimulate transcription in vitro (Chapter 3). Although many such studies emphasize the ability of the factor to stimulate transcription, it should not be forgotten that DNA-binding transcription factors are members of a larger class of proteins which have the ability to bind to DNA. Many of the methods developed for these proteins are, therefore, applicable to transcription factors also (Appendix 1). This characterization of the factor paves the way for its eventual purification, which in turn allows the partial protein sequence to be determined, thereby allowing the isolation of cDNA clones for the factor by screening cDNA libraries with appropriate oligonucleotides (Chapter 4). Other methods of isolating cDNA clones for the factor which may be more convenient in some situations also exist, for example direct screening of cDNA expression libraries with the DNA-binding site for the factor or antibodies to it (Chapter 5) or cloning by homology to other known factors (Chapter 6).
Preface to the First Edition Once the cDNA clones have been isolated, all the standard techniques of molcular biology can be applied to studying the gene structure, expression pattern, and DNA sequence of the transcription factor. It will also be important, however, to characterize the regions of the protein which are responsible for its various properties such as DNA binding or transcriptional activation, and this can readily be achieved using the cDNA clones (Chapter 7). Ultimately, therefore, an appropriate combination of the methods described here will allow the experimenter to move forward from the characterization of a DNA sequence involved in the basal or regulated transcription of a specific gene and to obtain a detailed understanding of the protein(s) binding to this sequence and the manner in which it controls transcription. Finally, I would like to thank all the contributors for the efforts they have made to render their methods accessible to others, as well as the staff of Oxford University Press for their continuous assistance. London May 1992
D.S.L.
Contents List of contributors Abbreviations 1. The DNA mobility shift assay
xix xxi 1
C. L. Dent, M. D. Smith, and D. S. Latchman 1. Introduction
1
2. Detection of DNA binding proteins Applications of the DNA mobility shift assay Selection of DNA probe Preparation of labelled oligonucleotide probes for retardation assay Labelling of fragment probes Preparation of protein extracts The binding reaction Preparation of mini-extracts
2 2 6 7 8 9 10 13
3. Other sources of protein for use in the binding assay Expression of DNA binding proteins in bacteria Expression of proteins in mammalian cells Expression by in vitro transcription and translation Expression of cloned transcription factor in baculovirus Purification of transcription factor protein
14 14 15 16 17 17
4. Investigation of DNA binding specificity
17
5. Characterization of DNA binding proteins Addition of antibodies Addition of potential ligands Proteolytic clipping band-shift assay
19 19 21 21
6. Study of protein-protein interactions
23
7. Concluding comments
25
References
25
2. Footprint analysis of DNA-protein complexes in vitro and in vivo
21
Craig Spiro and Cynthia T. McMurray 1. Overview
27
2. In vitro footprinting
29
Contents Analysis at base resolution of binding sites on 32P-end-labelled fragments Analysis of binding on closed, circular plasmid
29 41
3. In vivo footprinting Modification of DNA in vivo Nested gene-specific primers Linker for LMPCR Visualization to nucleotide resolution by LMPCR
47 48 55 55 56
References
61
3. In vitro transcription and characterization of transcription
63
Austin J. Cooney, Sophia Y. Tsai, and Ming-Jer Tsai 1. Introduction
63
2. In vitro transcription assays
63
3. Determination of the molecular weight of native transcription factors Molecular weight determination using gel filtration chromatography Molecular weight determination using glycerol gradient centrifugation Determination of molecular weight of native factors using nondenaturing gradient gel electrophoresis 4. Determination of the molecular weight of denatured transcription factors UV cross-linking of transcription factors to DNA UV cross-linking with a bromodeoxyuridine-substituted DNA UV cross-linking of transcription factors to non-substituted probes Renaturation of transcription factors from SDS-polyacrylamide gels 5. Analysis of the monomer/dimer structure of the DNA binding forms of a transcription factor Analysis of transcription factors by DNA mobility shift assay Analysis of transcription factor subunits by chemical cross-linking Analysis of cooperative binding between dimers bound to adjacent response elements
69 69 73 75 76 77 77 80 82 84 84 85 86
6. Identification and initial characterization of non-DNA binding transcription factors Assay of direct interactions between DNA binding and non-DNA binding transcription factors 'Supershift' gel mobility shift analysis Analysis of the dissociation of transcription factor-DNA complexes in the presence and absence of the non-DNA binding transcription factor Analysis of direct interactions by co-immunoprecipitation References
88 90 90 91 92 95
XII
Contents
4. Purification and cloning of DNA binding transcription factors
97
R. H. Nicolas, G. Hynes, and G. H. Goodwin 1. Introduction
97
2. Buffers and solutions
99
3. Preparation of nuclear extract
99
4. DNA-cellulose chromatography
103
5. DNA affinity chromatography
104
6. Reverse-phase chromatography
111
7. Production and isolation of peptides
114
8. Design of oligonucleotides for cDNA isolation
118
Acknowledgements
121
References
121
5. Cloning transcription factors from a cDNA expression library
123
Ian G. Cowell and Helen C. Hurst 1. Introduction
123
2. Handling bacteriophage expression libraries Library selection Library plating for screening Plaque purification
124 124 125 126
3. Screening methods Introduction Screening with DNA binding-site probes Immunological screening Other approaches to library screening and their relative merits
126 126 127 134 137
4. Proving the identity of the factor
139
References
142
6. Cloning transcription factors by sequence similarity
145
Alan Ashworth 1. Introduction
145
xiii
Contents 2. Methods for cloning related transcription factors Low-stringency hybridization Polymerase chain reaction approaches In silica approaches to identifying novel transcription factors
145 145 148 160
3. Some examples of the cloning of transcription factors by homology
163
Acknowledgements
163
References
163
7. Identification of target genes for a transcription factor by genomic bindingsite cloning
ies
Satoshi Inoue, Shigeru Kondo, and Masami Muramatsu
1. Introduction
165
2. Method for genomic binding-site (GBS) cloning Preparation of a transcription factor protein Source of DNA Selection procedure GBS cloning procedure GBS cloning from CpG islands
165 167 169 170 172 173
3. Molecular cloning of target genes using the DNA fragments obtained by GBS cloning Zoo blotting Northern blot analysis Sequencing and DNA database searches Binding activity of the genomic fragment Enhancer activity of the genomic fragment Molecular cloning of target genes using the DNA fragment obtained by cloning
174 174 175 175 176 176 177
4. Concluding remarks
177
References
178
8. Analysis of cloned factors
181
Roger White and Malcolm Parker 1. Introduction Identification of conserved domains
181 182
2. Mapping and analysis of domains by deletion and point mutagenesis Preparation of deletion mutants using PCR Point mutagenesis
182 182 185
xiv
Contents 3. Expression systems The use of in vitro translation systems and overexpression systems to analyse transcription factor function Expression in bacteria Expression in mammalian cells Overexpression in mammalian cells Overexpression in yeast and insect cells Comparison of expression systems
187
4. Analysis of the properties of cloned factors Transient transfection in mammalian cells Reporter genes and control plasmids Methods of transfection Assays for reporter genes in transfected cells Identification of transactivation domains using chimeric proteins
196 196 196 198 200 202
5. Analysis of protein-DNA interactions Analysis of DNA binding activity using a gel retardation assay
202 202
6. Analysis of protein-protein interactions in vitro
206
Analysis of interactions between proteins using a GST pull-down assay Analysis of protein-protein interactions using immunoprecipitation Analysis of protein-protein interactions using the gel retardation assay Analysis of protein-protein interactions on DNA using an ABCD assay Analysis of protein-protein interactions in cells using two-hybrid analysis
187 189 192 193 194 195
206 208 209 209 211
4. Summary
212
References
213
9. Neuronal promoter analysis by in vitro transcription using nuclear extracts from rat brain
215
M. L. Schwartz and W. W. Schlaepfer 1. Introduction
215
2. Background
216
3. Applications Comparison to transfection and transgenic mouse studies Studies of the effect of chromatin structure on transcription
216 216 217
4. Preparation of nuclear extracts Overview
217 217
xv
Contents Purification of nuclei from rat brain Extraction of nuclear proteins 5. In vitro transcription Overview of the reaction Typical results of in vitro transcription Notes on in vitro transcription Promoter templates 6. Concluding remarks References
10. Preparation of chromatin templates for transcription studies Joan Boyes 1. Introduction 2. Experimental approaches using chromatin templates Introduction to chromatin structure Initiation and elongation of transcription on chromatin templates Mononucleosome templates versus nucleosome arrays 3. Preparation of chromatin templates Technical considerations Xenopus nuclear extracts Drosphila embryo nuclear extracts Minichromosome preparation Mononucleosome preparation 4. Preparation of histones Principle of hydroxyapatite purification 5. Reconstitution of mononucleosomes by salt-urea dialysis Considerations for the DNA fragment for reconstitution Amount of DNA needed in the reconstitution reaction Calculation of the amount of histones in the reconstitution reaction Purification of mononucleosome reconstitutes Characterization of the reconstitutes 6. Transcription factor binding to nucleosome templates Acknowledgements References
11. Analysis of transcription factor modifications
217 220 222 222 224 224 226 227 227
229 229 229 229 230 230 232 232 233 233 234 234 236 236 243 243 246 248 249 252 255 257 258
261
N. Shaun B. Thomas 1. Introduction
261
xvi
Contents 2. Phosphorylation Gel electrophoresis Dephosphorylation in vitro Radioactive labelling Mapping phosphorylation sites Phosphorylation in vitro Generation and use of phosphorylation-site-specific antibodies Functional analysis Other methods for analysing phosphorylated proteins
261 263 266 270 274 281 283 283 284
3. Other post-translational modifications O-Linked glycosylation
285 285
Other modifications
290
4. Conclusions
290
Acknowledgements
291
References
291
Appendix 1 List of suppliers
295
Index
297
XVll
This page intentionally left blank
Contributors ALAN ASHWORTH
Chester Beatty Laboratories, The Institute of Cancer Research, Fulham Road, London SW3 6JB UK. JOAN BOYES
Chester Beatty Laboratories, The Institute of Cancer Research, Fulham Road, London SW3 6JB UK. AUSTIN J. COONEY
Department of Cell Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030 USA. IAN G. COWELL
Department of Biochemistry and Genetics, The Medical School, Newcastle University, Newcastle Upon Tyne, NE2 4HH UK. C. L. DENT Glaxo Wellcome Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SGI 2NY UK. G. H. GOODWIN
Haddow Laboratories, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NJ UK. HELEN C. HURST
ICRF Molecular Oncology Unit, Hammersmith Hospital, Du Cane Road, London W12 ONN UK. G. HYNES
Chester Beatty Laboratories, Institute of Cancer Research, Fulham Road, London, SW3 6JB UK. SATOSHIINOUE
Department of Biochemistry, Saitama Medical School, 38 Morohongo, Moroyama Iruma-Gun, Saitama 350-04, JAPAN. SHIGERU KONDO
Department of Biochemistry, Saitama Medical School, 38 Morohongo, Moroyama Iruma-Gun, Saitama 350-04, JAPAN. D. S. LATCHMAN
The Windeyer Institute for Medical Sciences, University College London Medical School, The Windeyer Building, 46 Cleveland Street, London W1P 6DB, UK.
Contributors CYNTHIA T. McMURRAY
Department of Pharmacology, Mayo Foundation, 200 1st Street, SW Rochester, MN 55905 USA. MASAMIMURAMATSU
Department of Biochemistry, Saitama Medical School, 38 Morohongo, Moroyama Iruma-Gun, Saitama 350-04, JAPAN. R. H. NICOLAS
Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn Fields, London WC2A3PXUK. MALCOLM G. PARKER
Molecular Endocrinology Laboratory, Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn Fields, London WC2A 3PX UK. W. W. SCHLAEPFER
Division of Neuropathology, 435 Johnson Pavillion, University of Pennsylvania Medical School, Philadelphia, PA 19104-6079 USA. M. L. SCHWARTZ
Division of Neuropathology, 435 Johnson Pavillion, University of Pennsylvania Medical School, Philadelphia, PA 19104-6079 USA. M. D. SMITH
The Windeyer Institute for Medical Sciences, University College London Medical School, The Windeyer Building, 46 Cleveland Street, London W1P 6DB, UK. CRAIG SPIRO
Department of Pharmacology, Mayo Foundation, 200 1st Street, SW Rochester, MN 55905 USA. N. SHAUN B. THOMAS
Department of Haematology, University College London Medical School, 98 Chenies Mews, London WC1E 6HX UK. MING-JER TSAI
Department of Cell Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030 USA. SOPHIA Y. TSAI
Department of Cell Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030 USA. ROGER WHITE
Molecular Endocrinology Laboratory, Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn Fields, London WC2A 3PX UK xx
Abbreviations A x a b s o r b a n c e a t wavelength x BLAST basic local alignment search tool BPV bovine papilloma virus BSA bovine serum albumin bZIP basic zipper CAT chloramphenicol acetyl transferase cdk cyclin-dependent kinase CIP calf intestinal phosphatase CNBr cyanogen bromide CoA coenzyme A COX7RP cytochrome oxydase subunit VH-related protein CRE cAMP-responsive enhancer DATP diallyl tartardiamide DCC dextran-coated charcoal dd dideoxy dATP 2'deoxyadenosine 5'triphosphate dCTP 2'deoxycytidine 5'triphosphate dNTP deoxynucleoside triphosphate dGTP 2'deoxyguanosine 5'triphosphate dTTP 2'deoxythymidine 5'triphosphate DBS diethylstilboestrol DMEM Dulbecco's modified Eagle's medium DMP dimethylpimelidate DMS dimethyl sulfate DNAse deoxyribonuclease DSP dithiobis (syccinimyl propionate) DTT dithiothreitol EBAG9 oestrogen receptor-binding fragment-associated gene 9 EDTA ethylenediamine tetraacetic acid EFP oestrogen-responsive finger protein EGTA ethylene glycol-bis (p-aminoethyl ether) N,N,N',N' tetraacetic acid EMSA electromobility shift assay ENU ethylnitrosourea ER oestrogen receptor ER-DBD DNA binding domain of oestrogen receptor ERE oestrogen-responsive element ESMS electrospray mass spectrometry FACT facilitates chromatin transcription GBS cloning genomic binding-site cloning
Abbreviations GST HMG HSV IPTG LB broth LDAO MALD-MS MBD NGF NP40 NURF OD PAGE PBS PCR PCV p.f.u. PMSF PR pRb PRE PVDF RSC SDS SRF SSC SV40 TCA TE TEMED TF TFA tk Tris vitERE
glutathione-5-transferase high mobility group herpes simplex virus isopropyl 3-D-thiogalactopyranoside Luria-Bertani broth lauryl dimethylamine oxide matrix-assisted laser desorption mass spectrometry methyl-CpG binding domain nerve growth factor Nonidet P-40 (octylphenoxypolyethoxyethanol) nwcleosome remodelling/actor optical density polyacrylamide gel electrophoresis phosphate-buffered saline polymerase chain reaction packed cell volumes plaque forming units phenyl methyl sulfonyl fluoride progesterone receptor retinoblastoma protein progesterone-response element polyvinylidene fluoride remodel the structure of chromatin sodium dodecyle sulfate serum response factor saline-sodium citrate Simian virus 40 trichloroacetic acid Tris-EDTA (buffer) N,N,N' ,N' ,-tetramethylethylenediamine transcription factor trifluoroacetic acid thymidine kinase Tris (hydroxymethyl)-aminomethane vitellogenin ERE
xxii
1 The DNA mobility shift assay C. L. DENT, M. D. SMITH, and D. S. LATCHMAN
1. Introduction A knowledge of the DNA binding protein content of a cell or tissue type can be an important aid towards a more thorough understanding of the functional role of that tissue. Important processes, such as the development of an adult organism from the single-celled zygote and the maintenance of the developed structure and biochemical characteristics of tissues, are increasingly being demonstrated to be dependent on DNA binding transcription factors. The spectrum of transcription factors present determines what genes may be transcribed in a cell type, including genes that encode further transcription factors. The expression of a single gene may be determined by a number of different transcription factors, and the ratio of their concentrations may be vital, particularly if competing positive and negative factors are involved. Factors other than those that bind the DNA may be involved, such as protein cofactors, metal ions, and ligand molecules, and a further important factor is the chromatin structure of the DNA. The gene must be available for binding of factors and subsequent transcription. The DNA mobility shift assay attempts to determine the potential for a gene to be transcribed in a particular cell type by providing an assay for the presence of DNA binding proteins capable of binding to a promoter, providing a very effective point of first entry into a more detailed understanding. This chapter will detail the techniques and considerations involved in analysing DNA-protein interactions using the DNA mobility shift assay, and the example of the herpes simplex virus 1 (HSV-1) immediate-early gene promoter TAATGARAT sequence that has been studied in our laboratory (1). Protein extracts from cell types that are permissive and non-permissive to lytic infection by HSV-1 were assayed for proteins binding to the TAATGARAT sequence (the TAATGARAT sequence is a promoter element that has been demonstrated to be important in immediate-early gene transcription via the binding of a complex of a cellular transcription factor protein, Oct-1, and a viral component, Vmw65—see refs 2 and 3). Both permissive and non-permissive cell types contain this cellular factor, but non-permissive
C. L. Dent et al. cell types were found also to contain a second factor believed to be a neuronal form of the B-cell-specific protein Oct-2, which is closely related, in DNA binding specificity and structurally, to Oct-1. However, Oct-2 cannot interact with the viral component Vmw65 (4) and cannot act as a transcriptional activator from the viral TAATGARAT sequence. It is, however, able to bind TAATGARAT, thus preventing the access of Oct-l/Vmw65 complexes, and subsequent transcription of the immediate-early genes of HSV-1. Figure 2 shows a DNA mobility shift assay demonstrating the presence of DNA binding proteins in permissive (BHK) and non-permissive (neuronally derived ND7) cells showing the presence of large amounts of the second protein (lower band) in the non-permissive cell line. Further experiments have supported the fact that this protein is a neuronal form of Oct-2 and does indeed have a repressive capacity (5), thus demonstrating how a single band from a mobility shift may eventually explain an important cellular phenomenon.
2. Detection of DNA binding proteins 2.1 Applications of the DNA mobility shift assay Sequence-specific DNA binding proteins are involved in the regulation of transcription and DNA replication. The DNA mobility shift assay provides a powerful tool for the detection of factors binding to specific sequences. The method relies on the ability of a protein to bind to a radiolabelled DNA fragment (probe) in vitro, followed by electrophoretic separation of DNAprotein complexes from the unbound DNA on non-denaturing polyacrylamide gels (6,7). One or more proteins binding to the DNA fragment may be identified. In general, the larger the DNA-protein complex that is formed, the greater the extent of retardation of mobility within the gel. The principle of the DNA mobility shift assay is illustrated in Figure 1. Figure 2 illustrates a typical example of such an assay. The unbound probe containing the octamer motif is represented by the very heavy unresolved band at the bottom of the photograph in all four tracks. Two of the tracks show the complexes formed by two DNA binding proteins of different mobilities binding to the same DNA sequence in extracts prepared from different cell types. The second track shows only one slowly migrating DNA-protein complex, whereas the fourth track shows two. The protein present in both tracks is Oct-1 and has a molecular weight of 100 kDa. The protein present only in the fourth track is Oct-2 and has previously been demonstrated to be smaller than Oct-1 (molecular weight 60 kDa). The complex formed by the smaller protein migrates further within the gel, as would be expected. An accurate determination of the molecular weight of a DNA binding protein is not possible on this type of gel. The protein must be somehow purified (for example by cutting out from a gel after UV cross-linking to the labelled DNA probe) and then 2
1: The DNA mobility shift assay
Figure 1. DNA mobility shift assay- Binding of a cellular protein (B) to the radioactively labelled DNA causes it to move more slowly upon gel electrophoresis and hence results in the appearance of a retarded band upon autoradiography to detect the radioactive label.
run on a denaturing sodium dodecyl sulfate (SDS)-polyacrylamide gel (see Chapter 3). The DNA sequence specificity of the protein within the complex can be tested by competing for binding with non-radiolabelled DNA fragments. If a molar excess of a DNA fragment capable of binding the same protein is introduced into the binding reaction, much of the protein will bind to the unlabelled DNA, leaving less protein available for binding to the probe. This will lead to a reduction in, or elimination of, the band corresponding to the complex formed by that protein (Figure 3). In Figure 2, the first track represents 3
C. L. Dent et al.
Figure 2. DNA mobility shift assay using nuclear extracts prepared from BHK cells (a) or ND cells (b) and a labelled octamer oligonucleotide. The tracks show the results in the absence (-) or presence (i ) of a 100-fold excess of unlabelled octamer oligonueleotide competitor. For further details see ref, 1.
the same binding reaction as the second track, but in the presence of a 100foJd excess of unlabelled oligonucleotide. The band formed by the interaction between the probe and Oct-1 is competed away. Similarly, the third track represents the same reaction as the fourth track in the presence of excess unlabelled oligonucleotide. The band formed by the interaction between the probe and Oct-1 is competed away. Both specific and non-specific DNA sequences should be used because the failure of a non-specific sequence to compete provides proof that the complex is indeed DNA-scquence specific. Identification of proteins within the complex may be made by including antibodies against known proteins in the binding reaction. These antibodies may bind to the complex, causing further electrophoretic retardation and 'supershifting' of the complex, or completely inhibit complex formation by binding to a vital site within the binding protein. These types of experiment will be discussed fully later in this chapter (Section 5.1). Applications of the DNA mobility shift assay include the identification of both known and novel factors binding to a candidate DNA fragment, usually the DNA sequences 5' to a transcription unit. It may also be used to identify fluctuations in the levels of known transcription factors in response to stimuli. 4
1: The DNA mobility shift assay
Figure 3. Use of unlabelled competitor DMAs in the DNA mobility shift assay. If the unlabelled competitor is capable of binding the same protein as the labelled probe, it will do so (B) and the retarded band will not be observed.
e.g. growth factors. In our laboratory, we have used the assay both for the study of known factors and identification of new factors. In one series of experiments (8), we have taken a sequence, identified within the human papillomavirus 16 enhancer as being related to the octamer motif, and used this 5
C. L. Dent et al.
Figure 4, DNA mobility shift assay using an overlapping octamer/TAATGARAT oligonucleotide (ATGCTAATGAGAT) from the HSV-1 IE1 gene promoter and extracts from 3T3 cells (track 1J, BHK-21 cells (track 2), Jurkat T cells (track 3), S115 mammary epithelial cells (track 4), 310 primary cervical cells with no evidence of papillomavirus infection (track 5), 310 A cells (310 cells transformed with HPV-16 DNA, track 6), and SiHa cervical carcinoma cells (track 7). The arrow indicates the cervical-specific band. For further details see ref. 8.
sequence to identify a protein, contained in cervical cell extracts, that binds to this sequence. Figure 4 shows a band-shift assay carried out using the papillomavirus octamer sequence, showing binding to Oct-1 in all seven cell lines studied, and to a second protein with a higher mobility only in those extracts made from cervical cell lines. It is important to realize, however, that the DNA mobility shift assay does have limitations. In particular, this assay does not reveal which nucleotides within the sequence are recognized by, and interact with, the protein. As with many techniques, it is at its most valuable when used in conjunction with the other binding and functional assays discussed in the accompanying chapters of this book.
2,2 Selection of DNA probe A restriction fragment or synthetic oligonucleotide probe may be used, but the size of the fragment is normally kept below about 250 base pairs (bp) to 6
1: The DNA mobility shift assay enable clear distinction of the probe from any complexes. The type and size of probe used depends on the nature of the investigation. If a previously identified factor is to be studied, then an oligonucleotide probe should be used. An oligonucleotide probe simplifies the interpretation of results as a site is isolated from other unidentified possible sites present within adjacent regulatory sequences. However, interactions of a protein on an isolated site may not mirror the situation in vivo as competition and cooperation between proteins binding to adjacent sites may be observed. This is exemplified in the U2 small nuclear RNA enhancer where Oct-1 and Sp-1 bind cooperatively to adjacent binding sites (9). In this case, oligonucleotides covering both sites were constructed, and their binding of the two proteins compared with oligonucleotides in which one or the other site was rendered non-functional by mutation. Protocols 1-3 below give methods for labelling both oligonucleotide and fragment probes.
2.3 Preparation of labelled oligonucleotide probes for retardation assay Synthetic binding sites are made as two complementary single-stranded oligonucleotides that are subsequently annealed to generate a double-stranded oligonucleotide. Annealing is achieved by mixing equimolar amounts of the two oligonucleotides, heating to 80°C for 5 min, and allowing the oligonucleotides to cool slowly down to room temperature. If so desired, the oligonucleotides may be designed to possess the overhanging ends of a restriction enzyme site when annealed. This permits them to be cloned into promoter constructs, facilitating the assay of their activity in cells. The most common method for the labelling of oligonucleotides is to add a 32 P-labelled phosphate to the 5' end using T4 DNA kinase (see Protocol 1): the enzyme catalysing the transfer of the gamma-phosphate of ATP to the 5' hydroxyl group of the terminal nucleotide. Fragment probes may also be labelled using this method but the terminal phosphate must be removed from the DNA by phosphatase treatment before the addition of labelled phosphate (Protocol 2). It is usually simpler to label fragment probes by filling in the recessed ends created by restriction enzymes. The methods for labelling restriction enzyme fragments are described in Section 2.4. All the methods for labelling DNA are described by Sambrook et al (10). Protocol 1. End labelling DNA with T4 kinase Equipment and reagents •
32
STE: 10 mM Tris-HCI pH 8.0, 100 mM NaCI, 1 mM EDTA Sephadex G-25 column Water bath at 37°C
P-labelled ATP, at 110 TBq/mmol (370 MBq/ml . 50 mM Tris-HCI pH 7.6, 10 mM MgCI2, 5 mM dithiothreitol (DTT), 0.1 mM EDTA . T4 DNA kinase
7
C. L. Dent et al. Protocol 1.
Continued
Method 1. Mix 2 pmol of annealed oligonucleotide with 20 uCi (0.74 MBq) [32P]ATP in the presence of 50 mM Tris-HCI pH 7.6, 10 mM MgCI2, 5 mM DTT, 0.1 mM EDTA, and 0.5 ul (5 units) of T4 DNA kinase. 2. Incubate at 37°C for 30 min. 3. Add 200 ul of STE to the reaction and separate the labelled oligonucleotide from unincorporated label by centrifugation at 2000 x g for 2 min at room temperature through a 1 ml Sephadex G-25 column. The probe passes through in approximately 200 ul, of which 1 ul (10fmol of DNA) is used per binding reaction.
Protocol 2.
Dephosphorylation of DNA
Equipment and reagents • Calf intestinal phosphatase (CIP) . 10 x CIP buffer: 0.5 M Tris-HCI pH 9.0, 10 mM MgCI2,1 mM ZnCI2, 10 mM spermidine . STE: 100 mM Tris-HCI pH 8.0, 1 M NaCI, 10 mM EDTA
PhenolArichloromethane (phenol:trichloromethane:/so-pentanol, 25:24:1) 10 mM Tris-HCI pH 8.0 Water bath at 37°C
Method 1. Dissolve DNA in a minimum volume of 10 mM Tris-HCI pH 8.0. 2. Add 5 ul 10 x CIP buffer and 0.01 units of CIP per picomole of DNA ends, and make up to 50 ul with distilled water. 3. Incubate at 37°C for 30 min. 4. Add 50 ul H2O,10 ul STE, and 5 ul 10% SDS. 5. Heat to 68°C for 15 min. 6. Extract the DNA with an equal volume of phenol/trichloromethane. 7. Take the upper aqueous layer and repeat step 6. 8. Transfer the upper aqueous layer to a fresh tube and extract with an equal volume of trichloromethane. 9. Take the aqueous layer and precipitate the DNA with 2 volumes of ethanol overnight at -20°C.
2.4 Labelling of fragment probes There are three classes of fragment probes, depending on the nature of DNA ends generated by the enzymes used for their isolation. The enzymology of labelling these fragments varies, depending on the type of ends generated. (a) Fragments with 5' overhanging ends, generated by enzymes such as BamHI and EcoRI. These fragments are the most straightforward to 8
1: The DNA mobility shift assay label using the Klenow fragment of DNA polymerase I; therefore, usually enzymes that generate these ends are chosen preferentially when deciding upon a strategy for the isolation of DNA fragments for labelling. (b) Fragments with 3' overhanging ends, generated by enzymes such as KpnI and SstI. These are labelled using T4 DNA polymerase which possesses a 3'-5' polymerase activity as well as a potent 5'-3' exonuclease activity (which must be kept inactive to prevent unwanted degradation of the DNA fragment). (c) Blunt-ended fragments, generated by enzymes such as Smal and Rsal. These are also labelled by T4 DNA polymerase after limited digestion by the exonuclease activity of the enzyme. Protocol 3. Filling in 5' overhangs using the Klenowfragment of E. coli DMA polymerase I Equipment and reagents 32
P-labelled dCTP (20 vC\, 0.74 MBq); 1 mM unlabelled dATP, dTTP, and dGTP 50 mM Tris-HCI pH 7.5, 10 mM MgSO4, 0.1 mM DTT
Klenow enzyme STE (Protocol 1) Sephadex G-50 column Water bath at 37°C
Method 1. Mix DNA, [32P]dCTP, unlabelled dATP, dTTP, and dGTP, 50 mM Tris-HCI pH 7.5, 10 mM MgS04, 0.1 mM DTT, and 1 ul (1 unit) Klenow enzyme. 2. Incubate at 37°C for 30 min. 3. Make volume up to 200 ul with STE and centrifuge through a Sephadex G-50 column (as described in Protocol 1).
Protocol 4. Filling in 3' overhangs using T4 DNA polymerase Equipment and reagents 32
P-labelled dCTP (20 uCi, 0.74 MBq); 1 mM unlabelled dATP, TTP, dGTP Acetate buffers: Tris acetate 33 mM pH 7.9, 66 mM K acetate, 10 mM Mg acetate Bovine serum albumin (BSA, 0.1 mg/ml)
STE (Protocol 1) T4 DNA polymerase Sephadex G-50 column Water bath at 37 °C
Method 1. Mix DNA, [32P]dCTP, unlabelled dATP, TTP, dGTP, acetate buffers, 0.5 mM DTT, 0.1 mg/ml BSA, and 1 ul (2.5 units) T4 DNA polymerase. 2. Incubate at 37°C for 30 min. 3. Make volume up to 200 ul with STE and centrifuge through a 1 ml Sephadex G-50 column (as described in Protocol 1).
9
C. L. Dent et al. Blunt-ended fragments are labelled by a modification of Protocol 4. The DNA is incubated with T4 DNA polymerase in the absence of dNTPs for about 1 min, allowing the exonuclease activity of the polymerase enzyme to cut back. If a single dNTP is included during this incubation, the exonuclease will only cut back until it reaches that base in the fragment, thus controlling the digestion. The label and remaining dNTPs are then added, and the digested DNA is resynthesized, incorporating the labelled dNTP.
2.5 Preparation of protein extracts Protein extracts may be prepared from whole cells or isolated nuclei. There are advantages to using both types of extract, or even a combination, and comparing results obtained with both types. The preparation of nuclear extracts results in the isolation of only those binding factors with access to the DNA. Factors isolated from the nucleus will thus have the potential to bind to sites on the chromosomal DNA. However, it must be considered that much of the chromatin is masked by histones and other DNA binding proteins, thus rendering it inaccessible to transcription factors, hence a binding site in vitro may not necessarily represent a binding site in vivo. The preparation of extracts from whole cells enables the entire DNA binding protein content of the cell to be examined. Some proteins may be present in the cytoplasm rather than the nucleus, and can be identified by the comparison of the binding profiles of nuclear and cytoplasmic extracts. Proteins present in the cytoplasm cannot be involved in transcriptional regulation at that time, due to their lacking access to the chromatin, but are likely to be on 'standby', ready for a quick transport into the nucleus following a certain stimulus. This transport of transcription factors from the cytoplasm to the nucleus may be studied by comparing whole-cell and nuclear extracts before and after treatment of the cells. Whole-cell extracts are easier to prepare, requiring fewer steps in their preparation, which makes their use favourable when a tissue sample is limiting because fewer manipulations present fewer stages at which protein will be lost or damaged. It is also necessary to prepare whole-cell extracts when a sample has been frozen, as freezing damages the nuclear membrane, preventing the preparation of intact nuclei, and thus the preparation of nuclear extracts. The method for the preparation of nuclear extracts is given in Protocol 5, and is a modification of that described by Dignam et al. (11). If fewer than 5 X 107 cells are to be used, the method in Protocol 5 may be scaled down accordingly. For very small numbers of cells, the mini-preparation method given in Protocol 8 should be used. Whole-cell extracts are made by a modification of the method (12) given in Protocol 5. Harvest the cells and wash with PBS. Resuspend in 1 ml of buffer C and homogenize with 20 strokes of a tight-fitting homogenizer. Then add 10
1: The DNA mobility shift assay NaCl to a final concentration of 300 mM and continue from step 9 of the nuclear extract preparation method.
Tissue samples can be more difficult to homogenize than cultured cells. Small pieces of soft tissue may be treated as cultured cells, and we have successfully used this method for the isolation of binding proteins from rat dorsal root ganglion and brain tissue. Larger pieces of tougher tissue or frozen samples may have to be treated more drastically to release the protein. It should prove sufficient for most tissues to use a tissue macerator instead of a 11
C. L. Dent et al. Dounce homogenizer, but particularly tough tissues or frozen samples may have to be frozen in liquid nitrogen and ground to a fine powder before homogenization. Samples that have at any stage been frozen may only be used for the preparation of whole-cell extracts. Fresh tissue samples should be dealt with as quickly as possible to prevent degradation by proteases.
2.6 The binding reaction Conditions for the binding of protein to DNA vary between research groups. We use a 45 min incubation on ice in order to maintain an extent of uniformity between different studies. The binding conditions routinely used in our laboratory are given in Protocol 6.
Protocols. Conditions for binding Equipment and reagents Binding solution: 20 mM Hepes pH 7.9, 1 mM MgCI2, 4% ficoll, 0.5 mM DTT Poly dldC (Pharmacia)
0.25 X TBE (1 X TBE = 100 mM Tris-HCI, 100 (um boric acid, 2 mM EDTA) Gel drying apparatus
Method 1. Make a 20 ul binding reaction by mixing binding solution with KCI to a final salt concentration of 50 mM,a 2 ug poly dldC, and 1 ul (10 fmol) 32 P-labelled probe and protein extract. 2. Incubate on ice for 40 min. 3. Run samplesb on a 4% polyacrylamide gel (0.25 x TBE). The gel should be pre-run at 150 V for about 2 h before electrophoresis (current will drop from 20-30 mA to approximately 10 mA during this time). Then run samples for 2.5 h (or until the bromophenol blue marker dye has run about two-thirds of the way down the gel). 4. Dry gel on to filter paper (1 h, 80°C, with vacuum) and autoradiograph overnight. 'Remember that any extract added is in 300 mM NaCI. 'Do not add any loading dye to samples; the ficoll in the binding buffer provides the density required for loading. Bromophenol blue in glycerol may be added to a spare track as marker. Poly dldC is added to the binding reaction as a non-specific competitor for the binding of any general DNA binding proteins, leaving the probe free to bind sequence-specific binding proteins. The amount of extract required will vary depending on the protein concentration of the extract and the abundance and affinity of the factor to be studied. It is advisable to determine the amount giving the best results experimentally. The concentration of protein in extracts should be determined by the method of Bradford (ref. 13, Protocol 7), allowing the comparison of equal amounts of protein from different extracts.
12
1: The DNA mobility shift assay Protocol 7. Bradford assay for protein concentration Equipment and reagents Dye reagent: 100 mg Coomassie brilliant blue G, 30 mg SDS, 50 mg 95% (v/v ethanol, 100 ml 85% (v/v) phosphoric acid dilute the mixture to a final volume of 1 litre, using distilled water
PBS 0.25 M Tris-HCI pH7.5 Liquid nitrogen and 37°C water bath
Method 1. Following transfection, wash the cells with PBS, harvest them, transfer to a 1.5 ml microcentrifuge tube and centrifuge at 1000 x g for 5 min at 4°C. 2. Add 100 ul of 0.25 M Tris-HCI to the cell pellet. 3. Disrupt the cells by freezing and thawing. To freeze-thaw, immerse the tubes in liquid nitrogen for 2 min and then transfer them to a 37°C water bath. Repeat the cycle three times. 4. Pellet the cell debris by centrifugation at 3000 x grfor 3 min at 4°C and save the supernatant to test for protein. Samples may be saved at this point by storage at -20°C. 5. Add 1 ml of dye reagent to 10 uJ of each sample. 6. Measure the absorbance of the sample at 595 nm (A595) after 15 min. 7. If the absolute concentration of protein is needed, construct a standard curve using BSA as standard (draw A5S5 vs. [BSA] mg/ml).
2.7 Preparation of mini-extracts Several methods have been published for the preparation of mini-extracts, when cells or tissue are limiting. Mini-extracts are particularly quick and easy to prepare, and all steps can usually be carried out in a microcentrifuge tube without the need for steps such as homogenization, eliminating the loss of sample that may occur when it is continually being transferred between tubes. The method given in Protocol 8 is for the preparation of mini-whole-cell extracts (14). Protocol 8. The preparation of mini-whole-cell extracts Equipment and reagents Microcentrifuge and microcentrifuge tubes Freezing bath (dry ice/ethanol) and 37°C water bath
PBS
Extraction buffer: 20 mM Hepes pH 7.8, 450 mM NaCI, 0.4 mM EDTA, 0.5 mM DTT, 25% glycerol, 0.5 mM PMSF
Method 1. Harvest the cells into 1 ml PBS in a microcentrifuge tube, centrifuge for 1 min at 1000 x grforS min at 4°Cto pellet. 13
C. L. Dent et al. Protocol 8. Continued 2. Wash with 1 ml PBS, centrifuge for 1 min at 1000 x g for 5 min at 4°C, remove all traces of PBS. 3. Resuspend cell pellet in 100 ul (or less) extraction buffer. 4. Freeze (dry ice/ethanol bath) and thaw (37°C water bath) three times. 5. Spin at 10000 x g for 10 min in a microcentrifuge at 4°C. 6. Use 10 (ul of supernatant for each binding reaction.
3. Other sources of protein for use in the binding assay Purified transcription factor expressed from the cloned gene may be used as a substrate for a DNA binding assay. The expression of a cloned transcription factor can allow the study of the binding of that factor in the absence of other proteins with which it may interact in vivo and, when expressed in bacterial systems, in the absence of some post-translational modifications. Expression can serve to confirm the identity of a clone by comparing the band formed by the expressed cloned protein with that observed in cellular extracts. It must be remembered, however, that a cloned protein may not necessarily bind in the same manner as the endogenous protein does in a cellular extract, or even bind at all. Several factors may contribute to differences in binding. Other proteins may be required for, or contribute towards, the formation of a complex, resulting in a different binding pattern, or inability to bind. Proteins synthesized in bacterial systems will not have undergone certain posttranslational modification that occur in a mammalian cell; the most common of these being phosphorylation (see, for example, ref. 15). One of the greatest advantages of using expressed cloned transcription factors for DNA binding and expression studies is that it is possible to manipulate specific regions of the transcription factor protein by mutating the cloned gene. Truncations, deletions, and point mutations of the protein can be made. Binding assays and expression assays can then be used to determine which mutations are defective in DNA binding or transcriptional activation (see Chapter 8). There are several methods of expressing cloned proteins, these include: (a) expression in bacteria (b) expression in mammalian cells (c) in vitro synthesis in reticulocyte lysate from an in vitro translated mRNA (d) baculovirus expression systems
3.1 Expression of DNA binding proteins in bacteria Expression in bacterial systems is one of the less commonly used systems for the synthesis of transcription factor protein. All the other systems described use eukaryotic cells or cell extracts for the synthesis of protein, and it makes good sense to synthesize a eukaryotic protein in a eukaryotic system. 14
1: The DMA mobility shift assay This system has been used in a number of cases. There are several factors that must be considered when using bacterial expression vectors for the expression of transcription factors. First, as with any expression vector, the coding sequence must be inserted into the vector in the correct orientation and reading frame, otherwise the RNA made will not be able to be translated into protein. It is also important to use a cDNA clone rather than one which is interrupted by introns, as bacteria are incapable of editing these from the RNA to give a mature translatable product. Proteins that have been expressed in bacteria will not have undergone certain post-translational modifications that would occur in the eukaryotic cell. This may be a problem when experiments are being carried out to determine, for example, whether the transcription factor encoded by a certain cloned piece of DNA encodes the same factor as that giving a certain band in a retardation assay, because proteins lacking certain modifications may not bind properly, may interact correctly with other proteins, or may even possess an incorrect apparent molecular weight. However, the production of unmodified protein may be an advantage when studying the modification process itself. If the protein expressed in a bacterial system behaves differently from that expressed in a cellular extract or eukaryotic expression system, it would suggest that that protein required post-translational modification for full functional activity. The converse experiment is also possible, i.e. a phosphorylated protein from a cell extract or eukaryotic expression system may also be dephosphorylated by treatment with phosphatases, and the effect of this treatment on binding activity studied. As a final comment, it is important to make sure that all experiments involving the expression of transcription factor protein are properly controlled. First, binding assays carried out using extracts expressing a cloned protein must be compared with assays using extracts made from cells expressing the intact vector only, in order to identify any binding of bacterial rather than expressed eukaryotic proteins. However, even when this precaution is taken it is often impossible to rule out the possibility that the expressed protein is binding with the aid of a bacterial cofactor protein (which may or may not be an analogue of a protein that is required in vivo), and results must be interpreted with this in mind.
3.2 Expression of proteins in mammalian cells The expression of proteins in mammalian cells is one of the most commonly used means of producing recombinant transcription factor for gel retardation or expression assay analysis (see Chapter 8, Section 3). It is often possible to express the cloned transcription factor in a cell line in which it is usually active, therefore ensuring that all cofactors and modification proteins required for the expression of that factor will be present. If this is done, it will be necessary to devise some means of distinguishing the cloned transcription factor from the endogenous factor present in the cell. This may be relatively 15
C. L. Dent et al. easy if the cloned factor is expressed as a fusion protein, or has been deleted or truncated, and is therefore a different size from the endogenous factor, but it is possible that this may constitute a major problem. If so, or if the nature of the investigation makes such an experiment of interest, it is also possible to express a transcription factor in a mammalian cell line in which it is not usually expressed. The transcription factor is cloned into an expression vector as already described in the discussion of expression of proteins in bacterial systems. The vector systems are similar to those found for bacterial systems, in that the coding DNA must be inserted in the correct orientation for expression, in the correct reading frame, and that the resulting expression product may be synthesized as a fusion protein. In addition, the vector must contain sequences to specify capping and polyadenylation of the transcribed RNA sequence. Protein expression is under the control of a mammalian promoter (often a mammalian viral promoter such as the cytomegalovirus gene promoter) which may be inducible. The methods for introducing DNA into mammalian cells by transfection are given in Chapter 8. Extracts can be made from the cell line expressing the transcription factor in order to detect the DNA binding of the transfected factor by use of the DNA mobility shift assay. Mini-preparation methods should initially be used to isolate protein, but it is possible that transiently transfected cells will contain insufficient protein for detection by a mobility shift assay. If this is the case, it is possible to prepare a protein extract from more plates of transfected cells, or to prepare stably transfected cell lines such that a higher proportion of the cells present are expressing the transcription factor protein.
3.3 Expression by in vitro transcription and translation In vitro transcription and translation is another method that is used very widely for the production of recombinant or cloned transcription factor protein (see Chapter 8, Section 3.1 and ref. 16). The major advantage of this method is that it gives a clean protein product which is likely to be free of contaminating transcription factors. cDNA encoding the transcription factor is cloned into a vector which possess the promoter sequence for a viral RNA polymerase; usually SP6, T3, or T7 polymerases are used (17). The bluescript vector is particularly suitable for this purpose as it contains both T3 and T7 RNA polymerase promoters either side of a multiple cloning site polylinker. This enables the in vitro transcription of either sense or antisense RNA from the cloned sequence, depending in which direction transcription is inititated. After checking an aliquot of the RNA by electrophoresis (there should be sufficient RNA to visualize on an agarose slab gel without the necessity for Northern blotting) it can be translated in a cell-free translation system. A good system, particularly for the translation of transcription factor proteins, is the rabbit reticulocyte lysate. Reticulocytes do not contain a nucleus and, 16
1: The DNA mobility shift assay therefore, have no requirement for transcription factors. This makes the interpretation of mobility shift assay results from the cloned transcription factors much simpler in the absence of additional endogenous factor or factors. However, it is still necessary to include an aliquot of translation extract (after incubation without RNA or with antisense RNA in a mobility shift) to make absolutely certain that it does not contain endogenous proteins that are capable of binding to the probe and thus confusing the interpretation of results. It is also possible to label any translation product radioactively with [35S]methionine during translation, allowing the protein to be sized accurately on an SDS-polyacrylamide gel. Commercially available kits now make simultaneous transcription and translation reactions possible.
3.4 Expression of cloned transcription factor in baculovirus Baculovirus vectors are a very efficient means of generating recombinant protein (see Chapter 8, Section 3.5). Baculovirus is a virus that infects insect cells and the cloned protein is, therefore, produced in an insect cell line. Vmw65 has been expressed in a baculovirus system (18), with the result that enough protein was expressed to be clearly visible when infected (with recombinant baculovirus) and mock-infected cell extracts were compared by electrophoresis on an SDS-polyacrylamide gel. In this case, the recombinant protein represented about 3% of the soluble protein extracted from the infected cells, equivalent to 20 mg of recombinant protein from 109 infected cells. This protein was used directly for DNA mobility shift studies.
3.5 Purification of transcription factor protein The purification of transcription factor proteins can be applied both to endogenous transcription factors and to an artificially expressed factor, and can be used to purify (or partially purify) a factor from a cell extract (see Chapter 4). The purified factor may then be used for DNA binding assays to further study the relationships involved in binding to the probe, or can be used as a substrate for protein sequence analysis as part of a strategy for the isolation of a clone encoding the factor. Purification methods may also be used to prepare an extract depleted in a factor. The depleted extract can be used to dissect the activity of the protein, for example by adding back a cloned transcription factor.
4. Investigation of DNA binding specificity Sequence-specific DNA binding proteins will often be capable of binding to a series of variations on a basic consensus sequence. A binding site that is further removed from the consensus may bind the factor less strongly and, therefore, be a weaker site for transcriptional activation. Differences in the sequence of flanking DNA outside of the core consensus binding site may also 17
C. L. Dent et al. affect binding. These differences in affinity of different sites for the same factor will contribute to the differential effects of a single transcription factor on different genes, and can be studied by competition analysis. The approach used for the measurement of the affinity of a transcription factor for different binding sites is discussed below. If a binding reaction is set up between a radiolabelled oligonucleotide and protein extract, the protein-DNA complexes will form retarded bands on electrophoresis as already explained. If, when the reaction is set up, as well as adding radiolabelled binding site oligonucleotide, a 100-fold molar excess of unlabelled oligonucleotide is added, then the DNA binding protein will be able to bind the unlabelled oligonucleotide and the radioactive probe. This will result in a decrease in the amount of factor available for binding to the probe by competition from the unlabelled site, and subsequent reduction in the intensity of the retarded band. If, rather than introducing an unlabelled oligonucleotide identical to the probe, an oligonucleotide corresponding to a different site to which the factor cannot bind is added, there should be no difference in the intensity of the retarded band because the competing oligonucleotide is not able to bind the factor. This is the standard means by which a transcription factor is demonstrated to bind in a sequence-specific manner (Figure 3). This kind of experiment may then be taken a stage further by introducing, as competitor, variations on the same binding site. The new sequences chosen may be related binding sites found in other genes in order to study the comparative affinities of natural binding sites, or they may be mutations of the consensus binding site designed to study the effect of base substitutions on the DNA-protein interaction. If a related site that binds the same factor is introduced at an excess into a binding reaction, the extent of competition should vary from that obtained using the site identical to the probe. A higher affinity binding site would compete more protein away from the labelled site, resulting in a stronger reduction in the intensity of the retarded band. A lower affinity site would be less efficient in competition, leaving more protein for complex formation with labelled oligonucleotide, resulting in less reduction in the retarded band. Some related sequences may be totally unable to bind, resulting in the competed binding reaction giving a retarded band identical to that obtained when no competitor DNA is added (or indeed, competitor DNA for a totally unrelated binding site). The comparative affinity of the protein for different sites can be determined by adding different amounts of competitor for the sites to a uniform binding reaction, and measuring the amount of competitor required to reduce the level of protein bound to the radioactive probe by a particular amount. For example, if one sequence competed all of the protein off the probe at a 10-fold molar excess of competitor, but another related sequence required a 100-fold excess, it could be concluded that the first sequence comprised the higher affinity binding site for the factor in question. Experiments of this type have been used in our laboratory to provide 18
1: The DNA mobility shift assay
Figure 5. DNA mobility shift assay using four different labelled octarner oligonucleotides (a-d) and extracts prepared from ND7 neuronal cells (A) and Daudi B cells (B). Arrowheads indicate the positions of Oct-1 and Oct-2, Note the different affinities of B cell and neuronal Oct-2 for the different oligonucleotides. For further details see ref. 19.
evidence that the neuronal and B-cell forms of Oct-2 are not identical (19). The affinities of the proteins for a panel of four oligonucleotidc variants of an overlapping octamer/TAATGARAT consensus sequence (Figure 5) were measured. A mobility shift assay was carried oul on oligonucleotide C and competed with varying amounts (1-, 10-, and 100-fold molar excess) of the four oligonucleotides and an unrelated Spl binding site as a negative control (Figure 6), Oct-2 from B cells binds oligonucleotide A with a higher affinity than any other sequence, as demonstrated by the fact that A competes for binding more efficiently. However, Oct-2 from neuronal cells behaves differently, binding to and competing most efficiently with C, thus demonstrating a higher affinity for this sequence.
5. Characterization of DNA binding proteins 5.1 Addition of antibodies Antisera raised against a transcription factor may affect its binding by one of two methods. First, the antibody may bind to a site on the transcription factor that is essential for DNA binding, thus totally blocking the ability of the factor to bind DNA and resulting in the complete absence of a DNA-protein complex from the gel. Second, if the antibody binds to a non-essential site on the factor, DNA binding may not be impaired, but the mobility of the complex 19
C. L. Dent et al.
Figure 6. Competition analysis of the B cell (B) and ND cells
will be altered by the binding of the antibody. The resulting complex will possess a lower mobility than the DNA-protein complex alone, due to the involvement of an additional factor. This will result in a super-shift of the DNA-protein complex to a position of lower mobility, due to binding of the antibody, Antisera may be used to determine whether a mobility shift is caused by a previously identified transcription factor. Evidence such as the size of the shifted band and binding site specificity of a protein could suggest that it may be a previously characterized factor. The binding of an antibody may help towards confirming that the protein is indeed the factor that it is suspected of being (or may demonstrate that it is unique). In one series of experiments, antibodies raised against the transcription factor Oct-1 were found to bind to NFIII, an adenovirus DNA replication factor (20). This provided strong evidence that NFIII and Oct-1 were indeed identical, and was supported by additional experiments demonstrating that the anti-Oct-I antibodies could block NFIII stimulation of adenovirus DNA replication, and that Oct-1 could functionally substitute for NFIII in this system. This work also serves to demonstrate how the results obtained from the DNA mobility shift assay are particularly valuable when coupled with evidence obtained by other means. If an antiserum does bind to a factor, it does not necessarily prove that it is identical to the protein to which the antiserum was raised; binding may result from the proteins sharing a common domain that includes the epitope for the 20
1: The DNA mobility shift assay antibody. However, antisera may demonstrate that two proteins that appear to be different in a mobility shift assay may be related if they share a domain containing the epitope. Antibody binding experiments are carried out as already described in Protocol 6, with the only modification being that the antisera and protein extract should be mixed together and pre-incubated for about 30 min on ice before the addition of the extract to the binding reaction. When setting up such an experiment, it is also important to include a control binding reaction containing the antisera in the absence of protein extract. This is because serum may contain proteins capable of binding to the DNA probe, resulting in extra shifted bands that may affect the interpretation of results. Similarly, a control should be included containing the extract and an unrelated antibody or pre-immune serum.
5.2 Addition of potential ligands This approach involves attempting to modulate the binding characteristics of a protein by adding to or removing from the binding reaction certain cofactors that may be required for binding. Such ligands would be added to the standard binding reaction mix described in Protocol 6. Factors that may influence the binding reaction include the presence of ions such as calcium, magnesium, and zinc. These may be removed by the addition of chelating agents such as EDTA and EGTA to the binding reaction mix. The activity of a transcription factor in a depleted extract can yield important information about its structure. Spl was demonstrated to be inactive in HeLa extracts that had been depleted of zinc by treatment with EDTA. This suggests that Spl probably binds to DNA by a zinc-dependent structure known as the zinc ringer (21). In the same series of experiments, Oct-1 was shown to be fully active in zinc-free extracts, demonstrating that its activity is not dependent on zinc. Some DNA binding proteins also act as receptors for endogenous substances, examples being the steroid and retinoic acid receptors. It would thus be obvious in these cases to study the effect of adding the natural ligand to the binding reaction, along with studies involving the addition of ligand analogues which may have either a stimulatory or inhibitory effect compared with the natural ligand (see Chapter 8).
5.3 Proteolytic clipping band-shift assay The proteolytic clipping band-shift assay can be used alongside antibody binding to examine the relatedness of two proteins. This type of assay involves the addition of various dilutions of a specific protease, e.g. trypsin or chymotrypsin, to a DNA-protein complex, resulting in the production of partial cleavage products that become more completely cleaved with the addition of higher concentrations of protease. The pattern of partial and complete 21
C.L. Dent el al.
Figure 7. Protease clipping assay in which DMA mobility shifts were carried out with an oligonucleotide which binds the octamer-binding protein Oct-1 (arrowed) using an untreated extract (track 1) and the same extract pre-treated with various amounts of chymotrvpsin (tracks 2-5).
cleavage products gives a typical 'fingerprint' to a protein. If two proteins are identical, they will give identical cleavage products. If two proteins are related, sharing some homologous domains, then some similar cleavage products may be present within a somewhat different fingerprint. Figure 7 shows a typical result from a proteolytic clipping band-shift assay, with the first track showing the binding reaction in the absence of protease, and the following tracks showing the cleavage products on addition of increasing amounts of protease. A method for proteolytic clipping using trypsin and chymotrypsin is given in Protocol 9. Protocol 9.
Proteolytic clipping band-shift assay
Equipment and reagents As in Protocol 6 Stock solutions of chymotrypsin: 0.004, 0.002, 0.001, and 0.0005 units/ul
Stock solutions of trypsin; 30, 10, 3, and 1 ng/ul
22
1: The DNA mobility shift assay Method 1. Set up binding reaction exactly as described in Protocol 6. Incubate at room temperature for 10 min (not on ice as in Protocol 6). Five tubes should be prepared for each type of protease to be included, for four different concentrations of protease and a control without protease. 2. During the binding incubation, prepare serial dilutions of the proteases in water. Keep a stock solution of protease at 4000 units/ml for chymotrypsin and 30 ug/ml for trypsin at 4°C. Working stock solutions of chymotrypsin and trypsin should be prepared by dilution before use. 3. Add 1 ul of each dilution of protease to the relevant binding reaction tube, and 1 ul of water to the no-protease control tube. Incubate at room temperature for a further 10 min. 4. Load samples on to a 4% polyacrylamide gel in 0.25 x TBE and electrophorese as described in Protocol 6.
6. Study of protein—protein interactions Many DNA binding proteins interact with other proteins during their activity. Factors such as Apl are active as a heterodimer of two proteins, Fos and Jun, that will then together recognize and bind to a site in the DNA. A different type of protein cofactor is Vmw65, a HSV-1 protein that binds to Oct-1, forming a complex which can then bind to the HSV-1 immediate-early gene TAATGARAT consensus and enable transactivation of viral RNA synthesis. The Vmw65 protein itself is not capable of binding DNA, although it does contact the DNA sequence when complexed with Vmw65 (2,3). The inclusion of additional proteins into DNA binding complexes may be studied using the gel retardation assay. The binding of an extra protein into a complex will further increase its apparent molecular weight on electrophoresis. Vmw65 is by far the most extensively studied cofactor involved in DNA binding complexes (2,3). Nuclear extracts made from cells that have been infected with HSV-1 are compared with extracts from mock-infected cells. The mockinfected extract will bind to a TAATGARAT probe, giving a shift typical of the Oct-1 protein, but the infected extract will give a further shift of lower mobility due to the binding of an additional factor, Vmw65, into the complex. Figure 8 shows the type of mobility shift given by Oct-1 when complexed with Vmw65 to form a larger complex. The shift typical of Oct-1 disappears and a new, lower mobility shift appears, providing further evidence that Oct-1 is the protein involved in the interaction with Vmw65 (3). 23
C.L.Dent et al.
Figure 8. DNA mobility shift assay using a radioactively labelled oligonucleotide containing the octamer-related TAATGARAT sequence. Note that incubation with HeLa cell extract alone results in Oct-1 binding to the probe [track 1). However, addition of increasing amounts of HSV virion extract containing Vmw65 results in the formation of the larger infected extract complex (IEC) containing both Oct-1 and Vmw65 (tracks 2-5K This complex is not formed upon incubation with HSV virion extract alone, indicating that it requires both Oct-1 and Vmw65, and that Vmw65 alone does not bind to DNA (tracks 6-10). Data kindly provided by Dr C. M. Preston, For further details see ref. 3.
24
1: The DNA mobility shift assay
7. Concluding comments The methods and examples given in this chapter demonstrate that the DNA mobility shift assay is a simple yet powerful technique for the identification and study of DNA binding, although it must be remembered that the technique does have its limitations and that the demonstration of DNA binding in vitro does not necessarily mean that a particular gene is under the control of a particular transcription factor in vivo. The following chapters give a detailed description of the types of experiment that can, and should, be carried out to support evidence gained using the DNA mobility shift assay.
References 1. Wheatley, S. C, Dent, C. L.( Wood, J. N., and Latchman, D. S. (1991). Exp. Cell. Res., 194,78. 2. O'Hare, P. and Coding, C. R. (1988). Cell, 52,435. 3. Preston, C. M., Frame, M. C., and Campbell, M. E. M. (1988). Cell, 52,425. 4. Gerster, T. and Roeder, R. G. (1988). Proc. NatlAcad. Sci. USA, 85,6347. 5. Lillycrop, K. A., Dent, C. L., Wheatley, S. C., Beech, M. N., Ninkina, N. N., Wood, J. N., and Latchman, D. S. (1991). Neuron, 7,381. 6. Fried, M. and Crothers, D. M. (1981). Nucleic Acids Res., 9,6505. 7. Garner, M. M. and Revzin, A. (1981). Nucleic Acids Res., 9, 3047. 8. Dent, C. L., Mclndoe, G. A., and Latchman, D. S. (1991). Nucleic Acids Res., 19, 4531. 9. Janson, L. and Pettersson, U. (1990). Proc. NatlAcad. Sci. USA, 87, 4732. 10. Sambrook, J., Fritsch, E. T., and Maniatis, T. (ed.) (1989). Molecular cloning, a laboratory manual (2nd edn). Cold Spring Harbor Press, NY. 11. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983). Nucleic Acids Res., 11, 1575. 12. Manley, J. L., Fine, A., Cano, A., Sharp, P. A., and Gefter, M. L. (1980). Proc. NatlAcad. Sci. USA, 77, 3855. 13. Bradford, M. (1976). Anal. Biochem., 72, 248. 14. Schreiber, E., Matthias, P., Muller, M., and Schaffner, W. (1989). Nucleic Acids Res., 17, 6419. 15. Roberts, S. B., Segil, N., and Heintz, N. (1991). Science, 253, 1022. 16. Neuberg, M., Adamkiewicz, J., Hunter, J. B., and Muller, R. (1989). Nature, 341, 243. 17. Green, M. R., Maniatis, T., and Melton, D. A. (1983). Cell, 32, 681. 18. Kristie, T. M., Le Bowitz, J. H., and Sharp, P. A. (1989). EMBO J., 8, 4229. 19. Dent, C. L., Lillycrop, K. A., Estridge, J. K., Thomas, N. S. B., and Latchman, D. S. (1991). Mol. Cell. Biol., 11, 3925. 20. Pruijn, G. J. M., van der Vliet, P. C., Dathan, N. A., and Mattaj, I. W. (1989). Nucleic Acids Res., 17, 1845. 21. Kadonaga, J. T., Garner, K. R., Musiarz, F. R., and Tjian, R. (1987). Cell, 51,1079.
25
This page intentionally left blank
2 Footprint analysis of DNA-protein complexes in vitro and in vivo CRAIG SPIRO and CYNTHIA T. McMURRAY
1. Overview Protein-DNA complexes mediate essential processes such as transcription and DNA replication. Footprint experiments use chemicals and enzymes that modify DNA to obtain detailed information on the individual nucleotides in protein-DNA complexes, even inside living mammalian cells. Chemical modification of a DNA molecule can inhibit binding of sequencespecific proteins because of changes at critical nucleotides (Figure 1A, step 1, 'Interference'). On the other hand, when sequence-specific proteins are bound to DNA they can protect nucleotides in the binding site from chemical modification and from nucleases (Figure IB, step 1, 'Protection'). When visualized by denaturing gel electrophoresis, interference or protection will bring about an empty spot that looks like a footprint in the pattern of bands (Figure 1A, steps 4 and 5; Figure IB, steps 3 and 4)). The footprint thereby identifies specific nucleotides in the protein-DNA complex and can indicate changes in the conformation of the DNA. Footprinting is a direct approach for analysing the interactions of individual proteins with DNA, the structure of DNA in control regions, and the interactions of binding sites (and their bound proteins). In 1978, Galas and Schmitz called footprinting a 'simple conjoining of the Maxam-Gilbert DNA-sequencing method and the technique of DNAaseprotected fragment isolation' for detecting protein-DNA binding specificity (1). Mirzabekov, Gilbert, and colleagues had previously studied proteinDNA contacts and chromatin structure using the alkylating agent dimethyl sulfate (DMS) (2). DMS and DNAase I remain the most commonly used agents, but other chemicals and nucleases are also valuable in the study of protein-DNA interaction and of DNA structure. The availability of thermostable DNA polymerases and thermal cyclers has simplified footprint experiments. Protein complexes with large molecules (such
Craig Spiro and Cynthia T. McMurray
as closed, supercoiled plasmids) can be analysed directly and, using ligationmediated polymerase chain reaction (PCR) (3), modification of individual nucleotides in living mammalian cells can be detected. While in vivo analysis requires many steps (described below), the individual steps are not technically difficult, so that footprinting can be used to study protein-DNA complexes and the interactions of DNA sites (and their bound proteins) during transcription. 28
2: Footprint analysis of DNA-protein complexes Figure 1. Schematic view of interference and protection footprinting methods. (A) Interference. 1. Double-stranded DNA molecule is 32P-end-labelled on one strand only and then modified with a chemical agent to alter at most one residue per molecule. Dots indicate positions of modification. The radioactively labelled, chemically modified DNA is mixed with sequence-specific DNA binding protein (oval). 2. The binding reaction is loaded on to a 5% native polyacrylamide gel to resolve protein-DNA complex from free DNA. The wet gel is exposed to film for several hours, and the film is used as template to cut the protein-bound DNA and free DNA from the gel. 3. The DNA is eluted from the gel, purified, and cleaved. Certain fragments will be under-represented in the plus protein sample (arrow), since modification of certain bases will have inhibited protein binding. 4. DNA fragments are resolved on sequencing gels. Number of counts loaded in each lane should be the same to allow comparison of bands. Bands represented in the free DNA lane but absent in the bound DNA lane indicate residues important for binding as their modification made protein binding less likely. 5. DMS is useful in both protection and interference reactions. It does not cleave the DNA backbone, but it modifies bases. Subsequent treatment with hot piperidine causes cleavage of the DNA specifically at modified Gs. The gel image shows that each G in the DNA is not equally susceptible to DMS modification. Comparison of naked and plus protein DNA indicates bases critical in DNA-protein contact (arrows). (B) Protection. 1. Double-stranded DNA molecule is 32Pend-labelled on one strand and is used in two separate binding reactions—one lacking and one containing a sequence-specific DNA binding protein (oval). Arrows indicate potential cleavage or modification sites. 2. The binding reactions are modified chemically (e.g. DMS) or treated with a nuclease (e.g. DNAase I), and the DNA is then purified. Chemically modified DNA is then cleaved. Certain fragments will be under-represented in the plus protein sample (arrow) because certain sites will have been protected from modification or cleavage. 3. The fragments from chemical modification/cleavage or nuclease cleavage are resolved on sequencing gels. Absence of certain fragments in plus protein lane (seen as a footprint) indicates base(s) protected from modification or cleavage by the bound protein. 4. DNAase I has been the most commonly used footprinting reagent. While not every nucleotide is equally susceptible to DNAase I cleavage, cuts are fairly evenly distributed along the length of DNA. Gel image shows DNA cleavage in the absence or presence of protein and the footprint created by bound protein.
2. In vitro footprinting 2.1 Analysis at base resolution of binding sites on 32P-endlabelled fragments Identification of the nucleotides modified in a footprint experiment (see Figure 1A, steps 4 and 5; Figure IB, steps 3 and 4) requires an unambiguous reference point. Footprints are visualized from the sequencing gels on which radioactive DNA fragments have been resolved. Orientation can be achieved by 32P-end-labelling a double-stranded molecule on one strand only (Figure 1, top; Figure 2). To analyse both strands, complementary sets of reactions are set up, each set with only one of the strands labelled (Figure 2B, bottom). Extension of a single 32P-end-labelled primer along the DNA is an alternative means of detection and can be used to analyse both in vivo and in vitro modified DNA in protection experiments (as described in subsequent sections; Figure 3, Figure 4, Figure 5). 29
Craig Spiro and Cynthia T. McMurray
Figure 2. Preparation of DNA molecule labelled on one strand only. (A) Region to be analysed ('promoter'), which is on a restriction fragment with unique ends, is inserted into multiple 'cloning site of a vector with additional unique sites (e.g. Xhol and fcoRI, indicated by arrows) outside of the sites used to insert promoter fragment. (B) New plasmid CpPromoter') is digested with enzymes that recognize outside sites (Xhol and EcoRI). The resulting fragment is 32P-end-labelled at both ends, and one of the inside sites (Hindlll or Xba\) is used to remove the label from one end only.
2.1.1 Linear DNA molecule for footprint Linear DNA molecules from 75 to 600 base pairs are suitable. The binding site can be between 20 and 400 bases from the end of the molecule, with a distance of 50 to 200 best for analysis on a 40 cm long, 0.4 mm thick, 6% poly30
2: Footprint analysis of DNA-protein complexes
Figure 3. DNAase I protection on closed circular plasmid (Protocol 7.) (A) For example, the DNA molecule is a closed, circular plasmid containing a mammalian cAMP-responsive enhancer (CRE; shaded rectangle in detail) and the coding region of the chloramphenicol acetyl transferase gene (filled region; wavy arrow shows direction of transcription). Analysis requires a primer for sequencing through the enhancer region on each strand (CREfp5' and CREfp3' primers). (B) Sequence of a section of the rat prodynorphin enhancer region which contains three CREs (enclosed in rectangles) (20). The primers are indicated by horizontal bars [arrow indicates direction of extension). (C) Protection of the top strand by increasing amounts of purified CREB (CRE-binding) protein (9) is visualized by extension of dynfp3' primer, for which fragments of the top strand are templates. Dideoxy G sequencing reaction (Protocol 5) of the bottom strand (i.e. using the dynfp3' primer) is used to identify specific bases. Note the size of the area protected from DNAase I, the contrast between protected and unprotected bands, and the greater resolution of smaller fragments. (C) adapted from ref. 9, with permission. 31
Craig Spiro and Cynthia T. McMurray
acrylamide, denaturing gel. Longer fragments are less well resolved than shorter fragments (see, for example, Figure 3C). The double-stranded DNA molecule 32P-labelled on just one end can be prepared from a restriction fragment subcloned into the multiple cloning site of a plasmid vector (e.g. Figure 2). The restriction fragment with your region of interest ('promoter' in Figure 2A) must have unique sites on the ends. If convenient sites do not flank your region of interest, create them by amplification of the region with primers designed to introduce the sites (e.g. HindIII and XbaI in Figure 2A). Using the unique sites (HindIII and XbaI), subclone the fragment into the multiple cloning site of the vector between two other unique restriction sites (Figure 2A, arrows) to create the plasmid with your region of interest ('pPromoter' in Figure 25). Cut the fragment from the plasmid using the outer restriction sites (XhoI and EcoKL in Figure 2B), dephosphorylate with calf intestinal phosphatase (CIP), heat inactivate at 15°C, and gel purify the fragment containing the region of interest (Xhol-EcoRl 'promoter' fragment in Figure 25). Store this fragment at -20°C until needed for footprinting. Then, end label the fragment using [32P]ATP and T4 polynucleotide kinase. (Protocol 1). Cut with one of the inside enzymes (i.e. 32
2: Footprint analysis of DNA-protein complexes Figure 4. LMPCR experimental design (re Protocols 8-14). (A) Flow chart for preparation of DNA for LMPCR. (1) Prepare duplicate sets of cultured cells (and treat with inducers of transcription if necessary). (2) Treat one set of cells with PBS only and the other set with DMS. (3) Harvest cells and purify DNA. (4) Modify some of the DNA from PBS-treated control cells in vitro with DMS. (Control DNA can be used for genomic sequencing or methyl cytosine analysis as well.) (5) Cleave DMS-modified DNA with piperidine and proceed to LMPCR. (B) Design of primers for LMPCR. LMPCR requires three nested primers, with successively higher Tm. Primers are shown along one strand only, but a set of primers should be prepared for each strand to flank the region being studied. Primer 3 (the final one used) should be about 30-100 bases (not less than 10) from the 5' end of the region being examined (shaded rectangle). Primer 1, used for primer extension to create bluntended molecules, should be 20 bases long with 12 G + C (60% GC). Primer 2, the amplification primer, must be 3' to primer 1. The distance between primer 2 and primer 1 is not critical. They can be separated by as much as 50 to 100 bases, but they can also overlap a little. Primer 2 should never overlap primer 1 by more than 5 bases. Primer 2 should be 25 bases long with 15 G + C (60% GC) (as is LMPCR.1). Primer 3 should overlap primer 2 by at least 15 bases (it is fine if they completely overlap) and must extend a few bases 3' to primer 2. Primer 3 should be 28 bases long with 17 or 18 G + C (60-65% GC). If the sequence of the gene does not allow these precise lengths and G + C content, then adjust the primer length and GC content so that the calculated Tm is the same. (C) Amplification and detection of one gene-specific fragment by LMPCR. 1. Genomic DNA is modified and cleaved. 2. Gene-specific primer 1 anneals to fragment from gene, and primer extension creates blunt-ended molecule. 3. Unidirectional linker is ligated to the blunt-ended fragments. 4. Gene-specific primer 2 anneals to fragment from gene and primer extension creates double-stranded molecule with sequence of linker primer (LMPCR.1) on the other strand. 5. During PCR amplification, gene-specific primer 2 and LMPCR.1 anneal to the complementary strands. 6. Fragment is amplified. 7. Extension of 32P-end-labelled genespecific primer 3 allows detection of fragment by gel electrophoresis and autoradiography.
HindllL or XbaI; Figure 2B) to create a double-stranded molecule labelled on just one end (one strand) (Figure 2B, bottom). DNA molecules labelled on just one end can be prepared by alternative methods, including amplification by PCR with one 32P-labelled primer (Protocol 1} and one unlabelled primer. Protocol 1. End labelling DNA molecules using T4 polynucleotide kinase and [32P]ATP Equipment and reagents End-labelling grade [32P]ATP: 259 TBq mmol, 22.7 uM, 5.92 GBq/ml (ICN) Spin desalting column (e.g. Bio-Spin 6; BioRad)
T4 polynucleotide kinase (New England Biolabs, 10U/ul 10 x T4 polynucleotide kinase buffer. 100 mM MgCI2, 50 mM DTT, 1 mM spermidine, 1 mM EDTA, 500 mM Tris-HCI pH 7.6 (store in aliquots at -20°C)
Method 1. Synthetic oligonucleotides with 5'-OH groups are ready for end labelling. Restriction fragments with 5'-PO4 must be dephosphorylated.8 33
Craig Spiro and Cynthia T. McMurray Protocol 1.
Continued
2. To label 40 pmol oligonucleotide primer, combine 19 ul H2O 3 ul 10 x T4 polynucleotide kinase buffer 3 (J end-labelling grade [32P]ATP 4 ul 10 (uM oligonucleotide (or DNA fragment) 1 ul T4 polynucleotide kinase (10 U/ul, New England Biolabs) 3. Incubate at least 15 min at 37 °C. 4. Stop with 20 ul 25 mM EDTA. 5. Remove unincorporated [32P]ATP with Bio-Spin 6 desalting column.6 6. Count 1 ul in scintillation counter (Cerenkov). Expect about 2 x 106 to 4 x 106 c.p.m./pmol for labelled oligonucleotides of 20-40 bases. Longer molecules will have lower specific activity. Store at 4°C. (If counts are significantly lower, e.g. less than 5 x 105 c.p.m./pmol, check reaction components.) "Dephosphorylate, if necessary, with calf intestinal alkaline phosphatase (which is active in restriction enzyme buffers) and then heat inactivate the phosphatase for 10 min at 75°C. (To completely remove phosphatase, gel purify the DNA or extract once with phenol: trichloromethane:iso-amyl alcohol (25:24:1) and ethanol precipitate the DNA.) ''Some unincorporated [32P]ATP will not be retained by column, but it will not interfere with subsequent reactions. Other methods, such as ethanol precipitation, can more effectively remove [32P]ATP, but they are more likely to remove labelled DNA as well, so the spin column is a good compromise.
2.1.2 Source of protein for binding reaction The protein-DNA complex being studied will affect the clarity of the footprint. In a protection experiment, a footprint will be difficult to detect if there is low occupancy of the binding site. Furthermore, the hypothesis being tested will dictate what source of protein is suitable. For example, crude protein may be used to locate the binding site or to study relative binding affinity, but purified protein is required for determination of absolute equilibrium binding constants (4). Nuclear extracts can be used for studies of interactions among sites. Dignam and colleagues described a method for extracting transcriptionally competent nuclear extracts (5), but more rapid preparation of nuclear extract from a relatively small number of mammalian cells can be satisfactory for evaluating the effect of a series of treatments (e.g. 6-8) (Protocol 2). From 10 to 150 ug nuclear extract may used for binding in a protection experiment. Figure 5. LMPCR. (Section 3.4, Protocol 14) (A) Portion of the rat proenkephalin enhancer region analysed by LMPCR (9). cAMP-response elements are enclosed in rectangles. Nested primers (Figure 4B) are numbered in order of use. (B) In vivo footprint of proenkephalin enhancer region in C6 glioma and R2C Leydig tumour cell lines. Proenkephalin gene is expressed in C6 but not in R2C cells. Naked DNA was purified and 34
2: Footprint analysis of DNA-protein complexes
then modified by DMS in vitro; '+ forsk' cells were treated with forskolin before DMS modification in vivo. Residues that are less reactive (open triangles) or more reactive (filled triangles) in cells expressing proenkephatin are indicated along the images of the gels and in the representation of the sequence. Top strand gel image was produced from reactions with bottom strand primers (Figure 5A). Reproduced from ref, 9, with permission. 35
Craig Spiro and Cynthia T. McMurray Protocol 2. Nuclear extract from small number of cultured mammalian cells Equipment and reagents PBS Low-salt buffer: 1.5 mM MgCI2, 10 mM KCI 0.5 mM DTT, 10 mM Hepes, pH 7.9 10% NP40 High-salt extraction buffer: 25% (v/v) glycerol 1.5 mM MgCI2, 1 mM DTT, 420 mM NaCI 20 mM Hepes pH 7.9
Dilution buffer: 5 mM Hepes pH 7.9, 20% glycerol, 1 mM DTT Protease inhibitors: e.g. PMSF (to 0.5 mM) may be used to supplement buffers Refrigerated microcentrifuge or refrigerated superspeed centrifuge with adapters to hold microcentrifuge tubes
Method 1. Wash cells (5 x 105 to 1 x 107 cells) with PBS and collect in microcentrifuge tube. (For cells in suspension resuspend in 1 ml PBS and transfer to microcentrifuge tube. For monolayers, scrape into 1 ml PBS and transfer to microcentrifuge tube.) Keep on ice until all cells have been harvested. 2. Pellet cells by centrifugation for 10 sec in microcentrifuge. 3. Resuspend cells in 400 ul low-salt buffer by pipetting up and down a few times. 4. Let swell 15 min on ice. 5. Add 25 (ul 10% NP40.
6. Vortex 10 sec. Return tubes to ice. 7. Spin 10 sec to collect nuclei. (Discard supernatant.) 8. Resuspend pellet in 50 ul high-salt buffer by gently stirring with pipette tip. Pellet of nuclei may be clumpy. The suspension should not become viscous. Keep tubes on ice. 9. Rock tubes at 4°C for 20 min for extraction of proteins. 10. Spin tubes at 16000 x g for 45 min at 4°C in refrigerated microcentrifuge or in refrigerated superspeed centrifuge. 11. Supernatant is the nuclear extract. Dilute with equal volume dilution buffer. 12. Aliquot; freeze in dry ice/ethanol bath, then store at -70°C until ready for use.
In a protection experiment, bases are protected from modification by the bound protein (Figure 1B, steps 3 and 4; Figure 3C). Sensitivity of DNA to modifying agents depends on local structure/environment and on the points of contact with the bound protein. Therefore, in a 'protection' experiment, some of the bases in or near the binding site may not be protected at all but instead 36
2: Footprint analysis of DNA-protein complexes may become more reactive (indicated by darker bands) (e.g. Figure 3C; Figure 5B). Using more than one probe can provide supplementary information on the site of binding and points of contact (Section 2.1.4). 2.1.3 Protection from DNAase I digestion Protection from DNAase I is the most commonly reported in vitro footprinting assay (Figure 1B; Protocol 3). DNAase I has relatively little sequence preference, so it cleaves along the entire length of the DNA backbone. Another advantage of DNAase I is that digestions can be carried out over a range of temperature, pH, and salt conditions. DNAase I footprints tend to be large because of the exclusion of the enzyme by bound protein, so the footprints are, therefore, often easily detected (e.g. Figure 1B, step 4; Figure 3C). Most footprint analysis is qualitative, but protection experiments can also yield thermodynamic profiles of protein-DNA interactions. Because DNAase I can probe complexes without perturbing the equilibrium, quantitative analysis of carefully controlled footprint experiments can provide data on equilibria in solution (4). Protocol 3. Protection from DNAase I of linear DNA molecule Equipment and reagents • 0.5 ml and 1.5 ml slliconized microcentrifuge tubes (Fisher Scientific) . DNAase I (RQ1; Promega, 1 U/ul) « Mg2+/Ca2+ supplement: 50 mM MgCI2, 10 mM CaCI2, 10 mM Tris-HCI pH 7.5 • Phenol:trichloromethane:iso-amyl alcohol (25:24:1) • DNAase I stop solution: 400 mM NaCI, 30 mM EDTA, 1% SDS, 200 ng/ml yeast tRNA • DNAase I dilution buffer: 1 mM MgCI2, 1 mM CaCI2,10 mM Tris-HCI pH 7.5
• DNAase I dilution (prepare just before use and keep on ice): 2 ul DNAase I (1 U/M.I, RQ1, Promega) + 98 ul DNAase I dilution buffer
(to 0.02 U/ul working
cyanol, 0.3% bromophenol blue, 0.37% EDTA made up in deionized formamide (store aliquots at -20°C) • Non-specific DNA (e.g. sonicated salmon sperm DNA)" . BSAb
Method 1. Prepare double-stranded DNA molecule strand only (see text; Figure 2; Protocol 1).
32
P-end-labelled on one
2. To generate G sequence ladder, methylate 32P-end-labelled DNA molecule with DMS and cleave with hot piperidine (Protocol 4). (If necessary. A, C, T sequence ladders can also be prepared by basespecific modification of 32P-end-labelled DNA molecule [13].) 3. Set up binding reactions in 0.5 ml siliconized tubes with 20000 c.p.m. 32 P-end-labelled DNA and protein (include a 'no protein' control) in total volume of 40 ul. These samples are radioactive and must be handled appropriately. Use binding conditions suitable for proteinDNA complex being studied.b 37
s
o
l
u
t
i
Craig Spiro and Cynthia T. McMurray Protocol 3.
Continued
4. Bind at temperature (4°C to 37°C) and for time (few min to overnight) suited to the protein-DNA complex being studied. Prepare reagents for DNAase I digestion and tubes for enzyme dilutions.c 5. Digest for 2 min at room temperature with DNAase I as follows (with appropriate pacing, 10 to 12 reactions can be conveniently handled as a group by treating samples in order): (a) (b) (c) (d) (e)
Put samples at room temperature. Begin 2 min timer countdown. Add 5 (ul Mg2+/Ca2+ supplement to each 40 ul binding reaction. When timer goes off, begin 2 min timer countdown. Add 5 ul appropriate DNAase I dilution to each tube in order and stir with pipette tip. (f) When timer goes off, add 50 ul DNAase I stop solution to each tube in order.
6. Extract with 100 ul phenol:trichloromethane:iso-amyl alcohol. Vortex. Separate phases by centrifugation for several min at full speed in microcentrifuge. 7. Transfer aqueous (upper) phase to 1.5 ml siliconized tube. 8. Precipitate by addition of 250 ul ethanol. Mix. Keep at -20°C for at least 30 min. 9. Collect pellet by full speed centrifugation in microcentrifuge for at least 10 min. 10. Dry pellet in SpeedVac concentrator. 11. Resuspend pellet in 6 ul sequencing stop/load dye. Vortex and spin briefly to collect sample. Repeat vortex and spin. Check that DNA is resuspended by holding 1 ul in pipette tip in front of Geiger monitor. Sample may be stored at -20°C. 12. Before analysis on sequencing gel (Protocol 75) denature sample for 5 min at 90°C and then put on ice. "In the presence of certain protein extracts, the correct amount of DNAase I could be 20 x as much and must be empirically determined. Use gel electrophoresis and autoradiography to determine the dilution of DNAase I that leaves half the molecules at full length. b Excess non-specific DNA (0.4-2.0 pg sonicated salmon sperm DNA) keeps constant the substrate for DNAase I and may reduce excess nicking outside the binding site, but it is not essential and at very high levels can compete for protein binding. BSA can also be included (2-20 ug). c Dilute enzyme just before beginning digestions. Keep diluted enzyme on ice.
2.1.4 Other reagents useful for protection analysis Other enzymes, such as nuclease P1 (9), and chemical nucleases, such as phenanthroline-copper, methidium-propyl EDTA, and ferrous EDTA (re38
2: Footprint analysis of DNA-protein complexes viewed in 10) are also useful reagents in protection experiments. Phenanthroline-copper has been used in a combination gel shift-protection experiment that can overcome the difficulty posed by low occupancy of sites in a binding reaction (11). After allowing complexes to form, protein-DNA complexes are resolved from free DNA on a native polyacrylamide gel (as in Figure 1A, step 2). The protein-DNA complex is digested with the chemical nuclease while still embedded in the gel matrix (11). This approach can also be used to analyse the individual retarded complexes observed in a gel shift (10). Ferrous EDTA produces the smallest chemical nuclease for footprinting— the hydroxyl radical, which is like a reactive water molecule (12). Hydroxyl radical has access which is denied the larger molecules such as DNAase I and it can, therefore, provide valuable complementary information by identifying very small patches of protection. In experimental design, hydroxyl radical footprinting is the same as DNAase I protection (Protocol 3) except for the cutting reagent used. Binding reactions are set up and then exposed to the nuclease, which is prepared from ferrous ammonium sulfate and EDTA stock solutions, mixed at a molar ratio of 1:2. The reaction is typically initiated by addition of 50 mM Fe(II)/100 mM EDTA solution, 0.84% H2O2, and 20 mM sodium ascorbate to final concentrations of 50 uM Fe(II):100 uM EDTA, 0.03% hydrogen peroxide, and 1 mM ascorbate (12). (To add the reagents, place a drop of each of the stock solutions on the side of the tube, and then tap the tubes to mix them with the DNA simultaneously.) Allow the reaction to proceed for 1-2 min at room temperature, then terminate by the addition of an equal volume of stop solution containing 135 mM thiourea (12). (Appropriate cutting conditions must be confirmed so that there is not more than one cut per molecule.) DNA can be purified by phenol:trichloromethane extraction, as in the DNAase I experiment (Protocol 3), then analysed by gel electrophoresis (Protocol 75). Chemical probes which modify specific bases provide information complementary to that obtained with nucleases. Protein-DNA complexes are treated with base-modifying reagents, such as those described for Maxam-Gilbert chemical sequencing (13,14). Dimethyl sulfate (DMS), which modifies purine bases, has been most widely used in protection and interference assays (e.g. 14-15) (see Protocols 4 and 5 and in vivo footprinting section, below). Depending on the method of cleavage after base modification, DMS can detect changes in susceptibility of G (Protocols 4 and 5) or of both G and A residues (13). Reagents that modify other bases have been used, as well, to probe DNA-protein interaction and DNA structure (reviewed in 16, 17). 2.1.5 Interference assays The interference assay is closely related to the protection assay, but the DNA is modified before it is incubated with binding protein so that bases critical for binding can be identified (Figure 1A). (The interference assay cannot be carried out on the genome of a mammalian cell.) Interference assays do have 39
Craig Spiro and Cynthia T. McMurray some advantages over protection assays. Inefficient binding does not hamper an interference experiment, since all of the probe in the slow-migrating complex is protein bound (Figure 1A, step 2). In the protection experiment, on the other hand, low occupancy of a site might result in only small changes in the intensity of bands on the gel, so that changes can be difficult to detect. One problem in the interference experiment is that recovery of the protein-bound and free DNA bands from polyacrylamide may be inefficient. For interference assays, the modification reagent must leave the backbone intact. Protein-DNA complexes are resolved on native gels (Figure 1A, step 2). The protein-bound DNA and free DNA bands are purified, cleaved, and then analysed by gel electrophoresis. Commonly used reagents for interference are DMS, which alkylates purines (Protocol 4; see Section 3.1), and ethylnitrosourea (ENU), which alkylates the backbone phosphates (14). DMS modification followed by cleavage in hot piperidine is G-specific (Protocol 4; Figure 1A, step 5; Figure 5B; ref. 13). A variation on the interference assay is the 'missing nucleoside' experiment (18). The DNA molecule is first treated with the hydroxyl radical to randomly remove nucleosides, then incubated with binding protein. Free DNA and protein-bound DNA are separated by gel retardation and analysed by denaturing gel electrophoresis to identify nucleosides important for binding (18). Protocol 4. Alkylation by DMS (and G sequence reaction)" Equipment and reagents • 200 ml of 5 M NaOH in 600 ml (or larger) beaker for DMS waste . DMS (Fluka) . TE: 10 mM Tris-HCI pH 8, 1 mM EDTA . Piperidine (Fluka)
• DMS stop buffer: 1 M B-mercaptoethanol, 1.5 M sodium acetate, 200 ug/ml yeast tRNA • Lid locks for microcentrifuge tubes (Fisher Scientific)
Method 1. Prepare double-stranded DNA molecule 32P-end-labelled on one strand only (see text; Figure 2; Protocol 1). (NB these samples are radioactive and must be handled appropriately.) 2. Bring 2 x 106to 1 x 107 c.p.m. of 32P-end-labelled DNA molecule to 175 ul in TE. 3. Immediately before using, prepare 1.5% DMS in TE (1.5 ul DMS + 98.5 ul TE) and vortex. Use fume hood for all manipulations of DMS. Decontaminate pipette tip by pipetting 5 M NaOH and then discard to solid DMS waste beaker in hood.a 4. Add 25 ul freshly prepared 1.5% DMS to DNA sample (step 2). Vortex. (Decontaminate pipette tips.) 5. Incubate 3 min at room temperature.b 40
2: Footprint analysis of DNA-protein complexes 6. 7. 8. 9.
Stop the reaction by adding 50 ul DMS stop buffer. Add 750 ul ethanol and vortex. Freeze 10 min in dry ice/ethanol bath. Pellet DNA by spinning 10 min at full speed in microcentrifuge. Discard supernatant to radioactive waste. 10. Wash with 1 ml 70% ethanol. Vortex. Spin at full speed in microcentrifuge and discard supernatant to radioactive waste. 11. Resuspend the sample in 50 ul water. (Sample should be at least 15000c.p.m. per ul.) 12. Molecules (step 11) are ready for use in interference assays (Protocol 5). Cleave a portion of the sample with piperidine for use as G sequencing standard and to check extent of modification. (Continue with step 13 for cleavage and analysis.) 13. Mix 9 ul methylated DNA (step 11) with 91 ul 11% piperidine (prepared fresh by dilution with water). (Manipulations with piperidine must be in properly functioning fume hood.) Put lid locks on tubes. Vortex samples. 14. Heat 30 min at 90°C. (If lid locks were not put on tubes, cover tubes with weights so volatile piperidine does not force lids to pop open.) 15. Spin tubes briefly to collect any condensation and then freeze in dry ice. 16. Evaporate samples to dryness in SpeedVac concentrator (at least 1 h). 17. Dissolve precipitate in 100 ul H2O and evaporate to dryness in SpeedVac. 18. Dissolve precipitate in 50 ul H20 and evaporate to dryness in SpeedVac. 19. Resuspend pellet in 12 ul TE (vortex, spin, vortex, spin) and use Cerenkov scintillation counting to determine c.p.m./ul. Add 8 ul sequencing stop/load dye (Protocol 3) and mix. Samples can be stored at -20°C. 20. For analysis on sequencing gel (Protocol 75), denature samples for 5 min at 90°C and then put on ice. Estimate extent of modification by electrophoresis of unmodified DNA, modified, uncleaved DNA, and DMS-modified, piperidine-cleaved DNA. To be sure of no more than one modified base per molecule, half the molecules should not be cleaved. a Dimethyl sulfate (DMS) is extremely hazardous, but it can be used safely and effectively if handled properly. Always wear protective clothing and use a fume hood with satisfactory air flow when handling DMS. DMS is very unstable in water, ethanol, p-mercaptoethanol, and sodium hydroxide. Therefore, DMS is effectively inactivated during the procedures described. Use a 600 ml (or larger) beaker containing 200 ml 5 M NaOH for disposal of DMS waste. Decontaminate pipettes and pipette tips by pipetting NaOH up and down a couple of times. 6 These conditions have worked well for molecules of different sizes and for different amounts of DNA, but check cleaved molecules by gel electrophoresis to confirm that molecules are modified no more than once each (step 20).
41
Craig Spiro and Cynthia T. McMurray Protocol 5.
DMS Interference
Equipment and reagents Elution buffer: 0.20 M NaCI, 1 mM EDTA, 20 (ig/ml yeast tRNA, 10 mM Tris-HCI pH 8 Piperidine (Fluka)
Spin filtration device (e.g. 0.22 (um Spin-X; Corning/Costar)
Method 1. Prepare 5% polyacrylamide native gel for resolving naked DNA and protein-bound DNA (Figure 1A, step 2).a 2. Incubate 1 X 105 to 2 X 105 c.p.m. methylated probe (Protocol 4; step 11) with sequence-specific DNA-binding protein in 50-100 ul (or in the appropriate volume as determined).a Samples are radioactive, so handle accordingly. 3. After appropriate binding period for the complex being studied, load the binding reaction on to the native gel (step 1), using 1-3 lanes, as necessary. 4. Separate by electrophoresis. 5. Identify and recover the free DNA (fast band) and protein-bound DNA (retarded band). (a) Remove one of the glass plates from the gel. (b) Wrap the gel with cling film and mark with fluorescent paint to allow unambiguous orientation. (c) Expose X-ray film to the wet gel in a light-proof container for about 4 h. (d) Develop X-ray film. (e) Cut spots corresponding to DNA-protein complex and naked DNA from the film. (f) Align film (using spots from fluorescent paint) with gel, and use film as template to cut bands from gel. 6. DNA molecules up to 300 bp can be recovered by crushing and soaking. (Longer molecules should be recovered by electroelution.) (a) Place the band into a microcentrifuge tube and crush by using a pipette tip to roll and press the gel slice against the sides of the tube. (b) Incubate in 0.5 ml elution buffer at 37°C with shaking for 12-16 h. (c) Spin the tube for at least 10 min at full speed in a microcentrifuge to pellet gel fragments as much as possible. (d) Transfer the supernatant to a spin filtration device (e.g. 0.22 um Spin-X; Corning/Costar), and centrifuge 2 min to collect solution containing DNA and to remove gel pieces. 42
2: Footprint analysis of DNA-protein complexes 7. Precipitate DNA by addition of 1 ml ethanol. Keep at -20°C at least 1 h. 8. Spin at least 15 min at full speed in microcentrifuge and discard supernatant. 9. Wash pellet with 1 ml 70% ethanol. Spin at full speed in microcentrifuge. Remove as much of the supernatant as possible. 10. Resuspend pellet in 100 ul 10% piperidine (prepared fresh by dilution with water) (NB all manipulations with piperidine should be in hood). Put lid locks on tubes. Vortex and leave at room temperature 15 min to allow DNA to dissolve. Vortex. Spin briefly to collect. 11. Heat 30 min at 90°C. (If lid locks not put on tubes, cover tubes with weights so volatile piperidine does not force lids to pop open.) 12. Spin tubes briefly to collect condensation and then freeze in dry ice. 13. Evaporate to dryness in SpeedVac concentrator (at least 1 h). 14. Dissolve in 100 ul H20 and evaporate to dryness in SpeedVac. 15. Dissolve in 50 ul H2O and evaporate to dryness in SpeedVac. 16. Resuspend pellet in 6 ul TE (vortex, spin, vortex, spin to resuspend) and use Cerenkov scintillation counting to determine c.p.m./ul. Add 4 ul sequencing stop/load dye (Protocol 3). 17. Analyse DNA from protein-bound and naked DNA bands by denaturing gel electrophoresis (Protocol 75). (Denature samples for 5 min at 90°C and then put on ice prior to loading on gel.) It is important to load the same number of c.p.m. per lane for comparison of proteinbound and naked DNA (try to load at least 5000 c.p.m. per lane.) aThe first several steps are essentially a gel shift experiment scaled up 5-10 times. Appropriate gel and binding conditions (including salt concentration and amount of non-specific DNA) can first be determined using smaller amounts of DNA and protein.
2.2 Analysis of binding on closed, circular plasmid Thermal cyclers and thermostable DNA polymerases allow a simple, direct approach to footprinting (Figure 3). Complexes of protein with closed, circular plasmids or with linear DNA fragments can be analysed by primer extension. Analysis of larger DNA molecules can provide information different from that obtained on shorter fragments, including information on interaction of sites (9, 19). The only special reagents required are sequencing primers that flank the region to be studied (Figure 3A). Test the primers in thermal cycle sequencing reactions (see Protocol 6). Then the region can be analysed to determine the site of and the effects of bound protein (Protocol 7; Figure 3). Reporter plasmids containing fragments of transcriptional control regions are ideal for this analysis. Typically, control regions in such plasmids have 43
Craig Spiro and Cynthia T. McMurray been modified by point mutation and deletion to study the effect of mutations on transcription. These mutant plasmids can be used to address questions about protein-DNA interaction during transcription, including the effect of mutation on the structure and interaction of DNA binding sites (9,19). After incubating protein with DNA, treat the reaction with DNAase I. Then purify the DNA and use the DNA as template for extension of 32P-end-labelled primers (Protocol 7; Figure 3). A single primer was used to analyse a region containing three CREs (cAMP responsive enhancers) in the rat prodynorphin gene (Figure 3B, C). Primers flanking other regions (such as the cap site) can be used to analyse the same DNA samples. While the requirements for the sequencing primers are not rigorous, both primers should have the same or similar Tm. [Tm = 81.5°C + 16.6 log M + 0.41 (%GC) - (500/n) - 0.61(%formamide), where M is the molar salt concentration, %GC is the percentage of Gs + Cs in the primer, and n is the number of bases in the primer (ref. 21).] Primers used for ligation-mediated PCR (described below) are suitable for sequencing and primer extension in these protocols as well. Primers with Tm > 50 consistently work well. Protocol 6. Thermal cycle sequencing of region of interest Equipment and reagents • 10 x Circum vent buffer: 100 mM KCI, 100 mM (NH4)2S04, 200 mM Tris-HCI pH 8.8 at 25°C, 50 mM MgS04 (ref. 22); store in aliquots at -20°C . 3% Triton X-100 • Deep Vent (exo-l DNA polymerase (New England Biolabs, 2 U/ul) • dNTP/ddNTP mixes (prepared in 1 x circumvent buffer):a A: 900 uM dideoxy ATP, 30 uM dATP, 100 uM each dCTP, dGTP, TTP
C: 250 (uM dideoxy CTP, 30 uM dATP, 37 (uM dCTP, 100 uM each dGTP, TTP G: 250 uM dideoxy GTP, 30 uM dATP, 37 (uM dGTP, 100 uM each dCTP, TTP T: 600 uM dideoxy TTP, 30 uM dATP, 37 uM TTP, 100 (uM each dCTP, dGTP . Template-primer mix (for each primer to be used): 1 ul plasmid template (10-100 ng/ul), 2 ul 32P-end-labelled primer (Protocol 7), 1.5 ul 10 x circum vent buffer, 1 ul 3% Triton X-100, 8.5 ul H2O"
Method 1. End label primers (Protocol 1). 2. Prepare thermal cycler by heating block to 95°C. Sequencing reactions will require 2 min denaturation at 95°C, followed by 20 cycles of 30 sec at 95°C, 15 sec at calculated Tm (see text) for the primer, and 40 sec at 72°C; cool to 4°C.C 3. For each primer, label a set of 0.5 ml tubes A, C, G, T, and to each tube add 3 ul of the appropriate dNTP/ddNTP mix. Keep tubes on ice. 4. Prepare template-primer mix for each primer to be used.b Stir with pipette tip and put on ice. 5. To template-primer mix, add 1 (ul Deep Vent (exo-) DNA polymerase (2 U/ul, New England Biolabs) and mix by gentle stirring or pipetting. 44
2: Footprint analysis of DNA-protein complexes 6. Put 3.2 (ul of the template-primer-polymerase mix into each of the four dNTP/ddNTP-containing tubes (on ice) and cover with 1 drop of mineral oil. 7. Put reactions into hot block of thermal cycler and start programme (see step 2).c 8. To completed reactions add 4 pl sequencing stop/load dye (Protocol 3) under the oil. 9. Spin tubes briefly. Samples can be stored at -20°C. 10. Prior to analysis on sequencing gel (Protocol 75), heat samples for 5 min at 90°C, then put on ice. a
These nucleotide concentrations are suitable for Deep Vent (exo-) DNA polymerase (New England Biolabs). Adjust as appropriate if another DNA polymerase is used. 6 For templates with very high GC content, use 1-2 p.1 formamide and reduce the amount of water. "Shorter extension and annealing steps or a two-step (denaturation, extension) programme may also work well (even for primers with calculated Tm as low as 50 °C).
Protocol 7.
DNAase I footprint on plasmid
Equipment and reagents Siliconized microcentrifuge tubes (0.5 ml, 1.5 ml) (Fisher Scientific) DNAase I reagents (Mg2+/Ca2+ supplement; DNAase I stop solution; DNAase I dilution buffer; see Protocol 3) DNAase I dilution to 0.013 U/ul: 2 (ul DNAase I (RQ1, Promega; 1 U/ul) + 148 ul DNAase I dilution buffer (Protocol 31" 2.5 mM dNTP mix: 2.5 mM each dATP, dCTP, dGTP, TTP
Non-specific DNA (e.g. sonicated salmon sperm DNA)b BSA (purified, not acetylated; New England Biolabs)* Phenol:trichloromethane: iso-arnyl alcohol (25:24:1) Deep Vent (exo-) DNA polymerase (New England Biolabs)
Method 1. Label primers (Protocol 7). 2. Check primer extension reactions and prepare sequence standard (Protocol 6).c 3. Set up binding reactions in total of 40 PLul(in0.5 ml siliconized tube) under conditions suited to protein-DNA interaction being studiedb [e.g. prodynorphin enhancer-CREB (cAMP responsive enhancer binding protein) binding (Figure 36-C): 100 ng (30 fmol) CAT reporter plasmid, sequence-specific DNA binding protein (0, 0.05, 0.2, 0.6, 1.2 uM), 1 ug sonicated salmon sperm DNA, 20 (ug BSA (not acetylated), 30 mM KCI, 4% glycerol, 0.5 mM DTT, 10 mM Tris-HCI pH 7.5). Bind 10 min to overnight at 4°C to 37°C as appropriate for protein-DNA complex being studied. 45
Craig Spiro and Cynthia T. McMurray Protocol 7. Continued 4. Prepare reagents for DNAase I analysis (Protocol 3) and tube for enzyme dilution. Dilute DNAase I immediately before use and keep on ice. 5. Digest with DNAase I (see Protocol 3, step 5, for suggestion on processing samples). (a) Equilibrate 2 min at room temperature. (b) Add 5 ul Mg2+/Ca2+ supplement. ( c ) A d d 5 ( u l diluted DNAase I a n d stir with pipette (e) Stop with 50 ul DNAase I stop solution. 6. Extract with 100 ul phenol:trichloromethane:iso-amyl alcohol (25:24:1). Vortex well and spin in microcentrifugeto separate phases. 7. Transfer aqueous to 1.5 ml siliconized microcentrifuge tube and precipitate the DNA with 260 ul ethanol. Keep at -20°C at least 1 h. 8. Spin sample at least 20 min at full speed in microcentrifuge to pellet the DNA. 9. Aspirate all the supernatant and wash with 185 ul 70% ethanol. Vortex and spin at full speed in microcentrifuge. Then aspirate the supernatant. 10. Dry the pellet in SpeedVac concentrator. 11. Resuspend the pellet in 12 ul 1 x circum vent buffer (Protocol 6). Let the pellet dissolve on ice (at least 1 h). 12. Prepare thermal cycler for primer extension by heating block to 95°C. Primer extension will require 2 min at 95°C, followed by 7 cycles of 30 sec at 95°C, 15 sec at calculated Tm for the primer, and 40 sec at 72°C.C 13. Aliquot 3 ul DNA (step 11) to duplicate sets of tubes (on ice) for analysis by primers flanking the region of interest (e.g. Figure 3B, C, dynfp5' and dynfp3'). Store remaining DNA at 4°C. The remaining DNA can be used to analyse other areas of the plasmid with different sets of primers. 14. Prepare master mixes (on ice) for each primer to be used in the analysis (e.g. Figure 36, one mix for dynfp5' primer and another for dynfp3' primer). In the primer extension master mix include, for each DNA sample, 0.5 (ul32P-end-labelled primer, 0.32 ul 10 x circum vent buffer (Protocol 6), 0.2 .ul 3% Triton X-100, 0.3 ul 2.5 mM dNTP mix, 1.58 ul H2O. Mix gently and chill on ice. For regions of very high GC content include 0.25-0.5 JJL! formamide and reduce amount of water. 46
2: Footprint analysis of DNA-protein complexes 15. Add to the master mix (for each sample) 0.3 ul Deep Vent (exo-) DMA polymerase and stir. Keep mix on ice. 16. Add 3.2 pj appropriate master mix (step 15) to each DNA sample on ice and cover samples with one drop of mineral oil. 17. Put samples in 95°C block of thermal cycler and run programme (step 12).c 18. Add 4 ul sequencing stop/load dye (Protocol 3) under the oil. 19. Spin samples briefly. Samples can be stored at -20°C. 20. Before analysis on sequencing gel (Protocol 15), heat samples to 90°C for 5 min then cool on ice. Use sequence reactions (Protocol 6) to identify bases on the gel (e.g. 'G' lane in Figure 3d. a
ln the presence of certain protein extracts, the correct amount of DNAase I could be 20 x as much and must be empirically determined. 6 Excess non-specific DNA (0.4-2.0 ug sonicated salmon sperm DNA) keeps constant the substrate for DNAase I and may reduce excess nicking outside the binding site, but it is not essential and at very high levels can compete for protein binding. BSA can also be included (2-20 M-g)c Primer extension conditions are the same as the conditions that yield good sequence ladders (Protocol SI but with fewer cycles.
3. In vivo footprinting Ligation-mediated polymerase chain reaction (LMPCR) uses (i) nested genespecific primers for specificity and (ii) ligation of a linker to allow amplification of fragments of genomic DNA (3, 23) (Figure 4C). The procedure is specific and sensitive enough for nucleotide-resolution analysis of DNA structure and protein binding within single-copy genes of mammalian cells. Whole genome analysis and genomic footprinting were previously hindered by the complexity and methodological difficulty of the steps (15, 24; reviewed in 25). In contrast, while LMPCR requires many steps, the individual steps are not technically difficult. This section describes the steps necessary for in vivo footprinting: modification of the DNA in vivo, purification of the DNA, and LMPCR (including design of the gene-specific primers, preparation of the unidirectional linker, and amplification of gene-specific fragments). LMPCR allows visualization of each nucleotide (genomic sequence), making possible the direct comparison of naked DNA and DNA in vivo (Figure 5B). In vivo footprinting is a variation of the protection experiment (Figure 1B; Figure 4), in which DNA is modified in vivo, most often with DMS (Protocols 8 and 9}. (Alternatives may also be used, as discussed below.) Genomic DNA is purified and cleaved to generate a collection of fragments (Figure 4A) (Protocols 10 and 12). Gene-specific primers (Figure 4B; Figure 5A) are used to amplify fragments and to label the fragments for analysis on sequencing gels (Protocol 15) (Figure 4C; Figure 5B). 47
Craig Spiro and Cynthia T. McMurmy • Primer 1 is extended to create blunt-ended molecules (Figure 4C, step 2). • A universal linker is ligated to the blunt-ended fragments (Figure 4C, step 3). • PCR with the linker primer and primer 2 amplifies the fragments (Figure 4C, steps 4-6). • The fragments are 32P-end-labelled (primer 3) for visualization by denaturing gel electrophoresis (Figure 4C, step 7). [Footprints may also be visualized by electrophoresis of the unlabelled amplified DNA, electrotransfer to nylon membrane, and hybridization with radiolabelled probe (23, 26, 27)]. Modification of DNA in cultured mammalian cells by DMS is a simple procedure (Protocols 8 and 9), and careful application of standard protocols will provide high-quality DNA (Protocol 10; other procedures, including kits such as G Nome, from Bio 101, can also produce satisfactory DNA). Thus, the source of greatest variability and uncertainty for generating genomic sequence is the design of gene-specific primers (Figure 4B; Figure 5A, and see text, below). Once the DNA is prepared, LMPCR comprises reactions of gene-specific primers with the purified DNA (Figure 4B, 4C; Figure 5). Use of high quality reagents and proper laboratory technique in applying the protocols will generate the genomic sequence (Figure 4; Figure 5). The procedure described for LMPCR (Protocol 14) is adapted from modifications of the original procedure (3) that use Vent DNA polymerase exclusively (28, 29). In addition to simplifying the procedure, LMPCR using Vent DNA polymerase allows direct analysis of DNA with 3'-hydroxyl ends (e.g. DNAase I-cut DNA) (28).
3.1 Modification of DNA in vivo DMS is a small molecule that can freely enter living cells. It does not disrupt protein-DNA complexes and its pattern of modification of bases is well understood: DMS is a very reactive alkylating agent that methylates the N7 of guanines (which is in the major groove of DNA) and to a lesser extent the N3 of adenine (which is in the minor groove) (13, 25, 30). N3 of cytosine and Nl of adenine, both potential sites for reaction, are protected from modification by hydrogen bonds of double-stranded DNA. Cleavage of DMS-modified DNA with hot piperidine (Protocols 8, 9, 11, 12} is G-specific (13, 31). While DMS is an effective probe for in vivo analysis, it is not perfect. DNA interaction with proteins that bind weakly, that bind within the minor groove, that interact with the backbone of DNA, or that bind to sites lacking Gs will be poorly detected by DMS modification. Modified cleavage chemistry allows detection of both Gs and As after DMS modification (32). Other reagents can provide supplementary information (reviewed in refs 25, 30). Reagents used for in vivo modification of DNA must have access to the nucleus and they must be reactive enough to modify the DNA efficiently. The reagent-modified DNA must be compatible with LMPCR. Both potassium 48
2: Footprint analysis of DNA-protein complexes permanganate (33) and UV irradiation (34) have been used to modify the DNA of intact cells for subsequent analysis by LMPCR. Enzymes such as DNAase I and micrococcal nuclease can be used with LMPCR, but they cannot freely enter cells. The enzymes can be introduced into cells after treatment with lysolecithin (33, 35), or the enzymes can be used to treat isolated nuclei (36, 37). Enzymes may also be introduced into intact nuclei attached to tissue culture dishes. Treatment of monolayers of cultured cells with NP40 will remove the plasma membrane, leaving intact nuclei on the dish and accessible to enzymes (38). • Treat monolayers for 10 sec with 1% NP40, 200 mM sucrose, 40 mM NaCl, 5 mM MgCl2, 5 mM EGTA, 30 mM Hepes pH 7.9. • Aspirate NP40-containing buffer. • Wash dish with 20 ml Hepes-buffered saline (150 mM NaCl) supplemented with 2.5 mM CaCl2,1 mM MgCl2. (Inspect the nuclei by light microscopy.) • Digest nuclei with enzyme (e.g. DNAase I), stop reaction with buffer containing SDS and EDTA, and proceed with DNA purification (Protocol JO). DNAase I-cleaved DNA can be used directly for LMPCR with Vent DNA polymerase (28). Micrococcal nuclease leaves 5'-OH groups, so the DNA must first be 5'-phosphorylated (by kinase reaction with T4 polynucleotide kinase and ATP) before proceeding with LMPCR (Protocol 14). Characteristics of reagents for in vivo footprinting have been reviewed (25, 30). Protocol 8. DMS treatment of monolayers of mammalian cells Equipment and reagents Cold PBS Lysis solution: 300 mM NaCI, 10 mM EDTA, 0.2% SDS, 50 mM Tris-HCI pH 8
> DMS(Fluka) . 5 M NaOH for DMS waste (200 ml in 600 ml or larger beaker).
Method 1. Grow cells from 1/2 to nearly confluent (or as suitable for maintaining health of cells) on one or two 15 cm dishes per treatment. Include 1-2 dishes for in vitro DMS treatment ('naked DNA' control). A minimum of 2 x 107 mammalian cells should yield an adequate amount of DNA. 2. Treat with inducers of transcription, as appropriate. (NB Carry out all manipulations with DMS in fume hood.) 3. Bring dishes of cells to fume hood and wash with PBS. 4. Prepare 0.1% DMS immediately before use by dilution into PBS, followed by vortex mixing in fume hood (e.g. add 25 (ul DMS to 25 ml PBS and vortex). Decontaminate pipette tip by taking up and expelling NaOH. 49
Craig Spiro and Cynthia T. McMurray Protocol 8.
Continued
5. Pipette 5 ml 0.1% DMS on to each dish for in vivo modification (decontaminate pipettes by taking up and expelling NaOH). Remember to treat some dishes with PBS alone for naked DMA control. 6. Leave DMS on dish for 10 min at room tempera ture.a 7. Pour DMS from dishes into DMS waste beaker. 8. Wash twice with 8 ml cold PBS (for each wash, allow PBS to cover dish and then pour into DMS waste beaker). 9. Use pipette to aspirate last of second PBS wash and dispose into NaOH/DMS waste beaker. 10. To each dish add 1.5 ml lysis solution and rock to let lysis solution cover dish. 11. Collect viscous lysate with help of rubber policeman and transfer to 15 ml polypropylene conical centrifuge tube (viscous lysate should drop into tube). Purify DNA (Protocol 10). "While these conditions have worked well for several cell types and genes, they may not be appropriate for all. Check size of DNA fragments after cleavage (Protocol 12). Modify if necessary. Incubation time beyond 10 min will not increase modification because of hydrolysis of DMS.
Protocol 9.
DMS treatment of suspension cells
Equipment and reagents Cold PBS Lysis solution: 300 mM NaCI, 10 mM EDTA, 0.2% SDS, 50 mM Tris-HCI pH 8
DMS (Fluka) 5 M NaOH for DMS waste (200 ml in 600 m or larger beaker)
Method 1. Treat cells with inducers of transcription as appropriate. Harvest and wash (3 X 107 to 5 X 107) cells with PBS and then resuspend in 0.5 ml PBS in 15 ml conical polypropylene centrifuge tube (include PBS-only control, which will not be modified with DMS in vivo). 2. Bring cells to fume hood and prepare 0.2% DMS immediately before use (e.g. add 20 p,l DMS to 10 ml PBS and vortex). Decontaminate pipette tip by pipetting NaOH. 3. Add 0.5 ml 0.2% DMS to 0.5 ml cells in PBS (step 1) (include PBS-only control). Tap and swirl tube to mix. 4.Incubate5minatroomtemperature.a 5. Add 9 ml ice-cold PBS. Spin 5 min at 500 x gto collect cells. Discard supernatant to DMS waste. 50
2: Footprint analysis of DNA-protein complexes 6. Wash pellet with 10 ml ice-cold PBS. Spin 5 min at 500 x gto collect cells. Discard supernatant to DMS waste. 7. Resuspend pellet in 1.5 ml lysis solution and purify DNA (Protocol 10). ' Check size of DNA fragments after cleavage (Protocol 72). Modify if necessary.
Protocol 10. Purification of genomic DNA Equipment and reagents • • . •
10 mg/ml RNAase (DNAase-free) 20 mg/ml proteinase K Trichloromethane:iso-amyl alcohol (24:1) Phenol equilibrated to pH > 7.6
• Phenol:trichloromethane:iso-amyl (25:24:1) * TE (Protocol 4}
alcohol
Method 1. To cells in 1.5 ml lysis solution (in 15 ml tubes) (Protocols 8 and 9) add 10 ul 10 mg/ml RNAase (DNAase-free). 2. Rock 20 min at room temperature. 3. Add 45 ul 0.5 M EDTA and 15 ul 20 mg/ml proteinase K. Incubate at 30°C for at least 2 h. (Extensive incubation at 37°C or higher may cause depurination of alkylated DNA.) 4. Lysate (step 3) should be clear. If it has not cleared by 2 h, supplement with 15 ul 20 mg/ml proteinase K, swirl tubes, and continue incubation for another 2 h. Continue incubation until lysate clears. The DNA is not in danger during this incubation, since EDTA, SDS, and proteinase K all inhibit DNAase activity. 5. When lysate has cleared, begin extractions (for solvents, see steps 6-10). Perform extractions (at room temperature) as follows: (a) Add indicated organic solvent, and mix by gentle inversion (30 X) of tubes (do not vortex). (b) Spin 1500 X g for 10 min to resolve phases. (c) Remove the lower (organic) layer using a glass Pasteur pipette. To remove the lower layer insert the pipette to the interface; if aqueous (DNA-containing) phase starts to enter the organic layer, force out a few bubbles to help get through to the organic layer. Leave the interface behind (err on the side of leaving behind some of the organic layer, since the viscous DNA can be at the interface and subsequent extractions will remove traces of organic solvent). 6. Extract with 2.0 ml phenol as described in step 5 (do not vortex samples). After separating the phases from first phenol extraction,
51
Craig Spiro and Cynthia T. McMurray Protocol 10.
Continued
the interface is typically fairly large and the aqueous layer is cloudy. The aqueous will clear and the interface sharpen with subsequent extractions. 7. Extract a second time with 2.0 ml phenol (as described in step 5). Aqueous phase should be clearer. 8. Extract twice with 2.0 ml phenol:trichloromethane:iso-amyl alcohol (25:24:1) (as described in step 5). If the aqueous phase is not clear extract a third time with phenol:trichloromethane:iso-amyl alcohol, otherwise extract with trichloromethane (step 9). 9. Extract with 2.0 ml trichloromethane:iso-amyl alcohol (as described in step 5). Remove all of lower (organic) phase (interface between trichloromethane and aqueous layer will be sharp). 10. For each sample, prepare a 15 ml tube containing 3 ml TE. 11. To aqueous phase (step 9), add 3 volumes cold ethanol. Invert the tube (at least 20 times); stringy, white precipitate will appear (if the precipitated DNA is not visible, collect by centrifugation). Do not let the DNA dry during the following purification procedure. Large genomic DNA will be very difficult or impossible to resuspend if it dries. 12. Remove stringy DNA by spooling around a plastic pipette tip. Carefully lift and transfer to tube containing TE (step 10). The DNA will be difficult to see on the pipette tip when it is lifted out of the liquid. It should come off the tip easily in TE. If it does not come right off, just turn the tip to let the DNA unwind. 13. The DNA (step 12) may dissolve right away, but it may be slow to dissolve. Rock slowly at room temperature for 2-4 h. 14. Prepare tube containing 1.5 ml TE. 15. To samples (step 13), add 330 ul 3 M sodium acetate, and rock to mix. Then add 6.7 ml ethanol and invert the tube (as in step 11) to precipitate the DNA. Spool the DNA (as in step 12) and transfer to tube containing 1.5 ml TE (step 14). Rock at room temperature several hours to dissolve. 16. The samples (step 15) will generally dissolve. If a sample does not dissolve, cut off the end of a 1 ml pipette tip and use that tip to pipette the DNA up and down several times. Rock at room temperature. 17. In vivo DMS-treated DNA must be cleaved by piperidine (Protocol 12). To prepare a portion for cleavage (scale up as needed): (a) Transfer 360 ul DNA (step 16) to 1.5 ml siliconized microcentrifuge tube. (b) Add 40 ul 3 M sodium acetate. 52
2: Footprint analysis of DNA-protein complexes (c) Precipitate with 1 ml ethanol. Collect by centrifugation. (d) Wash pellet with 70% ethanol. (For piperidine cleavage see Protocol 72). 18. DNA from control dishes must be modified in vitro for naked control DNA (see Protocol 11).
Protocol 11. In vitro modification with DMS for naked genomic DNA control (G sequence reaction) Equipment and reagents • DMS stop buffer: 1 M p-mercaptoethanol, 100 ug/ml yeast tRNA, 1.5 M sodium acetate pH 7.
• 5 M NaOH for DMS waste
Method 1. Resuspend 75-175 ug purified genomic DNA from control, PBStreated cells, (Protocol 10) in 175 ul TE in a 1.5 ml tube. (This DNA will be viscous. Cut off end of disposable pipette tip and pipette up and down to help resuspend.) 2. Prepare fresh 1.5% DMS immediately before use (add 3 ul DMS to 197 uJ TE and vortex). Decontaminate pipette tips with NaOH. 3. Add 25 ul 1.5% DMS to 175 ul DNA and vortex. 4. Incubate 2 min at roomtemperature.a 5. Stop with 50 ul DMS stop buffer. 6. Add 750 ul ethanol to precipitate. 7. Put tube in dry ice/ethanol bath for 10 min. 8. Spin tube 10 min at top speed in microcentrifuge. 10. Aspirate supernatant to NaOH/DMS waste. (Remove as much as possible.) 11. Wash pellet with 0.9 ml 70% ethanol (dislodge pellet). 12. For piperidine cleavage of modified DNA, see Protocol 12. "These conditions have worked well for a variety of samples, but they may have to be adjusted to allow direct comparison between in vivo and in vitro alkylated DNA.
Protocol 12. Cleavage of modified DNA with piperidine and preparation for LMPCR Equipment and reagents • Piperidine (Fluka) « TE (Protocol 4)
• 3 M sodium acetate pH 7 • 8 M ammonium acetate
53
Craig Spiro and Cynthia T. McMurray Protocol 12.
Continued
Method NB Transfer piperidine in fume hood. Piperidine is volatile, toxic, and may cause burns. 1. Spin nucleic acid (in 70% alcohol wash; see Protocols 10 and 11) at least 5 min in microcentrifuge to pellet. 2. Aspirate all of the supernatant, but do not allow pellet to dry. 3. Resuspend pellet in 200 ul 10% piperidine (diluted with water immediately before use). Transfer piperidine in fume hood. 4. Put lid locks on tubes. 5. Let pellet dissolve about 15 min at room temperature with intermittent brief vortexing. Make sure pellet is dissolved (it will be clear, so check carefully for floating pellet after vortexing). 6. Incubate at 90°C for 30 min (weights may be put on tubes if lid locks are not available to keep volatile piperidine from forcing lids open). Note: DNA will be cleaved at modified residues by this treatment; RNA will be hydrolysed. 7. Spin tubes briefly to collect precipitate. 8. Place tubes into powdered dry ice or dry ice/ethanol bath to freeze. 9. Evaporate to dryness in SpeedVac concentrator (at least 2 h). 10. Resuspend pellet in 360 ul TE plus 40 ul 3 M sodium acetate. This pellet will generally dissolve easily. If it does not, leave at room temperature for around 30 min and then proceed. 11. Add 1 ml ethanol, mix, and put at -20°C for about 1 h. 12. Spin at least 15 min at full speed in microcentrifuge to pellet DNA. 13. Aspirate all of the supernatant. 14. Resuspend pellet in 500 (ul TE plus 170 ul 8 M ammonium acetate. This pellet should dissolve rapidly. 15. 16. 17. 18.
Add 670 ul iso-propanol to precipitate. Put at -20°C for about 1 h. Spin at least 15 min at full speed in microcentrifuge to pellet. Aspirate supernatant with care (pellets may be loose). Wash once with 180 p.1 of 70% ethanol. Vortex. Spin at least 5 min at full speed in microcentrifuge. Aspirate all of the supernatant. 19. Resuspend pellet in 50 ul H2O. Evaporate in SpeedVac concentrator. This is the final step for removal of piperidine. 20. Resuspend pellet in 30 ul TE. 21. When pellet has dissolved, spin 10 min at full speed in microcentrifuge. Transfer the supernatant, which contains the DNA, to a new 1.5 ml microcentrifuge tube. (Discard any pellet.) 54
2: Footprint analysis of DNA-protein complexes 22. Quantitate DMA by measuring A260. Following the piperidine treatment, assume that the DNA is predominantly single stranded and therefore 40 ug/ml for A260 = 123. Dilute the DNA with TE to A260 = 10 (0.4 (ug/ml) for ligation-mediated PCR. 24. Distribution of DNA fragment sizes can be estimated by electrophoresis on denaturing agarose gels (50 mM NaOH). Average size of 600 bases is good.
3.2 Nested gene-specific primers Amplification of specific, rare fragments of DNA requires nested genespecific primers with successively increasing Tm (Figure 4B; Figure 5A). A set of top strand and bottom strand primers should be synthesized, as follows: (a) Primer 1 should be 20 bases long with 12 G + C. (b) Primer 2 should be 25 bases with 15 G + C. (c) Primer 3 should be 28 bases with 17 or 18 G + C (see Figure 4B and figure legend; Figure 5A). Primer 3 (the labelling primer; Figure 4C, step 7), should be at least 30 bases from the 5' end of the region of interest (see Figure 4B\ legend to 4B; Figure 5A). Avoid primers likely to form structures due to complementary ends (e.g. GGG at 5' end and CCC at 3' end). Because some genes will not accommodate the specific prescription for primers, the length and composition for primers 1-3 will need to be adjusted. Maintain the prescribed Tm (see Figure 4B legend) by compensating for changes in GC composition by changes in length.
3.3 Linker for LMPCR A staggered linker is ligated to the blunt-ended molecules created by extension of gene-specific primer 1 (Figure 4C, step 3) (3, 29). The staggered linker should be prepared in advance and can be stored in aliquots at -20°C. Protocol 13. Preparation of staggered, unidirectional linker for ligation-mediated PCR Method 1. Synthesize oligonucleotides LMPCR.1 and LMPCR.2" (ref. 29), using the 0.2 (jimol synthesis (Applied Biosystems). 2. Desalt by gel filtration (e.g. Econo Pac 10DG column, Bio-Rad) and elute with water. 3. Dry in SpeedVac concentrator. Resuspend in 150 p.I TE and determine molar concentration by measuring absorbance at 260 nm (extinction 55
Craig Spiro and Cynthia T. McMurray Protocol 13.
4.
5. 6.
7.
Continued
coefficients for the primers are 240, 500 for LMPCR.1 and 112, 200 for LMPCR.2). Dilute appropriate volumes of LMPCR.1, LMPCR.2, and 1 M Tris-HCI pH 7.7 to achieve these final concentrations: 20 uM LMPCR.1, 20 uM LMPCR.2, and 250 mM Tris-HCI pH 7.7. For example, to prepare 750 ul of unidirectional linker combine 30 ul 500 uM LMPCR.1, 30 ul 500 (uM LMPCR.2,187.5 ul 1 M Tris-HCI pH 7.7, and 502.5 ul H20. Vortex. After mixing well, aliquot 50 ul into 0.5 ml microcentrifuge tubes. Denature for 5 min at 95°C, cool to 70°C over 2 min, and hold at 70°C for 2 min. Then cool to 22°C over 1 h and hold at 22°C for 1 h. Cool to 4°C over 1 h and keep at 4°C for at least 1 h. Spin tubes briefly. Then store at -20°C.
• LMPCR.1: 5'-GCGGTGACCCGGGAGATCTGAATTC-3';LMPCR.2: 5'-GAATTCAGATC-3'.
3.4 Visualization to nucleotide resolution by LMFCR LMPCR allows visualization of rare changes within single-copy genes for high-resolution genomic sequencing. Changes between naked DNA (not modified in vivo) and in v/vo-modified DNA indicate alterations in DNA sensitivity due to protein binding or structural alteration (Figure 5B). DMSpiperidine treatment produces G ladders, so that protein binding and alterations in DNA structure are detected by changes in the pattern of modification of Gs (Figure 5B). Changes in charge distribution may cause appearance of certain As in this protocol due to alkylation of N7 of adenine (Figure 5B; ref. 9). Amplification with top strand primers yields the sequence of the bottom strand (Figure 5). Amplification through GC-rich regions may be hampered by secondary structure formation. If the pattern on the sequencing gel shows bias toward shorter fragments, include deaza-dGTP in nucleotide mix in place of some of the dGTP (see Protocol 14; recipe for 2.5 mM dNTP mix with deaza-dGTP). If the signal appears weak, reduce the amount of DNA from 2 n_g to 1 ug. If that does not solve the problem, modify the number of cycles of amplification. The labelling step (two cycles) should not be increased. Protocol 14. LMPCR Equipment and reagents 2.5 mM dNTP mix: 2.5 mM each dATP, dCTP, dGTP, TTP; store at -20°C Vent DNA polymerase (New England Biolabs, 2 U/M.I)
10 X First strand buffer: 400 mM NaCI, 50 mM MgSO4, 0.1% gelatin, 100 mM Tris-HCI pH 8.9 (at room temperature); store in aliquots at -20°C
56
2: Footprint analysis of DNA-protein complexes . 2.5 mM dNTP with deaza-dGTP mix: 0.625 mM dGTP; 1.875 mM 7-deaza-dGTP (Boehringer-Mannheim), and 2.5 mM each dATP, dCTP, TTP;' store at -20°C • 10 x Amplification buffer: 400 mM NaCI, 50 mM MgS04, 0.1% gelatin, 1% Triton X-100, 200 mM Tris-HCI pH 8.9 (at room temperature); store in aliquots at -20°C . T4 DNA ligase at SU/^I . 100 mM ATP
10 mg/ml BSA (not acetylated; use, e.g. purified DNA, New England Biolabs) 10 mg/ml yeast tRNA 3 M sodium acetate Siliconized 0.5 ml and 1.5 ml microcentrifuge tubes (Fisher Scientific) unidirectional linker (Protocol 13} primer sets (Figure 4B, Section 3.2)
Method Note: Use master mixes in setting up reactions. Put all common components together and then aliquot to sample tubes. Chill master reaction mixes and add enzymes last, as described below. Volumes given in the protocol are for each sample to be included in the master mix. 1. Label two sets of 0.5 ml siliconized tubes. One set is for top primers and the other for bottom primers (Figure 5A). Each set should contain naked DNA control and the in vivo-modified DNA samples. 2. Put 5 ul DNA (0.4 (ug/ul) into a 0.5 ml siliconized tube.b 3. Equilibrate heating block or thermal cycler to 95°C. (First strand synthesis will require denaturation for 5 min, followed by 30 min at 60°C and 10 min extension at 76°C; cool to 4°C.) 4. Prepare two first strand master mixes—one for top primer set and one for bottom primer set. Include in the first strand mix the following for each reaction: 3 uJ 10 X first strand buffer, 0.3 ul 1 uM primer 1 (top or bottom, as appropriate), 2.4 ul 2.5 mM dNTP mix (or 2.5 mM dNTP with deaza-dGTP mix), 19.05 ul H20. Chill. 5. Add to the chilled master mix, for each reaction, 0.25 ul 2U/ul Vent DNA polymerase. Stir the mix with the pipette tip and keep on ice. 6. Add 25 ul master mix to each tube with 5 ul DNA in 0.5 ml tube on ice. 7. Transfer samples from ice to 95°C heat block. Carry out first strand synthesis (see step 3). 8. During first strand synthesis prepare ligation dilution and ligation reaction master mixes. 9. Include in ligation dilution mix, for each sample: 2.2 ul 1 M Tris-HCI pH 7.5, 0.35 ul 1 M MgCI2,1 ul 1 M DTT, 0.25 ul 10 mg/ml BSA (do not use acetylated BSA), 16.2 ul H2O. Chill and keep on ice. 10. Prepare ligation reaction mix containing, for each sample: 0.25 ul 1 M MgCI2, 0.5 ul 1 M DTT, 0.75 ul 100 mM ATP, 0.125 ul 10 mg/ml BSA, 17.775 ul H2O. Mix and chill, then add in order to master mix, for each reaction: 5 ul unidirectional linker (see Protocol 73) and 0.6 ul 5U/(ul T4 DNA ligase. Stir with pipette tip and keep on ice. 57
Craig Spiro and Cynthia T. McMurray Protocol 14.
Continued
11. To each sample tube (step 7} add in order 20 ul ligase dilution mix (step 9), stir with pipette tip, and 25 ul ligation reaction mix (step 10). Then mix by stirring. 12. Incubate at least 6 h at 16°C. 13. Prepare precipitation salt mix containing, for each reaction: 8.4 ul 3 M sodium acetate pH 7 and 1 ul 10 mg/ml yeast tRNA. Keep on ice. 14. Put ligation reactions on ice (after step 12) and add 9.4 ul precipitation salt mix (step 13); stir. Add 220 ul ethanol and vortex. Put samples at -20°C for at least 1 h. 15. Spin samples for 15 min at full speed in microcentrifuge and aspirate all of the supernatant. 16. Wash pellet once with 180 ul of 70% ethanol. Spin at least 5 min at full speed in microcentrifuge. Aspirate all of supernatant. Dry in SpeedVac concentrator. 17. Resuspend pellet in 70 ul H20. Vortex. Let dissolve 30 min at room temperature with intermittent vortexing. Then place samples on ice. Prepare amplification and Vent DNA polymerase mixes during this time. 18. Equilibrate thermal cycler to 95°C. (Amplification programme: 4 min at 95°C, then 20 cycles of 1 min at 95°C, 2 min at 66°C, 3 min at 76°C with an increase of 5 sec per cycle of the extension time at 76°C; then a final additional extension of 5 min 30 sec at 76°C; followed by cooling to 4°C.) 19. Prepare two amplification mixes (one for top and the other for bottom primer set). Include in the amplification mix, for each sample: 10 ul 10 x amplification buffer, 1(1ul10 pM LMPCR.1 (Protocol 73), 1 ul 10 uM primer 2 (top or bottom, as appropriate), 8 ul 2.5 mM dNTP mix (or dNTP with deaza-dGTP mix), 10 ul H20. Stir and chill on ice. 20. Prepare Vent DNA polymerase mix containing, for each sample: 0.3 (xl 10 x amplification buffer, 2.2 ul H2O, and 0.5 ul 2U/ul Vent DNA polymerase. Stir. Keep on ice. 21. To DNA samples on ice (step 17) add 30 ul of appropriate (top or bottom) amplification mix (step 19). 22. Add 3 ul Vent DNA polymerase mix (step 20) to each sample and cover reaction mix with two drops mineral oil. 23. Place samples in thermal cycler (block at 95°C). Run programme (step 18). 24. During amplification, prepare bottom) (Protocol 1).
32
P-end-labelled primer 3 (top and
58
2: Footprint analysis of DNA-protein complexes 25. At conclusion of amplification (step 23), put samples on ice and heat thermal cycler to 95°C. (End labelling will require 3 min at 95°C, followed by 2 cycles of 1 min at 95°C, 2 min at 69°C, 10 min at 76°C, followed by cooling to 4°C). 26. Prepare two end-label master mixes (top and bottom) containing, for each sample: 0.8 (xl 10 x amplification buffer, 2.3 ul end-labelled primer (step 24), 4 ul 2.5 mM dNTP mix (or dNTP with deaza-dGTP mix), 0.4 ul H2O. Stir and chill, then add, for each sample, 0.5 ul 2 U/ul Vent DNA polymerase. 27. Pipette 8 ul appropriate (top or bottom) end-labelling mix under the oil to each sample on ice. 28. Place samples in thermal cycler (block at 95°C). Denature 3 min at 95°C, then extend 32P-labelled primer (see step 25). (One cycle is probably sufficient, and no more than two are needed to label the amplified DNA.) 29. Prepare Vent reaction stop solution. Include for each reaction: 25 ul 3 M sodium acetate pH 7, 2.5 ul 1 M Tris-HCI pH 7.5, 2 ul 0.5 M EDTA, 2 ul 10 mg/ml yeast tRNA, 20.5 ul H2O. 30. To end-labelled samples (step 28) introduce 52 ul Vent reaction stop solution under the oil. 31. Extract with 250 ul phenol:trichloromethane:iso-amyl alcohol (25:24:1). Vortex. Spin at full speed in microcentrifuge. 32. Transfer aqueous to 1.5 ml siliconized tube. Add 2.5 volumes (about 425 ul) ethanol to precipitate. Place samples at -20°C for at least 1 h. 33. Spin samples 15 min at full speed in microcentrifuge. Aspirate the supernatant. 34. Resuspend the sample in 6.2 ul TE, vortex, spin briefly. (You can check that sample is resuspended by taking up 1 ul in pipette and holding in front of Geiger monitor.) 35. Add 4 ul sequence stop/load dye (Protocol 3), vortex, spin briefly. Sample is ready for analysis on sequencing gel (Protocol 15) or may be stored at -20°C. * May be necessary for analysis of GC-rich regions; see text. 'As little as 1 ug DNA can suffice and lowering the amount of DNA may increase the signal.
Protocol 15. Sequencing gel Equipment and reagents Rain-X car windshield treatment Gel lift paper (Schleicher and SchuelD*
For in vitro footprints: 0.4 mm thick, 40 cm long gelc Well-forming combs (recommended)d
59
Craig Spiro and Cynthia T. McMurray Protocol 1.5.
Continued
Notes 1. Estimate proper length of run according to migration of dyes. Bromophenol blue migrates with 26 base fragment in 6% gel and with 19 base fragment in 8% gel; xylene cyanol migrates with 106 base fragment in 6% gel and with 76 base fragment in 8% gel. 2. In the initial run, use only a portion (perhaps one-quarter) of sample in order to allow later adjustment of sample loading for equal signal intensity. Method 1. Treat the inside (gel side) of inner plate with Rain-X or other siloxanecontaining windshield treatment to prevent gel from sticking to glass. Assemble sandwich of plates with spacers. 2. Prepare 7 M urea, 6% (or 8%) acrylamide sequencing gel. 3. Add 10% ammonium persulfate. Pour gel using a syringe. Hold sandwich at about 45° angle at start and pour gel along spacer to avoid trapping bubbles. Lower plates as you pour the gel. 4. Lay gel flat on bench and insert comb. Let gel polymerize at least 45 min. 5. Prepare 1 x Tris-borate-EDTA running buffer. Wet area around comb and carefully remove comb from gel. 6. Set up gel in apparatus. Rinse wells using pipette and upper reservoir buffer. 7. Pre-run gel at 50 W (40 cm gel) or 75 W (62 cm gel) for at least 30 min to allow gel to warm. (Constant power will maintain temperature during the run.) 8. Denature samples (in sequencing stop/load dye (Protocol 3); 90°C for 5 min) then place on ice before loading. 9. Very important: after pre-running gel, rinse wells (using pipette and buffer from upper reservoir) to clear out urea etc. before loading samples. 10. Run denatured samples for appropriate time (at least until bromophenol blue runs off the gel). 11. After electrophoresis, remove gel (remember that lower buffer will be radioactive) and cool under running water. 12. Carefully remove inner (siliconized) plate. Gel should stick to other plate. 13. For gels longer than 40 cm (i.e. too long for gel dryer), put spacer across gel at 40 cm from the bottom of the gel and cut gel by sliding spatula along the spacer. Sections should be peeled separately. Bottom (40 cm) section is the most important. 60
2: Footprint analysis of DNA-protein complexes 14. Press gel lift paper against 40 cm bottom section of gel and apply pressure along entire surface to ensure good contact. For 6% gel, peel the paper with attached gel right from the glass. For 8% gels, turn the paper/gel/glass sandwich over and bring out over edge of bench. Then peel paper with attached gel off the glass while gradually sliding glass with attached gel over edge of bench. 15. Dry gel.
16. Expose film or phosphor storage screen to dried gel.e • Better than 3MM, especially with 8% gels. b This mixture costs little more than the ingredients, reduces handling of acrylamide, and eliminates the need to dissolve urea. C 6% gels are easier to handle than 8% gels, they stick better to paper for drying; but 7% or 8% gels can help resolution of smaller fragments. For in vivo footprints, longer gels are usually required (62 cm should suffice). The amount of information in a sequencing gel can be increased by running electrolyte gradient gels, as described by Sheen and Seed (39). The bottom 40 cm will be most informative. ^Shark's tooth combs will work as long as there are blank wells between samples. (In contrast to sequencing reactions in which neighbouring lanes would have different bands, in a footprint reaction the bands in neighbouring lanes are the same; therefore, space between lanes can be helpful.) " Kodak Biomax MR single emulsion film is recommended as it gives good resolution with low background, but the sensitivity is lower than with double emulsion film, so that exposures will be longer.
References 1. Galas, D. J. and Schmitz, A. (1978). Nucleic Acids Res. 5,3157. 2. Kolchinsky, A. M., Mirzabekov, A. D., Gilbert, W., and Li, L. (1976). Nucleic Acids Res. 3,11-18. 3. Mueller, P. R. and Wold, B. (1989). Science 246,780. 4. Brenowitz, M., Senear, D. F., Shea, M. A., and Ackers, G. K. (1986). In Methods in enzymology (ed. C. H. W. Hirs and S. N. Timasheff), Vol. 130, p. 132. Academic Press, London. 5. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983). Nucleic Acids Res. 11, 1475. 6. Dyer, R. B. and Herzog, N. K. (1995). Biotechniques 19, 192. 7. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner W. (1989). Nucleic Acids Res. 17,6419. 8. Andrews, N. C. and Faller, D. V. (1991). Nucleic Acids Res. 19, 2499. 9. Spiro, C., Bazett-Jones, D. P., Wu, X., and McMurray, C. T. (1995). J. Biol. Chem. 270, 27702. 10. Sigman, D. S. and Chen, C. B. (1990). Ann. Rev. Biochem. 59, 207. 11. Kuwabara, M. D. and Sigman, D. S. (1987). Biochemistry 26, 7234. 12. Price, M. A. and Tullius, T. D. (1992). Methods in enzymology (ed. D. M. J. Lilley and J. E. Dahlberg), Vol. 212, p. 194. Academic Press, London. 13. Maxam, A. M. and Gilbert, W. (1980). Methods in enzymology (ed. L. Grossman and K. Moldave), Vol. 65, p. 499. Academic Press, London.
61
Craig Spiro and Cynthia T. McMurray 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29.
30. 31. 32. 33. 34. 35. 36. 37. 38. 39.
Siebenlist, U. and Gilbert, W. (1980). Proc. NatlAcad. Sci. USA 77, 122. Church, G. M. and Gilbert, W. (1984). Proc. NatlAcad. Sci. USA 81,1991. Palacek, E. (1991). Crit. Rev. Biochem. Mol. Biol. 26, 151. Hayes, J. J. (1995). Chemistry and Biology 2,127. Hayes, J. J. and Tullius, T. D. (1989). Biochemistry 28, 9521. Spiro, C. and McMurray, C. T. (1997). /. Biol. Chem. 272, 33145. Collins-Hicok, J., Lin, L., Spiro, C., Laybourn, P. J., Tschumper, R., Rapacz, B., and McMurray, C. T. (1994). Mol. Cell. Biol. 14, 2837. Meinkoth, J. and Wahl, G. (1984). Anal. Biochem. 138,267. Sears, L. E., Moran, L. S., Kissinger, C., Creasy, T., Perry-O'Keefe, H., Roskey, M., et al. (1992). Biotechniques 13, 626. Pfeifer, G. P., Steigerwald, S. D., Mueller, P. R., Wold, B., and Riggs, A. D. (1989). Science 246, 810. Church, G. M., Ephrussi, A., Gilbert, W., and Tonegawa, S. (1985). Nature 313, 798. Saluz, H. P. and Jost, J. (1993). Crit Rev. Eukaryotic Gene Exp. 3, 1. Pfeifer, G. P. and Riggs, A. D. (1993). In Methods in molecular biology, Vol. 23. DNA sequencing protocols (ed. H. and A. Griffin), p. 169. Humana Press, Totowa, NJ. Hornstra, I. K. and Yang, T. P. (1993). Anal. Biochem. 213,179. Garrity, P. A. and Wold, B. J. (1992). Proc. NatlAcad. Sci. USA 89, 1021. Mueller, P. R., Garrity, P. A., and Wold, B. (1992). In Current protocols in molecular biology (ed. F. A. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl), p. 15.5.1. John Wiley & Sons, New York. Cartwright, I. L. and Kelly, S. E. (1991). Biotechniques 11, 188. Mattes, W. B., Hartley, J. A., and Kohn, K. W. (1986). Biochim. Biophys. Acta 868, 71. Strauss, E. C., Andrews, N. C., Higgs, D. R., and Orkin, S. H. (1992). Mol. Cell. Biol. 12, 2135. Pfeifer, G. P. and Riggs, A. D. (1991). Genes Dev. S, 1102. Pfeifer, G. P., Drouin, R., Riggs, A. D., and Hohnquist, G. P. (1992). Mol. Cell. Biol. 12, 1798. Zhang, L. and Gralla, J. D. (1989). Genes Dev. 3, 1814. Rigaud, G., Roux, J., Pictet, R., and Grange, T. (1991). Cell 67, 977. McPherson, C. E., Shim, E., Friedman, D. S., and Zaret, K. S. (1993). Cell 75, 387. Leeds, J. M., Slabaugh, M. B., and Mathews, C. K. (1985). Mol. Cell. Biol. 5, 3443. Sheen, J. Y. and Seed. B. (1988). Biotechniques 6, 942.
62
3
In vitro transcription and characterization of transcription factors AUSTIN J. COONEY, SOPHIA Y. TSAI, and MING-JER TSAI
1. Introduction Once a cw-element and transacting factor have been determined to be important for regulation of transcription of a gene, gel retardation, DNAase I footprinting, methylation interference analyses, and in vitro transcription assays are generally employed for characterization of a factor during purification. The majority of transcription factors are present in very low quantities within a cell, making purification long and arduous, and requiring large quantities of starting material. Thus, the initial characterization of the factor is undertaken with partially purified material. This permits elucidation of vital information about the factor, such as the molecular weight, subunit composition, and interactions, if any, with non-DNA binding factors, before complete purification of the factor (1). This information is mostly derived from analysis of data from a combination of in vitro transcription assays and chromatographic and electrophoretic techniques, which will be covered in this chapter.
2. In vitro transcription assays In vitro transcription assays involve the reconstitution of gene expression in a test tube. They can be used for many different functional purposes, including mechanistic and kinetic studies of transcription, analysis of promoter and response elements, and identification and purification of transcription factors. In vitro transcription assays can also be used as functional assays to monitor the activity of a transcription factor during purification. In vitro transcription assays can also be used to monitor and study the activities of both DNA binding and non-DNA binding transcription factors (1). Using a chicken ovalbumin upstream promoter-transcription factor (COUP-TF)-dependent in vitro transcription assay, it was shown that the ovalbumin promoter activity was depen-
Austin J. Cooney et al. dent on an additional factor S300-II, a non-DNA binding factor. An S300-IIdependent in vitro transcription assay was used to purify and clone S300-II, which turned out to be identical to TFIIB (1,2). The basic components of a reconstituted in vitro transcription assay are a source of general transcription factors, specific transcription factors, and reporters. Reporters can be either driven by endogenous promoters such as the oestrogen responsive vitellogenin or mouse mammary tumour virus (MMTV) promoters or driven by minimal promoters containing specific response elements (3, 4). Minimal promoters containing only TATA boxes from the ovalbumin promoter have been successfully used with steroid response elements in in vitro transcription assays (5-8). Generally, multiple copies of a single response element are required to yield a robust response because endogenous promoters are complex and contain multiple response elements for various types of transcription factors, which generally interact synergistically to regulate gene expression (3, 4). For example, using a single progesterone response element led to 5-fold stimulation above the basal promoter activity while two copies led to a 30-fold induction (5). The reporter or template can be either linear or circular and similar results are obtained with either template (9). Several different types of in vitro transcription assays have been developed that are either direct, i.e. radiolabel is incorporated into the transcript, or indirect where the transcript is detected using radiolabelled probes. Direct assays include run-off assays or the G-free cassette assay. Indirect assays include nuclease SI analysis, primer extension, or RNAase protection. The G-free in vitro transcription assay is a direct approach to monitor gene expression and is based on the properties of the Tl RNAase which preferentially digests RNA containing G residues. Thus, Sawadogo et al. developed a G-free cassette, which when expressed would be resistant to Tl RNAase activity (10, 11). The transcription initiation site for the template lies 17 nucleotides within the 5' boundary of the G-free cassette; this permits distinction between specific and non-specific (read-through) transcriptional events after Tl RNAase digestion (Figure 1). Specific transcripts correctly initiated will be 360 nt long, while non-specific events, initiated anywhere within the plasmid, will yield a product of 377 nt, distinguishable on a denaturing urea polyacrylamide gel (Figures 1 and 2). A second G-free template is generally incorporated into the assay as an internal control. It contains a shorter G-free cassette (i.e. 190 nt specific and 200 nt non-specific transcripts) to permit easy distinction from the test plasmid (360 and 377 nt) (Figure 1). The second Gfree cassette is put under the regulation of a second general promoter, such as the adenovirus major late promoter. Such an internal control will allow the researcher to control for effects on basal transcription, which would have similar affects on both the control and test promoters. The G-free assay depicted in Figure 1 is given in detail in Protocol 2. Figure 2 is an illustration of the use to which the G-free in vitro transcription assay can be put. In this experiment progesterone receptor (PR) activity 64
3: In vitro transcription
Figure 1. Schematic diagram of the G-free in vitro transcription assay. (A) The test template (PRE TATA) which, after RNAase T1 processed transcription, yields correctly (360 nt) and incorrectly initiated (read-through) transcripts (377 nt). (B) The internal control, adeno major late promoter driven template, which yields correctly (190 nt) and incorrectly (200 nt) initiated transcripts.
is being assayed. The templates are PRE2 pLovTATA (progesterone response element two times upstream of the ovalbumin TATA box, lanes 1-6) and pLovTATA (lanes 7-9). When increasing amounts of progesterone receptor, in the presence of progesterone, are added, there is a dose-dependent increase in the specific transcript (arrow 3, lanes 2-6) relative to basal activity in the absence of receptor (lane 1). This increase is specific for the PRE elements as no increased expression is observed with the parent vector, pLovTATA which lacks the PREs (lanes 7-9) or indeed with the internal control (arrows 1 and 2). Note that the progesterone receptor only affects the level of correctly initiated transcripts (arrow 3, lanes 1-6) and not the non-specific transcription (arrow 4, lanes 1-6). Thus, in one test tube one can control for non-specific and specific effects with two templates that each yield two processed transcripts, which can be distinguished by the correctly and incorrectly initiated transcriptional events. This assay can be applied to many problems and has been used for functional and kinetic studies. A typical in vitro transcription assay involves the incubation of purified templates with RNA polymerase and ribonucleotides, the basal transcription machinery, and purified transcription factors under the appropriate temperature, salt, and buffer conditions. Transcription proceeds for 45-60 min, subsequently the reaction is terminated and the transcripts purified. We provide protocols for the preparation of transcriptionally active nuclear extracts and for the G-free assay itself which will be covered in this chapter. The con65
Austin J. Cooney et al.
Figure 2. Progesterone receptor dependent in vitro transcription. Progesterone receptor and progesterone (10 7 M) were added in increasing amounts to either PRE 2 pLovTATA (lanes 1-6) or the control pLovTATA (-PREI (lanes 7-9). Arrow 1, correctly initiated transcript from the adeno major late internal control; arrow 2, incorrectly initiated transcript from the adeno major late promoter; arrow 3, correctly initiated transcript from either PRE; pLovTATA or pLovTATA; and arrow 4, the incorrectly initiated transcript from either of the test templates PRE2 pLovTATA or pLovTATA.
ditions for optimum in vitro transcription will vary from factor to factor analysed and templates, assay, and extracts utilized. However, the optimum conditions can be determined empirically by systematically varying each of the components and analysing the results in in vitro transcription. Some of the variables that can be altered include the amount of transcription factor added, the concentrations of salt and Mg 2+ > as well as the amount of nuclear extracts. An excellent reference for such systematic optimization of in vitro transcription is the paper by Bagchi etal., who optimized PR-dependent in vitro transcription (9). The general transcriptional machinery, which includes RNA polymerases, basal transcription factors TF1IB-H, and associated transcription activation factors (TAFs) are generally contributed from nuclear extracts. Nuclear extracts that support high levels of in vitro transcription have been successfully generated form HeLa cells and Drosophila embryos (4, 12). Below we describe the generation of nuclear extracts from HeLa cells (Protocol I). See Chapter 9 for the methods used for preparation of such extracts from rat brain and their use in neuronal promoter analysis. 66
3: In vitro transcription Protocol 1. Preparation of HeLa cell nuclear extract Eauioment and reagents PBS: 150 mM NaCI, 16 mM Na2HP04,16nM NaH2P04 pH 7.3 Buffer A: 10 mM Hepes pH 7.9, 1.5 mM MgC12, 10 mM KCI, 2 mM DTT8 Buffer C: 20 mM Hepes pH 7.9, 20% glycerol, 1.5 mM MgC12, 0.2 mM EDTA, 2 mM DTT3
Buffer D: 20 mM Hepes pH 7.9,20% glycerol, 0.1 M KCI, 0.2 mM EDTA, 5 mM MgC12, 2 mM DTP Dialysis bag, M, cut-off 12000-14000 Da Beckman centrifuge, JA20 or JA14 rotor Dounce homogenizer (glass, B-type pestle)
Method 1. Harvest HeLa cells from culture by centrifuging at 1000 x g at 4°C for 10 min in a Beckman JA20 or JA14 rotor, depending on culture volume. 2. Resuspend the cell pellet in 5-10 packed cell volumes (PCV) of icecold PBS. 3. Centrifuge at 500 x g at 4°C for 10 min. 4. Resuspend the cell pellet in 5 x PCV of buffer A. 5. Centrifuge at 500 x g at 4°C for 10 min. 6. Aspirate the supernatant and resuspend the cells in 2 x PCV of buffer A. 7. Transfer the cells to a Dounce homogenizer. Lyse the cells with 10 strokes. 8. Examine the homogenate microscopically for maximum cell lysis (90% of cells should be lysed). 9. Centrifuge at 500 x g at 4°C for 10 min. Carefully aspirate the supernatant and recentrifuge the pellet at 27000 x g in a Beckman JA20 rotor at 4°C for 20 min to remove any residual supernatant. 10. Resuspend the nuclei pellet in 0.5 X PCV of buffer C containing 0.6 M NaCI or 0.66 x PCV of buffer C containing 0.55 M NaCI. 11. Transfer to an appropriately sized Dounce homogenizer and lyse the nuclei with 10 strokes. 12. Transfer the lysate to 50 ml polypropylene centrifuge tubes and cover with parafilm. Incubate on ice for 30 min, vortexing gently at 5 min intervals. 13. Centrifuge at 27 000 x g for 30 min at 4°C in a JA20 rotor. 14. Recover the supernatant (nuclear extract) and dialyse against 100 volumes of buffer D for 4 h, with one change of buffer. 15. Centrifuge the nuclear extract at 27000 x g for 20 min at 4°C in a JA20 rotor. Recover the supernatant, aliquot, and freeze at -80°C. " DTT is added fresh.
67
Austin J. Cooney et al. Protocol 2.
In vitro transcription using the G-free cassette
Equipment and reagents Transcription reaction mixture: 12.5-200 ng of control and test template DNAs;3 60 mM KCI, 12 mM Hepes pH 7.9, 5 mM MgC12, 12% glycerol, 0.12 mM EDTA, 2 mM DTT; ribonucleotide mix:500 nM ATP, CTP; 20 uM UTP; 2 (uCi/reaction [32P]UTP (800 Ci/mM); 10 lU/reaction nuclease T1; 1 fimol/reaction 3'-O-methyl GTP; herring sperm DNA (0.5-1 ug/reaction); 3-5 ul nuclear extract Stop solution: 10 mM Tris-HCI pH 8.0, 1 mM EDTA, 8 M urea
Transcription termination mixture: 30 mM Tris-HCI pH 8.0,10 mM EDTA, 0.5% SDS; 120 ug/H.1 yeast tRNA; 400 ug/ml proteinase K Phenol:trichloromethane:/so-pentanol (25:24:1 v/v; phenol buffered to pH 5.0 with 10 mM sodium acetate) 3 M sodium acetate pH 5.2 80% deionized formamide, 1 mM EDTA, 1 ng/ml xylene cyanol, 1 ng/ml bromophenol blue Dry ice/ethanol bath
Method 1. Make up the transcription reaction mixture in an Eppendorf tube to a final reaction volume of 25-30 uJ. Mix by gentle vortexing and spin down briefly. Start the reaction by adding the ribonucleotide mix and incubate at 30°C for 45 min. 2. Terminate transcription by adding 85 uJ transcription termination mixture. 3. Incubate at 37°C for 30 min. 4. Add 200 ul urea stop solution per reaction. 5. Extract twice with an equal volume of phenol:trichloromethane:/sopentanol. 6. Aspirate the upper aqueous phase and add one-tenth volume 3 M sodium acetate (pH 5.2),10 pig yeast tRNA, and 2.5 volumes of absolute ethanol. Incubate in a dry ice/ethanol bath for 30-40 min. 7. Centrifuge at 13000 x gfor 60 min at 4°C. Wash the pellet once with 80% ethanol (-20°C). 8. Centrifuge for 5 min, aspirate the supernatant, and dry the pellet. 9. Resuspend the pellet in 4 ul of 80% deionized formamide, 1 mM EDTA, 1 ng/ml xylene cyanol, 1 ng/ml bromophenol blue. Heat at 95°C for 5 min and cool quickly on ice. 10. Run the samples on a 7% acrylamide urea sequencing gel. Electrophorese at 1800 V. 11. Fix the gel in 10% methanol and 10% acetic acid for 5 min and dry the gel. 12. Autoradiograph overnight at —70°C with two intensifying screens. " The amount of DNA added depends on the strength of the promoter.
68
3: In vitro transcription
3. Determination of the molecular weight of native transcription factors Molecular weight determination under native conditions allows the researcher to estimate the total size of the factor/complex binding to an element and may aid in identifying whether the binding species is a monomer, dimer, or higher complex. Separation of factors on the basis of size, under native conditions, has the advantage of allowing direct assay of DNA binding and transcriptional activities, to assign the factor's molecular weight relatively easily with samples where purity is not very high. In order to determine accurately the molecular weight of the factor under native conditions, the factor must be fairly globular in conformation. Transcription factors exist as an arrangement of globular domains and thus lend themselves to this type of analysis.
3.1 Molecular weight determination using gel filtration chromatography Gel nitration chromatography separates proteins on the basis of their size, where size refers to the physical dimensions or Stokes' radius, rather than the molecular weight, which is related to mass. However, in the case of globular proteins that have a roughly spherical tertiary structure, the Stokes' radius is proportional to the molecular weight. Thus a semi-logarithmic standard curve can be produced plotting Km versus log molecular weight, where Kav is the partition coefficient (see Figure 3). The partition coefficient is defined by the equation
where Ve = elution volume of the protein, V0 = void volume, and Vt = total volume.
Figure 3. The sigmoidal dependence of Kav, the partition coefficient, on the logarithm of the molecular weight (Mol. Wt.).
69
Austin J. Cooneyet al. Thus the molecular weight of an unknown factor can be determined by linear regression from such a standard curve constructed from the chromatography of standard proteins of known molecular weight. The gel nitration matrix consists of porous beads that sieve proteins molecularly from the largest to the smallest. Gel filtration achieves two purposes: it permits determination of the molecular weight of a native factor binding to a response element (13,14) and it also achieves an additional step in the purification of the transcription factor (15, 16). Gel filtration columns can be calibrated with gel filtration protein standards of known molecular size (Bio-Rad Laboratories, Pharmacia LKB Biotechnology, or Sigma Chemical Co.). Identification of the elution volume of the DNA binding or transcriptional activities allows determination of the molecular weight of the factor by reference to the standard curve. Table 1. Fractionation ranges of some commercially available gel filtration matrices Matrix type9
Fractionation rangeb
SephadexG-10 SephadexG-15 Bio-Gel P-2 Bio-Gel P-4 Sephadex G-25 Bio-Gel P-6 Bio-Gel P-10 Sephadex G-50 Bio-Gel P-30 Bio-Gel P-60 Sephadex G-75 SephacrylS-100 Bio-Gel P-100 Sephadex G-100 Sephacryl S-200 Sephadex G-150 Sephadex G-200 Bio-Gel A-0.5M Sephacryl S-300 Bio-Gel A-1.5M Sepharose CL-6B Bio-Gel A-5M Bio-Gel A-15M Sepharose CL-4B Sepharose CL-2B Bio-Gel A-50M Bio-Gel A-150M
<7 x 102 <1.5X 103 1 X10 2 -1.8X 103 8 X 1 02-4 X 103 1 X 103-5X 103 1 X10 3 -6X10 3 1.5 X 103-2X 104 1.5 X 103-3X 104 2.5 X 103-4X 10" 3X 103-6x 104 3x 103-8X 104 1 X 1 03-1 X 105 5X 103-1 X 106 4X 103-1.5X 105 5X 103-2.5X 10 5 5x 103-3x 105 5 x l03-6 x 105 1 X 104-5X 105 1 X10 4 -1.5X10 6 1 x 104-1.5x 106 1 x 104-4x 106 1 X 104-5X 106 4x 104-1.5X 107 6x 104-2X 107 7 x 104-4X 107 1 X10 5 -5X10 7 1 X10 6 -1.5X10 8
" Sephadex, Sephacryl, and Sepharose are supplied by Pharmacia LKB Biotechnology and Bio-Gel is supplied by Bio-Rad. 6 The fractionation range denotes the molecular sizes of proteins that elute in a volume equal to the bed volume to proteins that elute in the void volume. 70
3: In vitro transcription Selection of the appropriate gel filtration matrix is important. Initially, for an uncharacterized transcription factor whose molecular weight is unknown, a matrix with a broad fractionation range is appropriate. However, once the molecular weight of the factor has been estimated, the most accurate determination can be achieved with a matrix from which the factor will elute midway in the fractionation range, where the plot of Km vs. log molecular weight is linear (see Figure 3). Sephacryl S-300 (Pharmacia) or Bio-Gel A-1.5M (Bio-Rad) have excellent broad fractionation ranges from 104 to 1.5 X 106 Da relative molecular mass (Mr), and are useful in the initial determinations of molecular weights. A number of different matrices, with different fractionation ranges and characteristics, are produced by Pharmacia LKB and BioRad (see Table 1). A potential, but infrequent, problem with gel filtration matrices is nonspecific interaction between a transcription factor and the gel matrix, leading to retardation of its elution or the opposite effect. This has been observed for some steroid receptors when agarose A15M or A-1.5M (Bio-Rad) is used; where this phenomenon is suspected, i.e. Km > 1, change the matrix from Sepharose to acrylamide or vice versa. However, the molecular weights of many native factors have been determined by gel filtration (1). Pharmacia also produces pre-poured gel filtration columns (Superose) for use with their FPLC system, which can be used for all the purposes described here. Protocol 3. Molecular weight determination by gel filtration chromatography Equipment and reagents Gel matrix Gel filtration column Automated fraction collector with on-line UV detector
Electrophoresis apparatus Dextran blue, potassium bichromate Protein standards
Method 1. Swell the dry gel matrix in the appropriate buffer or according to the manufacturer's directions. Allow the gel matrix to settle and aspirate the fines. Alternatively, if the gel matrix comes pre-swollen, wash the matrix in a sintered-glass funnel to remove the preservatives and to equilibrate it in the gel filtration buffer. De-gas the slurry. 2. Erect the column vertically in a 4°C cold room. Optimum resolution of proteins is best achieved with columns greater than 50 cm in length with a matrix diameter of 1 cm. 3. Fill the outlet tube with buffer and clamp it. Then add some buffer to the column gel matrix suspension and pour slowly to the desired bed height. Great care should be taken in pouring the column; it should be 71
Austin ]. Cooney et al. Protocol 3.
Continued
poured in a single motion to produce an homogeneous column matrix with no air bubbles. 4. Layer 1 cm of buffer carefully on top of the column bed, after the gel matrix has settled, without disturbing the matrix. Then connect the gel filtration buffer reservoir to the column. Open the column outlet and wash the gel matrix with 2-3 column volumes of the gel filtration buffer. 5. Determine the void volume (V0) and the total volume (Vt) of the column by filtration of dextran blue and potassium bichromate, respectively. 6. Carefully allow the buffer in the column to drop to the level of the bed and close the outlet. Disconnect the reservoir and gently load the protein standards (10-20 u,g each in a volume equivalent to 1-2% of the total column volume.) Open the outlet and let the protein standards enter the column, then close the outlet. Carefully pipette a 1 cm layer of gel filtration buffer on to the column bed and reconnect the buffer reservoir. 7. Open the outlet and commence elution of the protein standards at a flow rate of 8 ml/h.a Collect fractions equal to 1-2% of the total column volume using an automated fraction collector with an on-line UV detector. Alternatively, aliquots of each fraction can be taken to determine the protein peaks of the standards by measuring the absorbance at 280 nm (A2go). 8. Electrophorese aliquots of each fraction containing a protein peak on a denaturing 10% polyacrylamide-SDS gel, with a stacking gel using the discontinuous buffer system of Laemmli (17), to determine their molecular weight. This calibrates the column and allows the preparation of a standard curve to predict the size of a polypeptide which elutes in a particular fraction from the column. 9. Load the protein sample at a concentration of 0.2-0.5 mg/ml in a volume equal to 1-2% of the column volume. The loading and elution of the transcription factor preparations are the same as for the protein standards (see steps 5 and 6). 10. Measure the A2eo of aliquots from each fraction. Take 5-10 uJ aliquots from alternate fractions to assay for specific DNA binding, using gel retardation, DNAase I footprinting assays (see Chapters 1 and 2 respectively), and/or transcriptional activity. "The flow rate varies from column matrix to matrix and is determined by multiplying the linear flow rate (supplied by the manufacturer) by the cross-sectional area of the column in cm2 to yield the flow rate in ml/h.
72
3: In vitro transcription
3.2 Molecular weight determination using glycerol gradient centrifugation An alternative method can be used to determine and to confirm the native size determined by gel filtration and to eliminate possibilities of non-specific interactions between the gel matrix and the factor. This method uses density gradient sedimentation, developed by Martin and Ames (18). The formation of a glycerol gradient and sedimentation of the applied sample by ultracentrifugation permits the fractionation of partially purified factors on the basis of their sedimentation coefficients, which approximates to their molecular weight (14). Determination of molecular weight by sedimentation velocity has the advantage over gel chromatography of being a primary technique which permits the direct determination of hydrodynamic parameters, such as the sedimentation coefficient (s), from first principles. See Siegel and Monty (19) for a detailed discussion of the derivation and use of the equations. Protein standards of known s can be used to determine molecular weights rapidly and easily by glycerol gradient centrifugation. The use of glycerol or sucrose to form the gradient has the advantage, because of their viscosity and density, that essentially linear migration of the majority of biological macromolecules results. Thus, the ratio (R) of the distances sedimented by any two substances will always be constant. Given a standard protein of known s, the s of an unknown factor can be calculated from the equation
As the rate of movement of any macromolecule is nearly constant and assuming they have the same partial specific volumes, then
where S20,w is the sedimentation coefficient at 20°C in water. An approximate value for the molecular weight can be determined from
where MW = molecular weight. The glycerol gradient can be calibrated by sedimenting protein standards of known molecular weight (Bio-Rad) whose position in the gradient can be determined by electrophoresing aliquots from alternate fractions on an SDSpolyacrylamide gel (17). Identification of the position in the glycerol gradient to which the transcription factor sediments is determined by assaying fractions of the gradient for specific DNA binding and/or transcriptional activity. Measurement of the distance travelled by the unknown factor and standards 73
Austin J. Cooney et al. permits calculation of the factor's molecular weight. This technique has been commonly used to determine the native molecular weight of transcription factors (1,14, 20). Protocol 4. Determination of molecular weights by glycerol gradient centrifugation Equipment and reagents Buffer A: 20 mM Hepes pH 7.9, 100 mM KCI, 4 mM DTT, 0.2 mM EDTA Density gradient former (Beckman Instruments, Inc.) and mixing chamber SW50.1 tubes and rotor (Beckman) SP6 polymerase (Promega)
Auto Densi-Flow (Labconco Corp.) and fraction collector Molecular weight standards (Bio-Had) Electrophoresis apparatus
Method 1. Pour 4.4 ml linear 7-23% (w/v) glycerol gradients in buffer A, in SW50.1 tubes using a density gradient former and a mixing chamber. 2. Layer a 200 uJ aliquot of partially purified or affinity purified transcription factor carefully on to the pre-formed glycerol gradients. This sample should contain 15 ID of SP6 polymerase as an internal control. 3. Layer 10 to 20 ug of molecular weight standards carefully on to a balance gradient to construct a standard curve to calibrate the gradient. 4. Centrifuge the samples at 25000 x g (45000 r.p.m.) in an SW50.1 rotor (Beckman) for 16 h at 4°C. 5. Collect fractions of 150-200 ul from each gradient from the top to the bottom with an Auto Densi-Flow (Buchler) connected to a fraction collector, or puncture the bottom of the tube and collect fractions from the bottom up. 6. Assay each fraction for SP6 polymerase activity as per the manufacturer's instructions. It has a molecular weight of 98 kDa. 7. Electrophorese an aliquot of each fraction from the standard curve glycerol gradient under denaturing conditions in a 10% SDS-polyacrylamide gel (17). The positions of the standards are detected by silver or coomassie blue staining (21) to determine in which fractions they are located, to calibrate the glycerol gradients. 8. Assay 5-10 ul aliquots of each fraction for specific DNA binding, by gel retardation or DNAase I footprinting, and/or transcriptional activity to identify the fraction in which the transcription factor of interest sediments. This allows determination of the molecular weight by comparison with the standard curve. 74
3: In vitro transcription
3.3 Determination of molecular weight of native factors using non-denaturing gradient gel electrophoresis Non-denaturing gradient gel electrophoresis can be used to determine the native molecular weight of a transcription factor (22, 23). Gradients of polyacrylamide yield greater resolution of a protein mixture compared with a single polyacrylamide concentration and are thus more accurate for molecular weight determinations of native proteins. If the factor has been purified to homogeneity, it can be identified by silver staining (21), and if it has only been partially purified and an antibody is available, it can be identified by Western analysis (22,24). Here we will describe non-denaturing gradient electrophoresis and Western analysis. Although we describe the traditional use of radioiodinated protein A for the detection of proteins in Western analysis, many excellent non-radioactive kits are available from several manufacturers, with accompanying protocols, which allow rapid sensitive, safe, and reproducible analysis of Western blots. Many transcription factors in their native form are associated with other factors in relatively large complexes or as dimers, thus to facilitate the electrophoretic transfer of the factor, 20% of the N,N'-methylenebisacrylamide cross-linker can be replaced with the reversible cross-linker diallyltartardiamide (DATD): incorporation of DATD allows the polyacrylamide gel to be permeabilized by brief incubation with 5 mM periodic acid. A drawback of non-denaturing gradient electrophoresis is that it yields the best results with highly purified transcription factor preparations. Crude nuclear or cytosolic extracts tend to form insoluble aggregates which do not enter the gel and remain in the well, and also tend to produce ill-defined smeared bands on the Western immunoblot. Protocol 5. Molecular weight determination by non-denaturing gradient electrophoresis Equipment and reagents 0.5 x TBE: 50 mM Tris, 50 mM boric acid, 1 mM EDTA Transfer buffer: 49 mM Tris, 39 mM glycine, 0.04% SDS pH 9.2 5 mM periodic acid Pre-stained molecular weight markers (BioRad) Gradient gel casting chamber (Bio-Rad) Peristaltic pump (Gilson, Oberlin OH) Electrophoresis apparatus
Nitrocellulose or nylon membrane (e.g. Zeta-Probe or Immobilon P) Whatman No 3 paper Trans-blot apparatus Blotto: 2-3% non-fat dry milk (w/v), 10 mM Tris-HCI pH 8, 150 mM NaCI Western buffer: 10 mM Tris-HCI pH 8.0, 150 mM NaCI 125 l-labelled protein A (1.11 MBq/ng ICN)
Method 1. Cast a 3-25% gradient polyacrylamide gel (acrylamide:bisacrylamide: DATD = 79:0.8:0.2 w/w) in 0.5 x TBE with a gradient gel casting chamber. Maintain a 12 ml/min flow rate using a peristaltic pump.
75
Austin J. Cooney et al. Protocol 5.
Continued
2. Pre-run the gel at 300 V for 3 h to overnight in 0.5 x TBE at 4°C. 3. Incubate the samples at room temperature for 10-15 min. At this stage, DNA or ligands for particular experiments can be added. 4. Load 200 ng to 1 ug of transcription factor preparation and pre-stained molecular weight markers (Bio-Rad). Run at 300 V for 5 h at 4°C. 5. Rinse the gel in distilled H2O three times. 6. Incubate the gel in 5 mM periodic acid for 15 min at 30°C. 7. Repeat step 5. 8. Incubate in transfer buffer for 10 min. 9. Place the gel on a pre-cut, pre-wetted nitrocellulose or nylon membrane and sandwich between pre-wetted Whatman No 3 paper, three sheets on each side. 10. Place the sandwich in trans-blot apparatus and run at 20 V for 1 h in transfer buffer. 11. Disassemble the blot and block the membrane for 1 h at room temperature with blotto. 12. Decant the blotto and add the appropriate amount of antibody in 8-10 ml blotto. Incubate for 3-4 h at room temperature with gentle shaking. 13. Decant the antibody solution and wash the membrane with 40 ml Western buffer for 5 min with shaking. Decant and repeat twice. 14. If a monoclonal antibody was used, add the secondary antibody (rabbit anti-mouse IgG, commercially available) in 10 ml blotto and incubate at room temperature for 90 min with gentle shaking. If a polyclonal antibody was used, go straight to step 16. 15. Repeat step 13. 16. Add 2 ul of 125l-labelled protein A (1.11 MBq/ug) to 10 ml blotto. Incubate at room temperature with gentle shaking for 90 min. 17. Decant and dispose of the radioactive blotto carefully. Wash the membrane with 40 ml Western buffer for 10 min at room temperature. Decant and repeat twice. 18. Dry the membrane and develop the signal by autoradiography.
4. Determination of the molecular weight of denatured transcription factors Analysis of a factor under native conditions only permits estimation of the molecular weight of the total complex binding to an element. Electrophoresis 76
3: In vitro transcription under denaturing conditions (SDS-polyacrylamide gel electrophoresis (SDSPAGE)) allows accurate determination of the molecular weight of the individual transcription factors involved in that complex (14, 17, 25, 26). Comparison of the results will also yield invaluable insights into the factors binding to an element. If the factor binds as a dimer, then the native molecular weight will be approximately double that of the denatured factor. Also, if the complex is composed of a heterodimer, it may be possible to identify two species by SDS-PAGE if they have different molecular weights. Determination of the molecular weight of a factor under denaturing conditions requires the identification of a specific band on an SDS-polyacrylamide gel which corresponds to the binding or transcriptional activity being studied. The two methods outlined here differ conceptually as to whether the factor is identified before or after running the SDS-polyacrylamide gel. Ultraviolet (UV)-cross linking to DNA identifies the binding activity prior to running the SDS gel, while renaturation and assay for binding or transcriptional activity identifies the factor after running the gel. Both of these procedures have been employed successfully to identify the molecular size of many transcription factors early in the purification procedure.
4.1 UV cross-linking of transcription factors to DNA Irradiation of DNA with UV light produces purine and pyrimidine free radicals that are chemically reactive and can form covalent bonds such as thymidine dimers. This reactive property of UV-irradiated DNA can be used to link transcription factors covalently to their response elements. When a proteinnucleic acid complex is irradiated with UV light, it causes the formation of covalent bonds between pyrimidines and certain amino acid residues in the DNA binding domain in close proximity to the DNA. Thus a transcription factor can be selectively labelled indirectly by UV cross-linking as a consequence of its specific binding to a DNA sequence (27). Labelling the transcription factor in this fashion allows the easy and rapid determination of its molecular weight, under denaturing conditions in an SDS-polyacrylamide gel, even in crude extracts. We describe two techniques here, one involves incorporation of deoxybromouridine into the DNA prior to cross-linking, the other utilizes UV cross-linking to an unsubstituted oligonucleotide and gel retardation assay.
4.2 UV cross-linking with a bromodeoxyuridine-substituted DNA Halogenated analogues of thymidine (e.g. bromodeoxyuridine) are significantly more sensitive to UV-induced cross-linking because replacement of the thymidine methyl group with a bromine atom creates a molecule more susceptible to UV-light-induced free-radical formation (28). Bromodeoxyuridine can be functionally utilized in place of thymidine by many enzymes including 77
Austin J. Cooney et al. the Klenow fragment, which is used to prepare the substituted probe. An additional advantage of using bromodeoxyuridine is that a UV light of longer wavelength can be used for cross-linking than can be used with unsubstituted DNA. Longer wavelength UV light is less damaging to DNA because it causes fewer nicks in the phosphate backbone. After cross-linking of the factor and DNA, the probe is digested to remove the majority of the probe not protected by and covalently linked to the factor. This is a precautionary measure since UV light may also induce the formation of thymidine dimers in the DNA, leading to electrophoretic anomalies. Thus, the removal of excess DNA will minimize this problem. Protocol 6. Cross-linking with a bromodeoxyuridine-substituted DNA Equipment and reagents • 10 x Klenow buffer: 50 mM Tris-HCI pH7.5, . 10 mM MgCI2, 1 mM DTT, 50 mg/ml bovine serum albumin (BSA) • . [a32P]dCTP(110TBq/mmol) • . dNTP mix: 2.5 mM each of dATP, dGTP, 5bromo 2'-deoxyuridine trisphosphate (Pharmacia), and 0.25 mM dCTP • . 0.1 M DTT • Klenow fragment enzyme (25 IU, Promega) . • Phenol:trichloromethane:/so-pentanol (25:24:1 v/v) • Microcentrifuge • • 0.3 M ammonium acetate • Dry ice/ethanol bath • « 10 x loading buffer: 0.25% bromophenol blue, 0.25% xylene cyanol, 25% ficoll (type • 400) in H20 • Transcription buffer: 20 mM Hepes pH 7.9, . • 100 mM KCI, 20% glycerol, 4 mM DTT, 0.2 mM EDTA
TE buffer (pH 8) 10mM Tris-HCI ph 8.0, ImMEDTA Agarose gel electrophoresis set-up UV transilluminator emitting at 305-310 nm, with a maximum intensity of -7000 W/cm2 (e.g. Fotodyne UV lamp) 0.5 M CaCI2, DNAase I (Worthington Diagnostics), micrococcal nuclease (Worthington Diagnostics) ~~ 2 x SDS sample buffer: 0.125 M Tris-HCI pH 6.8, 6% SDS, 10% p-mercaptoethanol, 20% glycerol, 0.025% bromophenol blue SDS-PAGE set-up with 10% polyacrylamide gel and stacking gel "C-iabelled protein standards (BRL, Life Technologies, Inc.) Fluor (e.g. Enhance, MEN) Kodak XAR-5 X-ray film Dupont Cronex Lightening Plus intensifying screen
Method 1. Subclone a DNA fragment or oligonucleotide containing the specific response element for the transcription factor into M13. 2. Mix 5 ug of the recombinant single-stranded M13 clone containing the binding site with an equimolar amount of the 17 nucleotide M13 universal primer. Add 10 (JL! of 10 x Klenow buffer. 3. Heat at 95°C for 5 min and cool very slowly at room temperature, this should take several hours. 4. Make the following additions to the annealed mixture: 50 uI [a32P]dCTP (110 TBq/mmol) 3.5 (ul of dNTP mix 1.75(11 0.1 MDTT 78
3: In vitro transcription 7.5 ul 10 x Klenow buffer 7 ul H20 5 ul Klenow fragment enzyme (25 1U, Promega) 5. Incubate at 16°C for 90 min. 6. Heat the reaction to 68°C for 10 min to inactivate the Klenow enzyme. 7. Digest the double-stranded M13 recombinant vector with an excess of enzymes, under appropriate reaction conditions, which will liberate the inserted response element. 8. Extract the reaction once with phenol:trichloromethane:iso-pentanol. Microcentrifuge for 5 min at 11 000 X g and aspirate the aqueous phase. 9. Precipitate the DNA with 0.3 M ammonium acetate and 2 volumes of 100% ethanol, incubate in a dry ice/ethanol bath for 10 min and microcentrifuge for 15 min at 11000 x g. Wash the pellet with 0.5 ml 70% ethanol. Dry the pellet and resuspend in 20 ul TE buffer (pH 8) and add 2 ul 10 x loading buffer. 10. Load the DNA on to an agarose gel and electrophorese. Isolate the required fragment by your favourite technique (or use Geneclean (Bio 101) or NA45 DEAE membrane (Schleicher and Schuell), according to the manufacturers' protocols). 11. Dilute and count an aliquot of the probe using a scintillation counter and determine the DNA concentration by measuring the A260. Then determine the specific activity of the probe. 12. Set up a number of binding reactions. Incubate at room temperature under conditions determined previously (generally those used for gel retardation assays), for 15-30 min. The reactions should contain 105 c.p.m. of labelled probe, the extract or fraction containing the transcription factor, transcription buffer and 10-20 ug of non-specific competitor, e.g. poly(dl-dC)-poly(dl-dC); bring the volume up to 50 ul with H2O. Check for successful binding by running a gel retardation assay. 13. Cover the top of the tube with UV-transparent cling film. 14. Irradiate the binding reaction from a distance of 5 cm (see Figure 4) with a UV transilluminator for 5-60 min. The effect of UV irradiation can also be checked by running a gel retardation assay. 15. Add 1 ul 0.5 M CaCI 2 ,4 mg DNAase I, and 1 IU micrococcal nuclease to each reaction and incubate at 37°C for 30 min. 16. Add an equal volume of 2 x SDS sample buffer to each binding reaction and boil for 5 min. 17. Load the samples on a 10% polyacrylamide-SDS gel with a stacking gel, include a marker lane containing 14C-labelled protein standards. 79
Austin J. Cooney et al. Protocol 6. Continued 18. Electrophorese for 2-3.5 h at 35 mA (6). Remove the portion of the gel at the dye front, which contains the majority of the radioactivity in the digested nucleic acids. 19. Fix the gel with 7.5% acetic acid and 50% methanol for 60 min. Then impregnate the gel with a fluor, to enhance detection, according to the manufacturer's instructions. 20. Dry the gel for 1 h at 60°C and then 1 h at 80°C. Then autoradiograph with Kodak XAR-5 X-ray film and a Dupont Cronex Lightening Plus intensifying screen. Expose the film at —70°C for 1-4 days to visualize the cross-linked protein.
Figure 4. Experimental set-up for UV irradiation of binding reactions.
4.3 UV cross-linking of transcription factors to nonsubstituted probes DNA can be cross-linked to a bound transcription factor in the absence of substitution with bromodeoxyuridine, however, at lower efficiency (1). In this case cross-linking occurs directly between the DNA bases and the polypeptide. In the protocol we describe here, an end-labelled oligonucleotide is UV cross-linked in situ as the final step in a gel retardation assay. A short oligonucleotide with overhangs should be chosen, to minimize the effects of UV light on the electrophoretic mobility of the DNA, because the probe will not be digested with nucleases, and to allow easy radiolabelling by the Klenow frag80
3: In vitro transcription ment of DNA polymerase 1 by a fill-in reaction. The advantage of this procedure is that labelling an oligonucleotide obviates the time-consuming subcloning and probe preparation in M13. The gel retardation assay is a very useful analytical tool for identifying and studying the binding of specific factors. It can also be used as a preparative procedure. Gel retardation both identifies and separates a factor from the milieu of crude extracts or partially purified fractions. Use is made of these dual properties to determine the molecular weight of a factor which binds to a specific element. In order to increase the success of cross-linking a transcription factor to DNA, the binding sequence must be A:T rich, as thymidine is the most reactive of the bases. Also certain response elements bind multiple proteins and the gel retardation assay allows individual factor DNA complexes to be visualized and isolated, and then analysed by SDS-PAGE. Protocol 7. UV cross-linking of non-substituted DNA Equipment and reagents [a32P]dCTP Klenow fragment 10 x Klenow buffer (Protocol 6) TE buffer pH 7.5 10mM Tris-HCI pH 7.5, 1mM EDTA 0.5 M EDTA Phenol:trichloromethane
Sodium acetate pH 5.2 Dry ice/ethanol bath Microcentrifuge 1 M ammonium acetate Electrophoresis set-ups as in Protocol 6 dNTP mix (Protocol 6)
Method 1. To end-label the oligonucleotide, make the following additions: 100 ng of double-stranded oligonucleotide 100 uCi of [a32P]dCTP 2.5 ul dNTP mix 5 ul 10 x Klenow buffer H2O to a final volume of 50 ul Incubate at room temperature for 60 min. 2. Stop the reaction by adding 4 ul 0.5 M EDTA, bring the volume up to 100 ul with TE buffer (pH7.5) and extract with an equal volume of phenol:trichloromethane:iso-pentanol (25:24:1, v:v:v). Aspirate the aqueous phase. 3. Add one-tenth of a volume of sodium acetate (pH 5.2) and 3 volumes of ethanol. Incubate in a dry ice/ethanol bath for 30 min. 4. Microcentrifuge at 11000 x g at 4°C for 40 min and discard the radioactive supernatant carefully. 5. Resuspend the pellet in 100 ul 1 M ammonium acetate, vortex vigorously, add 250 ul ethanol and incubate in a dry ice/ethanol bath for 30 min. 6. Microcentrifuge for 40 min at 11000 X g at 4°C and aspirate the supernatant. 81
Austin J. Cooney et al. Protocol 7.
Continued
7. Repeat steps 5 and 6. 8. Wash the pellet with 0.5 ml 80% ethanol, dry the pellet and resuspend it in 50 ul TE buffer (pH 7.5). 9. Determine the specific activity of the probe (see Protocol 6, step 11). 10. Incubate the partially purified transcription factor with the probe under binding conditions determined previously (see Protocol 6, step 12). 11. Cross-link the probe and transcription factor. The UV light wavelength used should be 254 nm. The duration of irradiation can be varied from 5 min to over 3 h, as this reaction is less efficient. 12. Electrophorese each reaction in a native 5% polyacrylamide gel to separate the protein-DNA complexes from the unbound probe. 13. Autoradiograph the gel for 1-3 h at 4°C with Kodak XAR-5 X-ray film. 14. Excise the retarded protein-DNA complexes. 15. Layer the gel slices on to a 10% polyacrylamide-SDS protein gel with a stacking gel. Load a lane of l4C-labelled molecular weight standards. 16. Electrophorese and autoradiograph the gel (as in Protocol 6, steps 17-20).
4.4 Renaturation of transcription factors from SDSpolyacrylamide gels Fractions containing partially purified transcription factors can be separated on the basis of size, with high resolution, by SDS-PAGE. Proteins eluted and renatured from the gel can be assayed for specific DNA binding and/or transcriptional activity. This technique allows accurate determination of the molecular weight of individual factors that bind to an element. However, this is dependent on the factor being able to bind to DNA as a monomer or a homodimer. If the active form is a heterodimer, specific DNA binding or transcriptional activity may not be detected by this procedure. The most critical parameter of this procedure is the ability of a transcription factor to renature into its active form. Many transcription factors are composed of domains with distinct structural conformations, which aids the process of renaturation. However, the likelihood of successful renaturation increases with decreased size. The recovery of active transcription factor after this procedure is very low. On average, a 5% recovery is assumed (this will vary from factor to factor, and also with size) to calculate the amount of the factor that has to be loaded on a gel to yield enough active factor after renaturation to be detectable by in vitro transcription or gel mobility shift assays. The method of Hager and Burgess (29), with a few modifications, is recommended and has been successfully employed to determine the molecular size of transcription factors (30). 82
3: In vitro transcription Protocol 8. Renaturation from SDS-polyacrylamide gels Equipment and reagents • 5 x SDS loading buffer: 0.25 M Tris-HCI pH 6.8,15% SDS, 50% glycerol, 0.025% bromophenol blue; before boiling add to each sample B-mercaptoethanol to 5% • SDS-PAGE apparatus and silver staining reagents
• • • •
Small dialysis bag (Mr cut-off 10000 Da) BSA, nuclease free (Boehringer-Mannheim) Transcription buffer (Protocol 6) 6 M guanidine-hydrochloride in transcription buffer
Method 1. Add one-fifth volume of 5 x SDS loading buffer to an aliquot of up to 100 ul of partially purified or affinity-purified transcription factor and boil for 2 min. 2. Load the supernatant on to a denaturing SDS-polyacrylamide gel (7.5-10%, depending on protein size) with a stacking gel (17). 3. Electrophorese for 3-5 h at 30 mA (17). 4. Remove the molecular weight markers and a portion of the sample lane and silver stain (21). 5. Cut the unstained sample lane into 5-10 mm horizontal strips from the bottom to the top of the gel. 6. Place each gel strip in an individual small dialysis bag (Mr cut-off 10000 Da) containing 0.5 ml of SDS-gel running buffer and 100 ug/ml BSA. Place the dialysis bags perpendicular to the electric current in a large horizontal gel trough, filled with SDS-gel running buffer. Apply the current at 50 mA for 3 h to elute the proteins from the gel. 7. Recover the buffer containing the electroeluted proteins from the dialysis bags and precipitate by the addition of acetone (4:1 v/v) in 15 ml Corex tubes and incubate at -70°C for 30 min or -20°C overnight. Centrifuge the precipitate at 10000 x g for 30 min at 4°C. This step concentrates the protein and removes the SDS. 8. Rinse the pellet once with 80% acetone and 20% transcription buffer and dry. 9. Dissolve the pellets in 100 ul of 6 M guanidine-hydrochloride in transcription buffer and incubate at room temperature for 20 min. This treatment denatures the polypeptides. 10. Place the resulting solutions in individual small dialysis bags and dialyse against transcription buffer for 16 h at 4°C, with one change of buffer during that time. 11. Assay 5-10 ul of the dialysed samples for specific DNA binding by gel mobility shift assay or DNAase I footprinting and/or transcriptional activity. 83
Austin J. Cooney et al.
5. Analysis of the monomer/dimer structure of the DNA binding forms of a transcription factor Another characteristic of transcription factors requiring examination is the subunit composition of the active DNA binding form. Many transcription factors exist as monomers, dimers, or even trimers as their active DNA binding forms. At this stage of characterization of a transcription factor there should be substantial evidence to indicate its subunit composition. One indicator is the sequence of the DNA response element itself. Symmetry within the sequence of the response element, whether it is palindromic or directly repeated, suggests that the DNA binding form of the transcription factor may be a dimer or a higher order structure. Symmetric response elements are the binding elements for many groups of transcription factors, including helixloop-helix factors and the steroid/thyroid hormone receptor superfamily. Both families bind to their cognate response elements as dimers. DNAase I protection and methylation interference analysis will provide evidence as to whether a factor protects and contacts the repeated sequence motif. The response element will then indicate the subunit structure of the transcription factor. Comparison of the molecular weights of a transcription factor determined under both native and denaturing conditions will provide more direct evidence of the subunit structure of the DNA binding form. If a factor binds as a monomer, its molecular weight determined under native and denaturing conditions will be the same. If the factor binds as a dimer, its native molecular weight will be approximately double the molecular weight determined under denaturing conditions, and so on for higher order structures. If the native molecular weight is not an exact whole-number multiple of the denatured molecular weight, this may indicate that the DNA binding form is a heterodimer of two subunits with different molecular sizes. Heterodimers have been observed for many transcription factors. With this preliminary information, more direct experiments are required to determine the subunit structure of the transcription factors. These experiments involve analysis by gel retardation and chemical cross-linking. In addition, cooperative DNA binding can be observed between dimers bound to adjacent response elements. This cooperativity can be analysed by gel mobility shift assays.
5.1 Analysis of transcription factors by DNA mobility shift assay The tertiary structure of transcription factors can be analysed indirectly by gel retardation. The use of double-stranded oligonucleotides as probes allows easy and rapid analysis of factor-binding requirements by incorporation of base mutations into the sequence during synthesis. Methylation interference will often highlight the symmetric nature of the purine contact points. These nucleotides are good points to start mutational analysis, by changing them to 84
3: In vitro transcription pyrimidines and analysing their effect on factor binding by gel retardation. In this fashion, mutation of certain residues of a half site of the symmetric response element may lead to loss of binding activity. This suggests that the factor binds as a dimer, requiring binding of both subunits. To provide absolute proof that the active DNA binding form is a dimer, the factor needs to be cloned. The cloned gene permits genetic manipulations, including deletion analysis and formation of fusion proteins, which allows analysis of structure-function relationships, such as dimer formation. The subunit structure of a transcription factor can be analysed by attempting to form heterodimers between the full-length factor and either truncated (31) or extended (32) forms of the factor that retain the capability of binding DNA. These experiments can be performed using an in vitro transcription/translation system (Promega) to synthesize the factor and these mutants. By mixing the translation products or cotranslating their mRNA, the subunit composition can be assayed by gel retardation (33). If a factor binds as a monomer, two retarded complexes will be formed, corresponding to the full-length factor and either a truncated or an extended form. However, if the factor forms a dimer, then three retarded complexes will be observed. There will be two homodimers and a heterodimer of intermediate mobility, which contains one molecule of full-length factor and a molecule either of the truncated or extended factor.
5.2 Analysis of transcription factor subunits by chemical cross-linking The monomer/dimer structure of a factor and interactions between transcription factors can be analysed directly by chemical cross-linking. If a factor exists as a dimer, cross-linking of the two subunits will double its molecular weight as observed under denaturing conditions such as SDS-PAGE. Cross linking compounds react with chemical groups in proteins, including those found in the amino acid backbone and those found in the side chains. They form a covalent bond between two reactive groups and thus stably link them. Owing to the small size of these compounds, the cross-linked chemical groups must be in close proximity, inferring a direct interaction between their cognate polypeptides. Thus cross-linking is a sensitive method for directly assaying protein-protein interactions, such as dimer formation, and other interactions. There are many different chemical cross-linkers that are characterized and grouped according to their cross-linking properties (34). Each compound of this extensive array of cross-linkers has distinctive chemical characteristics and is used to cross-link different chemical groups separated by varying distances. They include homobifunctional and heterobifunctional compounds, some of which are cleavable or reversible. Extensive review of these cross-linking reagents is beyond the scope of this chapter. The Pierce catalogue contains an extensive list of cross-linking 85
Austin J. Cooney et al. reagents and protocols for their use. However, we will give an example of this powerful technique. The choice of a particular cross-linker depends on the groups that are to be cross-linked. However, with uncharacterized transcription factors, the information to make the best choice is not available, thus more general cross-linkers are used. The best results are achieved by trial and error. For example, Aranyi et al. (35) used several related compounds, bisimidates (e.g. dimethyl succinimidate, dimethyl adipimidate, and dimethylpimelidate) to cross-link the progesterone receptor (PR) to show that it exists as a dimer in solution. However, only dimethylpimelidate (DMP) successfully cross-linked the PR. DMP (Sigma) is a homobifunctional imidoester which forms a covalent bond between opposing primary amines. Protocol 9. Cross-linking transcription factors with DMP Equipment and reagents • 2.2 M triethanolamine pH 8 . 200 mM ethanolamine * 100 mM DMP/HCI: 100 mM DMP/HCI in 200 mM ethanolamine pH 8, adjusted with NaOH . 2 x SDS loading buffer
• TESH buffer: 10 mM Tris, 1 mM Tris, 1 mM EDTA, 12 mM 1-thioglycerol pH 7.6 • 7.5% polyacrylamide-SDS gel with stacking gel • Nitrocellulose or Zeta-Probe membrane
Method 1. Make the following additions:
2. 3. 4. 5. 6. 7.
0.1 volumes of 2.2 M triethanolamine pH 8 0.2 volumes of 100 mM DMP/HCI 100-200 ng of transcription factor Make up the volume to 30 ul with TESH buffer. Incubate the reaction for 30 min at room temperature. Stop the reaction with 0.1 volumes 200 mM ethanolamine. Add an equal volume of 2 x SDS loading buffer and boil the sample for 2 min. Run the sample on a 7.5% polyacrylamide-SDS gel with a stacking gel. Transfer the proteins to nitrocellulose or Zeta-Probe membrane. Detect the cross-linked factors by Western immunoblot analysis (see Protocol 5).
5.3 Analysis of cooperative binding between dimers bound to adjacent response elements Often enhancer elements act synergistically to enhance transcription. This phenomenon has been studied extensively using transient transfections and in 86
3: In vitro transcription vitro transcription. As an example, tandemly linked progesterone-response elements (PREs) upstream of a basal heterologous promoter fusion gene (TK-CAT) confer synergistic progesterone inducibility when compared with induction from single PREs (36). This observed synergism could be due to cooperative binding of two PR dimers to adjacent elements. To determine if PR dimers bind cooperatively to tandem PREs, varying concentrations of PR DNA binding domains were assayed by gel retardation and two retarded complexes were observed, II and IV (see Figure 5). Methylation interference showed they were formed by binding of a single dimer and two dimers to the probe, respectively. At low concentrations of receptor, only complex II was detected; however, at increasing concentrations complex IV was detected. With increasing receptor concentrations, the formation of complex IV was progressively enhanced to become the predominant protein-DNA complex. The levels of complexes II and IV and free DNA can be quantitated using a betascope 603 blot analyser (Betagen, Waltham, MA), phosphor imaging, or excision of the respective bands and scintillation counting. Quantitation showed that complex II reached approximately 10% of bound DNA, but no higher. In contrast, complex IV is present only at higher concentrations of receptor, where it rapidly becomes the predominant form. Analysis of the binding indicates that cooperative DNA binding displays sigmoidal kinetics (see Figure 5) (36). If no cooperativity is observed between the binding of the dimers, then complex II will reach 50% before the appearance of complex IV.
Figure 5. Quantitation of the two mobility shift complexes II and IV at different receptor concentrations and plotted as the percentage of DNA bound in complexes II and IV.
87
Austin J. Cooney et al.
6. Identification and initial characterization of non-DNA binding transcription factors Interaction of a transcription factor with itself or other transcription factors to form DNA binding dimers is relatively easy to detect and analyse. In contrast, the interaction of a transcription factor with a non-DNA binding transcription factor is not as easy to detect. However, techniques have been developed to study these interactions. The requirement for a non-DNA binding transcription factor is generally discovered during the purification of the DNA binding transcription factor by a loss of transcriptional activity as the two factors are separated. Transcriptional activity can be restored by mixing two different fractions. In contrast to a requirement for an additional DNA binding factor, the other fraction required for transcription activity will not bind DNA specifically, as determined by gel mobility shift assays and DNAase I footprinting. The interactions between DNA binding and non-DNA binding transcription factors can be either strong or weak and necessitate different methods of analysis depending on their strength. Strong interactions are stable under the conditions of native electrophoresis and can be studied by gel mobility shift analysis and also by DNAase I footprinting. Weak interactions are unstable and fall apart under the conditions employed for native gel electrophoresis and thus necessitate less stringent assays. These methods include immunoprecipitation, chemical cross-linking, or kinetic analysis. The requirement for a non-DNA binding factor is generally discovered fortuitously during the purification of a DNA binding factor. There may be a significant or total loss of transcriptional activity as the DNA binding transcription factor is progressively purified and assayed. An authentic loss of activity indicates the requirement for an additional transcription factor in addition to the DNA binding factor. DNAase I footprinting and gel retardation can be employed to determine if it is capable of binding specifically to DNA. The requirement of a DNA binding transcription factor for a non-DNA binding partner for transcriptional activity is not predictable. These requirements are peculiar and individual to each pair studied, thus it is difficult to describe protocols for the initial identification and analysis of non-DNA binding transcription factors. The first indications of a requirement for a non-DNA binding transcription factor may not be as dramatic as a total loss of activity, it may first manifest itself as a non-alignment of DNA binding and transcriptional activities in chromatographic fractions, as was observed for COUP-TF (a specific DNA binding factor) and S300-II (a non-DNA binding transcription factor) when chromatographed over a Sepharose S300 column (1-38). The two activities (DNA binding and stimulation of transcription) overlapped, but the peaks of each activity were not coincident. Gel mobility shift assays and DNAase I 88
3: In vitro transcription footprinting can be used to determine whether one or both peaks contain a specific DNA binding activity. Where a requirement for a non-DNA binding factor can be established, additional chromatographic steps can be used to further separate the two activities, leading to a total loss of transcriptional activity from the specific DNA binding activity. COUP-TF and S300-II fractions containing the DNA binding and non-DNA binding activities were re-chromatographed on a smaller 33 ml Sephacryl S-300 column to obtain a better resolution and separation of the two activities (see Figure 6). The fractions collected from this column, containing the COUP-specific DNA binding activity, were incapable of supporting transcriptional activity in the reconstituted system. However, when a fraction containing the non-DNA binding factor, i.e. No 57, was added to these assays, a peak of transcriptional activity was detected around fractions 41 and 42 (see Figure 6), which corresponded to the peak of DNA binding activity. Fraction 57 was chosen to avoid COUPTF contamination, as it was located on the side of the peak distal to the DNA binding activity. Similarly, the S300-II fractions supported only a low level of transcriptional activity; addition of fraction 41, containing COUP-specific DNA binding activity most distal from the non-DNA binding activity required for transcription, elicited a dramatic increase in transcriptional activity. Thus, the second Sephacryl S-300 chromatographic step achieved separation of the specific binding and non-DNA binding transcription factors and clearly demonstrated that transcriptional activity was dependent on both factors. Complementation of chromatographic fractions to the DNA binding activity will lead to the restoration and identification of the fractions containing the non-DNA binding activity. This outline highlights the approaches used to identify and study non-DNA binding transcription factors. Such an initial characterization of the requirement for a non-DNA binding factor establishes
Figure 6. Dependence of the ovalbumin promoter expression on two factors, COUP-TF I (peak I) and S300-II (peak II). COUP-TF is a DNA binding transcription factor, S300-II is TFIIB, which does not bind directly to the ovalbumin promoter.
89
Austin J. Cooney et al. a reconstituted assay system for the non-DNA binding factor, which will be required for subsequent purification and analysis of its function.
6.1 Assay of direct interactions between DNA binding and non-DNA binding transcription factors Having established a functional requirement of a non-DNA binding factor for the transcriptional activity of a DNA binding factor, the next step is to analyse this functional interaction. As it does not bind the response element, the nonDNA binding transcription factor must interact directly, in some fashion, with the factor bound at this site. It may also interact with the general transcriptional machinery, by bridging or adapting the binding of the DNA binding transcription factor with a functional response from the RNA polymerase II transcriptional machinery. Thus, the interactions of the DNA binding and nonDNA binding transcription factors need to be studied. Interactions between factors can be analysed by such methods as co-immunoprecipitation, chemical cross-linking, or using 'supershift' gel mobility shift assays, or kinetic analysis of transcription factor and DNA binding stability. Generally, more than one technique is employed in the analysis of direct interactions, and the particular choices are guided by the strength of the observed interaction.
6.2 'Supershift' gel mobility shift analysis If the interaction between the DNA binding transcription factor and the nonDNA binding transcription factor is sufficiently strong, it can be detected indirectly in a conventional gel mobility shift assay. The non-DNA binding transcription factor, by its nature, will be incapable of binding to the probe, but it will bind to the DNA binding transcription factor bound to the probe, further retarding the migration of the complex during electrophoresis. This 'supershift' is similar in nature to that observed upon addition of specific antibodies. The conditions for the 'supershift' have to be determined empirically for each pair of DNA and non-DNA binding transcription factors; however, the interaction generally occurs under the transcription conditions used to assay their functional interaction (37). Protocol 10. 'Supershift' gel mobility shift assay Equipment and reagents • Hinfl-digested pBR322 or poly(dl-dC)poly(dl-dC) . Native 4 or 5% polyacrylamide gel • 0.5 X TBE
• Whatman 3MM paper . Kodak XAR-5 X-ray film . Dupont Cronex Lightening Plus intensifying screens
Method 1. Mix the partially purified DNA binding and non-DNA binding transcription factors with the labelled DNA fragment or oligonucleotide with 90
3: In vitro transcription non-specific competitor (0.5 ug Hinfl-digested pBR322 or 1 ug poly(dldC)-poly(dl-dC) under transcription conditions determined previously. 2. Incubate at room temperature for 15-30 min. 3. Load the samples on to a native 4 or 5% polyacrylamide gel (the acrylamide percentage depends on the probe size). 4. Electrophorese for 1.5-3 h at 160-180 V in 0.5 x TBE. 5. Transfer the gel to Whatman 3MM paper and dry the gel at 80°C for 30 min. 6. Autoradiograph the dried gel with Kodak XAR-5 X-ray film with two Dupont Cronex Lightening Plus intensifying screens at-70°C.
6.3 Analysis of the dissociation of transcription factor-DNA complexes in the presence and absence of the non-DNA binding transcription factor If the interaction between the specific DNA binding and the non-DNA binding transcription factors is insufficiently strong, they will not be stable enough to detect as a 'supershift' in a gel retardation assay. However, non-DNA binding factors affecting the DNA binding stability can be assayed in a gel retardation assay by analysing the stabilization of the binding of the DNA binding transcription factor to its response element. Stabilization of binding by the non-DNA binding transcription factor can be determined and quantified by analysing the 'off rate' of the DNA binding transcription factor after it has bound to the response element. The 'off rate' is determined by challenging the transcription factor-labelled DNA complex with unlabelled response element in a kinetic experiment (38). The amount of unlabelled DNA added must be sufficient to eliminate completely the gel mobility shift if co-incubated with the probe and factor. Thus, the amount used will vary from factor to factor and will depend on its DNA binding affinity. The amounts of transcription factor and labelled response element used in each reaction in this experiment should be similar to those used to detect the transcription factor by gel mobility shift assay and should be incubated under similar conditions. Protocol 11. Analysis of the dissociation of transcription factor-DNA complexes in the presence and absence of non-DNA binding transcription factor Equipment and reagents • Transcription factor, partially or affinity purified • 32P-labelled DNA fragment or oligonucleotide • Specific competitor DNA fragment or oligonucleotide, unlabelled
91
• BSA • Native electrophoresis gel, 4 or 5% polyacrylamide • Densitometer (or phosphor imaging or beta scanner)
Austin J. Cooney et al. Protocol 11.
Continued
Method 1. Mix the partially or affinity-purified transcription factor with 32P-labelled DNA fragment or oligonucleotide under conditions determined previously for a gel mobility shift assay (Chapter 1). Carry out one reaction for each time point. The reaction at each time point should be duplicated using an equivalent amount of BSA instead of non-DNA binding factor as a control for non-specific stabilization. (Non-specific stabilization is sometimes observed when a highly purified factor is mixed with other fractions or proteins.) 2. Incubate at room temperature for 10 min to allow the transcription factor to bind to the response element. 3. Add a 50- to 200-fold molar excess (depending on the DNA binding affinity of the individual factor) of unlabelled specific competitor DNA fragment or oligonucleotide to each reaction after 10 min. 4. Terminate each reaction at specified time points by loading on to the gel and applying a very low voltage (this separates the bound and unbound probe immediately and stops the binding reaction). The addition of unlabelled competitor and the termination of the reaction should be timed accurately and spaced between reactions to produce an accurate and reproducible time curve. Typical kinetic time points may include 0, 2, 4, 8, 12, 16, 24, 32, and 60 min. 5. Analyse the reactions by native electrophoresis in a 4% or 5% polyacrylamide gel (depending on the probe size) and autoradiography as in a typical gel mobility shift assay. 6. Scan the autoradiograph with a densitometer, or scan the gel by phosphor imaging or with a beta scanner to quantitate the radioactivity in the retarded factor-DNA complexes. 7. Plot the amount of undissociated factor-DNA complex versus time to determine the tl/2 of the dissociation of the complexes in the presence and absence of the non-DNA binding transcription factor (see Figure 5 for example).
6.4 Analysis of direct interactions by coimmunoprecipitation Co-immunoprecipitation is a powerful technique that can detect direct interactions between two factors (39). It relies on the specificity of antibodies to recognize one of the components and protein A-Sepharose to precipitate the cross-linked immunocomplexes. Protein A-Sepharose is commercially available (Pharmacia). If the interaction between two factors is sufficiently strong, immunoprecipitation of one will bring down the other. However, if this inter92
3: In vitro transcription action is not sufficiently strong, it can be stabilized by using a reversible chemical cross-linker such as dithiobis(succinimylpropionate) (DSP) (35, 40). It is a homobifunctional cross-linking reagent which reacts with primary amine groups. It can be cleaved with excess thiol and is thus reversible under denaturing SDS-PAGE conditions in the presence of B-mercaptoethanol. Thus, SDSPAGE will separate the cross-linked species into their individual components. This procedure is especially useful if the factors have been cloned and can be labelled with [35S]methionine by in vitro transcription/translation, or if antibodies are available. A drawback of co-immunoprecipitation is that non-specific entrapment of proteins can occur, especially when using polyclonal antibodies, which recognize many antigens, leading to highly cross-linked aggregates. Controls are required to distinguish between specific co-immunoprecipitation and nonspecific entrapment, such as use of another factor which is known not to react with the immunoprecipitation target. The immunoprecipitated pellets are washed several times with buffer to remove non-specific proteins, but the stringency of these washes can be increased by adding small amounts of non-ionic detergents (e.g. 0.5% NP40 or 0.1% Triton X-100). In order to identify the co-precipitating factor, an antibody raised against it is required for Western immunoblot analysis, unless a clear identification can be made on the basis of molecular size, or the cloned protein can be labelled with [35S]methionine during in vitro translation of its mRNA. Protocol 12. Detection of direct interactions between factors by co-immunoprecipitation Equipment and reagents Partially purified transcription factors Primary antibody: mouse monoclonal or rabbit polyclonal Secondary antibody: rabbit anti-mouse IgG Protein A-Sepharose TE buffer pH 7.5
• Microcentrifuge • Wash buffer: 20 mM Tris-HCI pH 7.4, 100 mM NaCI • 1 x SDS sample buffer • 7.5-10% polyacrylamide-SDS gel with stacking gel
Method 1. Pre-incubate the partially purified DNA binding and non-DNA binding transcription factors in a 100 ul reaction volume under transcription conditions at a concentration of approximately 5 ug/ml for 1 h at 4°C. 2. Add 5 ug primary antibody (mouse monoclonal) or rabbit polyclonal antibody to the reaction. The final antibody concentration is approximately 50 ug/ml, but will depend on the individual affinity and titre of antibodies used. 3. Incubate for 2 h at 4°C with gentle agitation. 4. If a mouse monoclonal antibody has been used, add the secondary
93
Austin J. Cooney et al. Protocol 12.
Continued
antibody to a final concentration of 100-200 ug/ml. Incubate for 2 h at 4°C with gentle agitation. If using a rabbit polyclonal primary antibody, go directly to step 5. 5. Add 100 uJ protein A-Sepharose 1:1 suspension in TE buffer pH 7.5. Incubate for 1 h at 4°C with gentle agitation. 6. Microcentrifuge at 11 000 X g for 5 min at 4°C. 7. Carefully aspirate the supernatant and wash the pellet three times with 1 ml wash buffer, to remove non-specifically bound proteins. 8. Resuspend the pellet in 50 ul 1 X SDS sample buffer, boil for 2 min, load on to a polyacrylamide-SDS gel (7.5-10%, depending on protein size) with a stacking gel and electrophorese (17). 9. The co-immunoprecipitation of the non-DNA binding factor can be detected by Western transfer and immunoblot analysis using an antibody raised to the non-DNA binding factor or by autoradiography if it has been labelled with [35S]methionine.
Protocol 13. Stabilization of weak interactions with DSP Equipment and reagents • Transcription buffer • DSPa
• Ethanolamine • 3 x SDS-PAGE buffer, B-mercaptoethanol
Method 1. Incubate the transcription factors in transcription buffer at 37°C for 30 min in a total volume of 50 ul, to allow association. 2. Add DSP to a final concentration of 2 mM. 3. Incubate at room temperature for 1 h. 4. Add ethanolamine to a final concentration of 0.1 M, to stop the crosslinking reaction. 5. Immunoprecipitate the cross-linked species (see Protocol 11). 6. Reduce and reverse the cross-linked immune complexes by boiling in 3 x SDS-PAGE buffer containing 15% B-mercaptoethanol. 7. Analyse by SDS-PAGE (6) and fluorography, if a [35S]methionine labelled factor has been used, or by Western analysis. •Buffers used with DSP should be free of Tris as it contains primary amino groups which will quench the DSP reaction.
94
3: In vitro transcription
References 1. Sagami, I., Tsai, S. Y., Wang, H., Tsai, M.-J., and O'Malley, B. W. (1986). Mol. Cell. Biol. 6, 4259. 2. Ing, N. H., Beekman, J. M., Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W. (1992). J. Biol. Chem. 267, 17617. 3. Corthesy, B., Hipsking, R., Theulaz, I, and Wahli, W. (1988). Science 239, 1137. 4. Freedman, L. P., Yoshinaga, S. K., Vanderbilt, J. N., and Yamamoto, K. R. (1989). Science 245, 298. 5. Klein-Hitpass, L., Tsai, S. Y., Weigel, N. L., Allan, G. F., Riley, D., Rodriguez, R., et al. (1990). Cell 60, 247. 6. Bagchi, M. K., Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W. (1990). Nature 345, 547. 7. Elliston, J. F., Fawell, S. E., Klein-Hitpass, L., Tsai, S. Y., Tsai, M.-J., Parker, M. G., and O'Malley, B. W. (1990). Mol. Cell. Biol. 10, 6607. 8. Klaff, M., Gross, B., and Beato, M. (1990). Nature 344, 360. 9. Bagchi, M. K., Tsai, S. Y., Weigel, N. L., Tsai, M.-J., and O'Malley, B. W. (1990). J. Biol. Chem. 265, 5129. 10. Sawadogo, M. and Roeder, R. G. (1985). Cell 43, 165. 11. Sawadogo, M. and Roeder, R. G. (1985). Proc. Natl Acad. Sci. USA 82, 4394. 12. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983). Nucl. Acids Res. 11, 1475. 13. Andrews, P. (1970). In Methods of biochemical analysis, Vol. 18 (ed. D. Glick), pp. 1-53. Interscience, New York. 14. Laue, T. M. and Rhodes, D. G. (1990). In Methods in enzymology, Vol. 182 (ed. M. P. Deutscher), pp. 566-87. Academic Press, London. 15. Fischer, L. (1980). Gel-filtration chromatography. Elsevier, Amsterdam. 16. Stellwagen, E. (1990). In Methods in enzymology, Vol. 182 (ed. M. P. Deutscher), pp. 317-28. Academic Press, London. 17. Laemmli, U. K. and Favre, M. (1973). J. Mol. Biol. 80, 575. 18. Martin, R. and Ames, B. (1961). J. Biol. Chem. 236, 1372. 19. Siegel, L. M. and Monty, K. J. (1966). Biochim. Biophys. Acta 112, 346. 20. Chodosh, L. A., Baldwin, A. S., Carthew, R. W., and Sharp, P. A. (1988). Cell 53, 11. 21. Merril, C. R. (1990). In Methods in enzymology, Vol. 182 (ed. M. P. Deutscher), pp. 477-88. Academic Press, London. 22. Rodriguez, R., Weigel, N. L., O'Malley, B. W., and Schrader, W. T. (1990). Mol. Endocrinol. 4, 1782. 23. Slater, G. G. (1968). Anal. Biochem. 24, 215. 24. Timmons, T. M. and Dunbar, B. S. (1990). In Methods in enzymology, Vol. 182 (ed. M. P. Deutscher), pp. 679-88. Academic Press, London. 25. Garfin, D. E. (1990). In Methods in enzymology, Vol. 182 (ed. M. P. Deutscher), pp. 425-41. Academic Press, London. 26. Weber, K. and Osborn, M. (1969). J. Biol. Chem. 244, 4406. 27. Chodosh, L. A., Carthew, R. W., and Sharp, P. A. (1986). Mol. Cell Biol. 6, 4723. 28. Lin, S.-Y. and Riggs, A. D. (1974). Proc. Natl Acad. Sci. USA 71, 947. 29. Hager, D. A. and Burgess, R. R. (1980). Anal. Biochem. 109, 76. 30. Bagchi, M. K., Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W. (1987). Mol. Cell. Biol. 7, 4151. 95
Austin J. Cooney et al. 31. Kumar, V. and Chambon, P. (1988). Cell 55, 145. 32. Tsai, S. Y., Carlstedt-Duke, J., Weigel, N. L., Dahlman, K., Gustafsson, J.-A., Tsai, M. J., and O'Malley, B. W. (1988). Cell 55, 361. 33. Ladias, J. A. A. and Karathanasis, S. K. (1991). Science 251, 561. 34. Pierce catalogue and references therein. 35. Aranyi, P., Radanyi, C., Renoir, M., Devin, J., and Baulieu, E.-E. (1988). Biochemistry 27, 1330. 36. Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W. (1989). Cell 57, 443. 37. Buratowski, S., Hahn, S., Guarente, L., and Sharp, P. A. (1989). Cell 56, 549. 38. Tsai, S. Y., Sagami, I., Wang, H., Tsai, M.-J., and O'Malley, B. W. (1987). Cell 50, 701. 39. Lee, W. S., Kao, C. C., Bryant, G. O., Liu, X., and Berk, A. J. (1991). Cell 67, 365. 40. Yang-Yen, I. I.-F., Chambard, J.-C., Sun, Y.-L., Smeal, T., Schmidt, T. J., Drouin, J., and Karin, M. (1990). Cell 62, 1205.
96
4
Purification and cloning of DNA binding transcription factors R. H. NICOLAS, G. HYNES, and G. H. GOODWIN
1. Introduction If you have just identified a protein binding to a novel regulatory sequence, the next step is to clone the cDNA encoding the protein. Most practitioners in this field would first attempt direct screening of expression libraries with the DNA binding site (see Chapter 5) before embarking on the protein purification/peptide sequence/oligonucleotide screening approach. However, in many cases, direct screening of libraries has not proved successful or has not been possible (for example when the protein is part of a multiprotein complex and more than one protein is required for DNA binding) and protein purification may then have been the only method available. The purification of DNA binding proteins has been remarkably successful with the development of sequence-specific DNA affinity chromatography and the band-shift technique for rapidly analysing chromatography fractions. With the recent advances in protein-sequencing techniques (e.g. sequencing peptides immobilized on blots following electrophoretic separation), the protein purification approach has become less arduous and one can expect to get good sequence results from 50 pmol of protein. Also, mass spectroscopy techniques are being used to mass fingerprint proteins for the identification of protein sequences in databases, and tandem mass spectroscopy is now able to obtain peptide sequences from femtomole amounts of protein. One of the major difficulties faced by the protein purifier is the abundance of the transcription factor in the cell. Eukaryotic transcription factors are present in the cell nucleus in widely varying quantities, ranging from 103 molecules per cell for some retinoic acid receptors to well over 105 per cell for the GATA1 factor in erythroid cells. If at least 100 pmol of pure protein are required for production of peptides for sequencing, it is apparent that for a protein of average abundance at 104 molecules per cell, more than 1011 cells of starting material are required, assuming 5% recovery of protein. The successful isolation of protein also requires that the molecular weight of the protein has been determined (for monitoring the final stages of purification
R. H. Nicolas et al. of the protein) and that a DNA sequence with high affinity and specificity for the protein has been identified. As a rough guide, the ratio of the strengths of binding to specific versus non-specific DNA sequences should be at least 100. This can be determined using competitive DNA binding analyses in the bandshift assay. The molecular weight of the protein can be determined by twodimensional electrophoretic techniques (1), by photoaffinity labelling (2), or by Southwestern blotting techniques (3). In this chapter, we describe the techniques used to purify moderately abundant factors, as illustrated by the purification of a zinc-finger factor termed CTCF, a ubiquitous protein which binds to a GC-rich element in the promoter region of the chicken c-myc gene (4), and chicken GATA1 (formerly termed EF1, NF, El, EryFl), a protein expressed in erythroid cells, megakaryocytes, and platelets (1, 5). This is outlined schematically in Figure 1. In these purifications, DNA-cellulose chromatography is carried out to isolate DNA binding proteins prior to DNA affinity chromatography. Other chromatographies commonly used to achieve partial purification before affinity chromatography include heparin-sulfate, phosphocellulose, or ion-exchange.
Figure 1. The steps required to clone a transcription factor via protein isolation.
98
4: Purification and cloning In our view, gel filtration rarely has sufficient resolution or capacity to make it worthwhile. Following an affinity chromatography step, final purification is achieved by further cycles of affinity chromatography or by reverse-phase chromatography.
2. Buffers and solutions When the aim of purifying a transcription factor is to obtain some primary sequence of the protein, it is important that all solutions should be scrupulously clean. Any glassware used should be acid washed by soaking overnight in nitric acid (one part nitric acid, two parts HPLC-grade water), then rinsed four times in HPLC-grade water and dried in an oven at 150°C. Sterile disposable plasticware is a useful alternative, and tissue-culture flasks make good reagent bottles. Only high-quality chemical reagents should be used, and stock solutions should be filtered through 0.22 um filters. Many of the buffers contain glycerol for protein stability, but it is very difficult to measure viscous reagents by volume, so glycerol is added by weight. It is also a good idea to make a glycerol-containing stock solution such as Ns (Table 1) which can be used to make all the buffers for DNA chromatography.
3. Preparation of nuclear extract Consideration should be given first to which tissue or cell line will give the greatest yield. In general, tissue culture is expensive, but relatively pure nuclei can be prepared in high yield in a couple of steps using just low-speed centrifugations. To prepare nuclei and obtain undegraded nuclear proteins from tissues, the starting material must be fresh. This may present difficulties when working with human tissue. Animal tissue may be more readily available, but it should be remembered that tissues do not contain a homogeneous cell population and only a few cell types may be expressing the protein of interest. Some tissues, such as thymus and spleen, may be gently disrupted in phosphatebuffered saline (PBS) and filtered through gauze to yield a crude cell suspension and then Protocol 1 may be followed to prepare a nuclear extract. With tougher tissues, it is better not to prepare cells but prepare pure nuclei directly by centrifugation through a high-sucrose gradient as described in Protocol 2. The preparation of nuclei gives between 10- and 100-fold enrichment of a nuclear-localized protein, depending on the size of the cells. The cytoplasmic supernatant fractions should be assayed for activity because in some cases weakly bound factors may be lost from the nuclei. Some transcription factors may be susceptible to denaturation by the detergent treatment used to lyse the cell membrane, in which case cells may alternatively be lysed by hypotonic shock (6). In many cases, lower concentrations of Triton are sufficient to lyse cells and this can be investigated for each cell type, but for optimum yields it should be ensured by microscopic examination that all the cells are lysed. 99
R. H. Nicolas et al. Table 1. Solutions (a) Stock solutions 200 mM Hepes-NaOH pH 7.9 200 mM EDTA pH 8.0 1 M Tris-HCI pH 7.6 1 M MgCI2 4MNaCI 2 M (NH4)2SO4 10% Triton X-100 (Pierce) 10% Brij-35(Pierce) Glycerol 1 M DTT (store in aliquots at -20oC and add to solutions on day of use) (b) Stock of protease and phosphatase inhibitors 50 mM PMSF (dissolve in propan-2-ol and store in a dark bottle at 4°C for up to 3 months, as long as it is kept free of water) 50 mm benzamidine in water 100 mg/ml leupeptin in water 100 mg/ml aprotinin in water 100 mg/ml pepstatin in methanol 200 mM levamisole in water 1 M B-glycerophosphate in water All these solutions are 100 x concentration and should be added to the pre-cooled solutions on the day of use. All except PMSF can be stored as aliquots at -20°C for up to 3 months or at 4°C for 1 week. (c) Solutions for preparation of nuclear extracts TM TTM PBS
N100 NDil
10 mM Tris-HCI pH 7.6, 5 mM MgCI2 10 mM Tris-HCI pH 7.6, 5 mM MgCI2, 0.5% Triton X-100 Dulbecco's phosphate-buffered saline. Dissolve 1 tablet (OXOID) in 100 ml or dissolve 0.2 g KCI, 0.2 g KH2P04, 8.0 g NaCI and 2.16 g Na2PO4.7H2O in 1 litre. The pH should be 7.3-7.4 See Table 1(d) See Table 1(d)
All the above solutions should have the inhibitors added just before use. (d) Buffers required for DNA chromatography Buffer
N100 N200 N1000 NDil E250 WOO/50b
Reagent required (ml) to make 100 ml of buffer Nsa Water 4 M NaCI 2 M (NH4)2SO4 1 M DTT
50 50 50 75 50 50
40.4 37.9 17.9 17.9 30.4 10.4
2.5 5.0 25 2.5
12.5 -
a
0.1 0.1 0.1 0.1 0.1 0.1
Inhibitors
7x 1 7 X1 7X1 7 X1 7 X1 7x 1
Ns = 40% v/v glycerol (= 50% w/v glycerol), 10 mM MgCI2, 0.2 mM EDTA, 40 mM Hepes (pH 7.9), 0.1% Brij-35. b Make up to volume with glycerol (37.5 g).
100
4: Purification and cloning Transcription factors are then extracted from the nuclei with a buffer containing 0.3 M NaCl. The highest concentration of salt that can be used without extracting histone H1 is 0.35 M NaCl. Extraction of H1 at higher salt concentrations results in chromatin decondensation, nuclear lysis, and formation of a gel that can only be effectively removed by ultracentrifugation. H1 also causes problems during the subsequent chromatography steps since it is very abundant and will bind to the DNA-cellulose and bind non-specifically to the DNA affinity columns. Although H1 can be removed by ion-exchange chromatography, it is better to avoid extracting the H1 in the initial nuclear extraction, provided the factor of interest is extracted in high yield by 0.30.35 M NaCl. Since the nuclear extraction buffer contains other components which contribute to the ionic strength, the NaCl should be added to only 0.3 M final concentration to minimize H1 solubilization. Following extraction of the nuclei, the NaCl concentration of the extract is reduced either by dilution or dialysis before loading on to the DNA-cellulose column. This causes precipitation of proteins, and some transcription factors may come out of solution at this point. Since the solubility is usually inversely proportional to NaCl concentration, the highest NaCl concentration that will still allow binding to the DNA-cellulose column should be determined. Conversely, if the factor remains soluble at low salt concentration, then by optimizing this precipitation a two- to three-fold purification can be achieved. The use of a non-ionic detergent such as Brij-35 does keep some factors soluble, but it may also be detrimental to other binding activities. Ammonium sulfate fractionation can be included before the DNA-cellulose chromatography. This has the advantage of concentrating the protein and removing some nucleic acid, but since the precipitate has to be redissolved in buffer and then dialysed against N100 buffer before loading on to the column, there is little saving in the time taken for the preparation. Ammonium sulfate precipitation can be detrimental; e.g. in the case of GATA1, some activity was lost due to denaturation or incomplete dissolution of the protein precipitate. Interestingly, when 3.5 g (NH4)2SO4 is added per 7.5 ml of 0.3 M nuclear extract, the majority of the proteins precipitate, leaving only the high mobility group (HMG) proteins in solution. Thus, after pelleting the ammonium sulfate precipitate by centrifugation (40000 X g, 30 min), the HMG proteins can simply be prepared in an undenatured form by extensively dialysing the supernatant. Protocol 1.
Preparation of nuclear extract
Equipment and reagents * Centrifuge • PBS * TTM * TM buffera
*N100 buffera
buffera . NDil buffera • Dounce glass homogenizer
101
R. H. Nicolas et al. Protocol 1.
Continued
Method 1. Collect cells by centrifugation at 2000 x g. 2. Resuspend the cells in PBS, centrifuge 2000 x g for 10 min. 3. Resuspend in 10 volumes of TTM buffer, homogenizing with a loosefitting Dounce glass homogenizer, five strokes is usually enough. 4. Check that cells have lysed by examining a methylene blue stained sample under the microscope. 5. Centrifuge at 5000 x g for 20 min. 6. Resuspend the crude nuclei in 10 volumes TM buffer and centrifuge at 5000 x g for 10 min. 7. Resuspend in TM buffer. Use 1 ml for every 5 X 108 starting cells. Make the suspension 0.3 M NaCI by adding 4 M NaCI. Ensure that the extract is mixed thoroughly while adding the 4 M NaCI. Leave at 4°C for 30 min and then centrifuge at 40000 x g for 30 min. 8. (a) Dialyse the supernatant versus N100 buffer overnight, or (b) Add 2 volumes of zero salt dilution buffer (NDil). Mix by gentle stirring. Leave on ice for 1 h. 9. Clarify the nuclear extract by centrifugation for 1 h at 40000 x g and collect the supernatant. Freeze rapidly on solid C02 in aliquots or load directly on to the DNA-cellulose column. " See Table 1.
Protocol 2.
Preparation of nuclei from whole tissue, e.g. liver
Equipment and reagents • 2.4 M sucrose in TM buffera • Surgical gauze • Centrifuge
• Domestic blender • TM buffera with 0.25 M sucrose • TTM buffera with 0.25 M sucrose
Method 1. Dice 100 g liver and homogenize for 2 min at low speed in a domestic blender or equivalent with 1 litre of TM buffer plus 0.25 M sucrose. 2. Filter through four layers of surgical gauze. 3. Centrifuge at 2500 x g for 15 min. 4. Discard the supernatant, add 1 litre of TTM buffer containing 0.25 M sucrose and stir or very gently homogenize. Stir for 15 min and centrifuge as above. 102
4: Purification and cloning 5. Discard the supernatant. Gently homogenize the pellet with 5 volumes of 2.4 M sucrose in TM buffer and then centrifuge at 35000 x g for 1 h. 6. Remove supernatant and resuspend the nuclear pellet in 70 ml of TM buffer. ' See Table 7.
4. DNA-cellulose chromatography Calf thymus DNA-cellulose chromatography is a soft-gel technique and does not require any special apparatus apart from a peristaltic pump, column, fraction collector, and UV monitor. The sample should be loaded in a reasonably low ionic strength buffer; most DNA binding proteins bind at 100 mM NaCl. In some cases (e.g. for the GATA1 factor), yields from the DNA-cellulose column can be low unless the detergent Brij-35 is included in the buffer. After loading, the eluate from the column should be monitored by measuring the absorbance at 280 nm (A280) and washed until the absorbance returns to baseline. It is advisable not to stop the buffer flow for long during the chromatography as this results in an increase in absorbance, presumably due to some DNA eluting off the column. The DNA binding proteins are eluted from the column at high ionic strength (E250 buffer, 250 mM (NH4)2SO4), and usually all the protein is eluted in less than a column volume. There is usually little advantage in using more complex chromatographic elutions (i.e. using gradient or multiple salt steps). The ratio of bound to non-bound protein is usually 1:10 and, in the case of GATA1, an approximate yield of 70% is usually obtained. Protocol 3. DNA-cellulose chromatography Equipment and reagents • DNA-cellulose (Sigma) • Column: 1.6 mm diameter, 20 ml volume * 10 mM Tris-HCI pH 7.6, 1 mM EDTA *
. N100 buffera • E250 buffera N200 buffera
Method 1. Weigh out 10 g of DNA-cellulose (Sigma) and allow it to swell in 300 mM NaCl, 10 mM Tris-HCI pH 7.6, 1 mM EDTA. Suspend in 100 ml of buffer and allow to stand for a few minutes. Remove the fines by aspiration. Pack the cellulose into a 20 ml column (1.6 mm diameter) and place in a 4°C cold room. 2. Wash column with 1 volume of 2 M NaCl, 10 mM Tris-HCI pH 7.6, 1 mM EDTA at a flow rate of 0.2-0.5 ml/min. 103
R. H. Nicolas et al. Protocol 3.
Continued
3. Wash column with 1 volume 100 mM NaCI, 10 mM Tris-HCI pH 7.6, 1 mM EDTA. 4. Wash column with at least 3 volumes of N100 buffer. 5. Pump clarified nuclear extract on to the column. Large volumes can be loaded at a slow flow rate overnight. Approximately 200-400 mg of protein is obtained from 1011 cells. 6. Once loaded, wash the column with at least 2 column volumes N100 buffer until the A280 returns to background level. 7. Elute the DNA binding proteins with E250 buffer.b Most of the protein is eluted in 1 column volume as judged by A280. 8. Pool the fractions and dialyse against at least 20 volumes N200 buffer for a minimum of 5 h. 9. Flash freeze in aliquots at -70°C to store or continue with affinity chromatography. aSee Table 1. b Aliquots of fractions should be kept for band-shift analysis. Also, an estimate of the yield of protein is useful at this stage. This can be determined using the Bio-Rad protein assay with minimal interference by non-ionic detergents. Check that there is no activity remaining on the column following elution with E250 by eluting with a higher (NH4)2SO4 concentration (e.g. 500 mM).
5. DNA affinity chromatography In this method, originally developed by Kadonaga and Tjian (7), a large number of binding sites are linked to the column by first polymerizing an oligonucleotide containing a high affinity protein binding sequence and this is then covalently attached to the column matrix (Sepharose). One should aim for more than 2 nmol per millilitre of matrix. This maximizes the concentration of protein binding sites in the column so that there are a large number of specific sites to compete with the competitor DNA that is required for selectivity. Commercially available cyanogen bromide (CNBr)-activated Sepharose 4B (Pharmacia) works well, provided it is not close to its expiry date (Protocol 4). Double-stranded DNA is very unreactive towards CNBr Sepharose 4B, so the oligonucleotide has to have an overhang of at least four base pairs at the end of the DNA and should contain a G base. ACGT is commonly the overhang used. In order to anneal the complementary strands of the oligonucleotide, the extinction coefficients of both strands must be calculated and their concentrations determined accurately. Great care should be taken that the two strands are annealed in equimolar amounts so that no single-stranded DNA remains to be attached to the Sepharose. 104
4: Purification and cloning The binding site for the transcription factor should have been thoroughly characterized by band-shift analysis (see Chapter 1), footprinting, and related techniques (see Chapter 2). The sequence chosen for affinity chromatography should, if possible, bind only one factor specifically and should be the strongest site that has been found. It may be necessary to screen a number of potential sites and also generate mutants to find a binding site with high specificity and affinity. Ideally, the affinity column should bind the protein strongly enough so that it does not elute off the column below 0.5 M NaCl; if it elutes below 0.3 M NaCl, the protein will be very difficult to purify without a number of other steps in the purification procedure. The selectivity of the method is determined by the immobilized polynucleotide and by the concentration and character of the competitor DNA. All the proteins loaded on to the column have the potential to bind to the column. The trick is to add as much competitor DNA as possible so that most non-specific DNA binding proteins partition on to the mobile competitor DNA. In practice, one is limited in how much non-specific DNA can be added without precipitating some of the factor of interest. As a rule of thumb, one can add up to an equal weight of poly(dI-dC) as total weight of protein in the sample to be loaded on to the column. More complex DNA such as E. coli DNA is a more effective competitor but usually starts to compete for the specific protein at lower concentrations. Other synthetic DNA polymers that may help the factor bind more specifically can also be included (8). The sequence used to purify the CTCF factor also binds a poly(G)-binding protein and SP1 (4). Since band-shift analysis showed that poly(dG)-poly(dC) would compete for the poly(G)-binding factor and not CTCF, this was included In the final mix and this prevented binding to the column. Typically, in the purification of CTCF, 16 ml of the E250-eluted fraction from the DNA-cellulose column (1 mg/ml protein) was mixed with 8 ml of poly(dI-dC) and 160 ml of poly(dG)-poly(dC), both at 1 mg/ml in 100 mM NaCl. Non-specific binding of proteins to the affinity column can have several causes. (a) Another protein(s) may bind to a site adjacent to or overlapping the sequence of interest. This problem can be corrected by band-shift analysis and redesigning the oligonucleotide bound to the column; remember that on ligation a new site may be formed. (b) Some proteins may have an affinity for Sepharose 4B. For example, the GATA1 factor binds to Sepharose and elutes gradually at salt concentrations between 100 and 300 mM NaCl. This may be solved by including a pre-column of Sepharose 4B before the affinity column. (c) There are proteins that bind to the DNA of the affinity column because they do not have a high affinity for the competitor DNA. The nature of these contaminants will depend on the nuclear extract, the DNA of the affinity column, and the competitor DNA. One such example are the 105
R. H. Nicolas et al. single-strand nucleic acid binding proteins associated with nuclear hnRNA. During the purification of GATA1, four or five of these proteins consistently co-purified with GATA1. GATA1 could be separated from their contaminants by reverse-phase chromatography (see below), or by recycling through the affinity column, although this resulted in lower yields since contaminated side fractions had to be discarded. If there is evidence that these 40 kDa proteins are binding to the column, then they can be removed by passing the extract through a single-strand DNAcellulose column after the double-stranded DNA-cellulose column (5). (d) It is possible that a DNA binding protein has one or more non-DNA binding proteins associated with it. Such large molecular complexes may be manifested by slowly migrating bands in band-shift analysis. Indeed, a slow broad band might hide a number of complexes. Cross-linking experiments with deoxybromouridine (2) can be used to determine the molecular weight and complexity of the DNA binding components but may give no indication of the size and complexity of the non-DNA binding components (see Chapter 3). It has been shown that a modification of a method relating mobility to molecular weight described by Ferguson (9) for proteins can be applied to the DNA-protein complexes (10). This type of approach may help in determining the overall composition of the complex. If one is sure that all the proteins bound to the column are components of the complex, then in principle they could all be isolated, sequenced, and hence cloned. In practice, one should consider raising antibodies to the complex to generate reagents that will aid in the purification and cloning, and help elucidate the structure of the complex. The pre-column step is included in Protocol 5 but is not mandatory; it may help to remove some of the contaminants from the final products. The precolumn matrix is usually Sepharose 4B with an immobilized polymerized oligonucleotide having a sequence unrelated to that bound by the factor being purified. In practice, we have used the run-through peak from one DNAaffinity-chromatography column to load on to a second different DNA affinity column to purify a second transcription factor. Thus a number of factors were prepared from the same nuclear extracts. The run-through peaks are especially valuable as they have competitor DNA added and should be stored by fast-freezing and kept at —70°C until required. Figure 2 shows an SDS-polyacrylamide gel and the band-shift analysis of the fractions from DNA affinity chromatography during the purification of CTCF from chicken tissue-culture cells. The contaminating hnRNA binding proteins can be seen in the early fractions and elute from the column at approximately 300 mM NaCl. The sample loaded on the column had already been passed through a GATA1 binding column which effectively removed most of these contaminating proteins. CTCF eluted at 500 mM in a total volume of 4 ml. It can be seen from the analysis of Figure 2 that a major protein 106
4: Purification and cloning
Figure 2. (A) SDS-PAGE analysis of fractions obtained following affinity chromatography of CTCF. 10 ul of each sample plus an equal volume of SDS loading buffer was electrophoresed on a Pharmacia Excel gel and stained with silver. Numbering of fractions starts with the start of the gradient. Most of the CTCF eluted at 500 mM NaCI in fractions 17 and 18. M, protein markers (BCL) loaded at 1 ug and 100ng per band; B, the pooled protein from the previous DNA-cellulose chromatography; L, the protein loaded on to the affinity column after adding competitor DNA and centrifuging; W, the wash fractions eluted with N200 buffer. (B) Band-shift analysis of CTCF DNA binding activity in chromatography fractions. The 32 P-labelled DNA probe FPV (2 fmol) was incubated with various competitors and protein fractions and electrophoresed on a 4% polyacrylamide gel (1). From left to right: probe alone; Load, protein loaded on to affinity column; RT, protein not bound to the column; Wash, protein eluted with N200 buffer; PPT, precipitate formed on addition of competitor DNA prior to chromatography (-5% of total CTCF); 15-20, fractions of the affinity chromatograph. Fractions 15, 17, and 18 were also incubated with a 100-fold molar excess of unlabelled FPV probe or with the same amount of an oligonucleotide containing an SP1 binding site, as indicated.
107
R. H. Nicolas et al. of 130 kDa co-elutes with the DNA binding activity. Since photoaffinity labelling of CTCF had characterized CTCF as a 130 kDa protein, it was assumed that the protein band seen on the SDS gel was the CTCF protein. Band-shift and footprinting analyses demonstrated that the purified protein had the same characteristics as the original CTCF in crude nuclear extracts. The protein was finally purified by reverse-phase chromatography as described in Section 6. An alternative affinity purification technique first described by Gabrielsen et al. (11) utilizes biotinylated oligonucleotides which can be immobilized on streptavidin beads. In this method one of the oligonucleotide strands containing the binding site for the protein is chemically synthesized with a biotin moiety at the 5' end. After annealing the complementary strand, the doublestranded oligonucleotide is incubated with the nuclear extract in the presence of poly(dI-dC) using the same conditions used for the band-shift analysis. Magnetic streptavidin beads (Dynabeads M-280 streptavidin, Dynal) are then added and these can be washed rapidly several times using a magnet to draw the beads to the side of the incubation tube. Protein bound to the beads can then be eluted with 0.3-1.0 M NaCl steps. The advantage of the method is the simplicity of the oligonucleotide immobilization and the speed with which the binding, washing, and elution can be performed. Furthermore, since the initial binding of the protein to the oligonucleotide is carried out with the oligonucleotide in solution, the conditions for binding can readily be extrapolated from the band-shift conditions. Protocol 4. Preparation of DNA affinity columns Equipment and reagents • 10 x K buffer: 400 mM Tris-HCI pH 8.0, 100 mM MgCI2, 0.1 mM EDTA . 10 X ligation buffer: 500 mM Tris-HCI pH 7.8, 100 mM MgCI2 • 5 M ammonium acetate . 10 mM ATP pH 7.5 . 370 GBq/ml [32P]ATP (Amersham) • 100 mM potassium phosphate pH 8.0
1 mM HCI 1 M ethanolamine-HCI pH 8.0 1 M KCI, 1 mM EDTA pH 7.6 300 STE: 300 mM NaCl, 10 mM Tris-HCI pH 7.6, 1 mM EDTA NAP-5 column (Pharmacia) CNBr-activated Sepharose 4B (Pharmacia) 0.22 um 115 ml filter (Nalgene)
Method 1. Phosphorylate the two DNA oligonucleotides separately with polynucleotide kinase and ATP. For each strand mix the following: 10 ul 10 x K buffer 20 nmol DNA oligonucleotide 10 ul 10 mM ATP 0.1 ul 370 GBq/ml [y32P]ATP H2O to make up to 100 ul 2. Incubate for 2 h at 37°C with 100 IU of T4 polynucleotide kinase.
108
4: Purification and cloning 3. Add 50 ul of 5 M ammonium acetate, followed by 300 ul ethanol. Leave on dry ice for 5 min and collect the precipitate by centrifugation. Wash the precipitate with 80% ethanol and dry under vacuum. 4. Dissolve the DNA oligonucleotides in 40 ul of water and mix them together. Add 10 ul of 10 X ligase buffer. 5. Heat to 90°C for 5 min and allow to cool to room temperature. Anneal at room temperature for at least 30 min. 6. Add and mix the following: 1 M dithiothreitol (DTT) T4 DNA ligase
1 ul 8 IU
10 mM ATP
10 ul
and incubate for 16 h at 16°C in a water bath in the cold room. 17. Extract the DNA with phenol/trichloromethane followed by trichloromethane. 18. Purify the DNA from any buffer components containing amino groups and ATP by gel filtration chromatography by either of these methods: (a) Load the aqueous phase on to a Pharmacia NAP-5 gel filtration column that has been equilibrated with 100 mM potassium phosphate buffer pH 8.0. Collect 200 ul fractions and monitor the absorbance at 260 nm or use a beta counter to monitor the 32Plabelled DNA. (b) Alternatively, use a spinning column (12). Pack the matrix from a NAP-5 column into a 1 ml syringe and equilibrate with 100 mM potassium phosphate pH 8.0. 9. Estimate the yield of DNA from its A260 and retain an aliquot for scintillation counting the 32P. A sample should also be analysed by agarose gel electrophoresis to measure the extent of ligation, which is usually between 10 and 30 oligonucleotides per chain. 10. Swell 1 g CNBr-activated Sepharose in 100 ml 1 mM HCI for 1 h. 11. Filter off the supernatant under a slight vacuum but do not allow the Sepharose to become dry. 12. Wash the Sepharose with a further 200 ml of 1 mM HCI. 13. Wash the Sepharose with 100 ml of water and transfer to a 15 ml screw-cap plastic tube. Allow the 3.5 ml of Sepharose to settle out and remove all but 1.0 ml of the supernatant. 14. Add 0.5 ml 100 mM potassium phosphate buffer pH 8.0, immediately followed by the oligonucleotide solution from step 8. Rotate the tube on a roller for 20 h at room temperature. 15. Remove supernatant and add 100 ml of 1 M ethanolamine-HCI pH 8.0 and rotate for a further 3 h.
109
R. H. Nicolas et al. Protocol 4. Continued 16. Transfer to a filter and wash slowly (approximately 10 ml/min flow) with: (a) 100 ml 1 M ethanolamine-HCI pH 8.0 (b) 100 ml 10 mM potassium phosphate buffer pH 8.0 (c)
100 ml 1 M KCI, 1 mM EDTA pH 7.6
(d) 100 ml 300 STE plus 0.04% w/v NaN3 17. The material is now ready to be packed into a column. 18. Estimate the yield of oligonucleotide bound to the Sepharose by counting the radioactivity and compare with the results obtained at step 8. Usually between 20 and 40% of the DNA is bound to the column.
Protocol 5. Affinity chromatography Equipment and reagents • N200 and N1000 . 300 STE
buffersa
. N100/50 buffer: N100 buffer containing 50% (v/v) glycerolb
Method 1. Pack a 3-5 ml column with the specific binding oligonucleotide of interest linked to Sepharose 4B. Pack an equivalent sized pre-column with a non-binding oligonucleotide linked to Sepharose 4B. Both columns should be 1 cm diameter and washed with 300 STE. 2. Connect the columns in tandem and wash with N200 buffer at a flow rate of 0.2 ml/min at 4°C. 3. Thaw the DNA binding protein sample and add the solution of the non-specific DNA competitor slowly with careful mixing. Leave on ice for 1 h to allow any precipitate to form. 4. Centrifuge at 40 000 x g for 6 min. 5. Pump the supernatant on to the affinity columns. 6. Wash the columns with N200 buffer until the A280 returns to baseline. 7. Disconnect the pre-column and keep for later elution. 8. Wash the specific column with N200 buffer and then elute with a 60 ml linear salt gradient between 0.2 and 1.0 M NaCI (buffers N200 and N1000) and collect 2 ml fractions. 9. Take aliquots of each fraction for band-shift analysis and SDS-PAGE. Store fractions on ice until these analyses are complete.
110
4: Purification and cloning 10. If required, elute pre-column with a similar gradient of N200 vs. N1000. 11. Wash both columns with 2 M NaCI TE followed by 300 mM NaCI TE, 0.04% NaN3, and store at 4°C. 12. Protein fractions containing the DNA binding activity may be (a) stored (step 13) (b) recycled (step 14) (c) finally purified by reverse-phase chromatography (see below) 13. Dialyse active samples against 10 volumes of N100/50 buffer. After 4 h the sample can be centrifuged out of the dialysis bag and then stored at -20°C. Do not store at -70°C because this results in a large loss of activity, especially with these dilute protein samples. 14. Active samples from step 13 may be reapplied to the affinity column. Normally one would only use the specific column with a small amount of competitor, i.e. 1:1 ratio of competitor DNA to protein. So repeat steps 2-12 omitting steps 7 and 10. a b
See Table 1. 50% v/v glycerol = 62.5% w/v glycerol.
6. Reverse-phase chromatography Ideally, after the affinity chromatography there should be one band on an SDS gel in the fractions that contain all the DNA binding activity. This is not usually achieved in one cycle of affinity chromatography. One can recycle the protein through the affinity column, in which case the amount of competitor DNA should be reduced. The yields of protein are usually quite high; in principle, therefore, this procedure can be continued until the protein is pure. At any stage when there is a simple mixture of proteins (say five bands) several methods (see Chapter 3) can be used to identify which protein is the one of interest: (a) renaturation of protein eluted from SDS gel slices (13); (b) photoaffinity cross-linking to labelled DNA (2); or (c) by two-dimensional electrophoresis of the band-shift gel (1). Once the protein has been unambiguously identified on the SDS-polyacrylamide gel, one is no longer reliant on nondenaturing forms of chromatography, and the high resolution of preparative electrophoresis and reverse-phase chromatography can now be used. Electrophoresis requires that the protein eluted from the affinity columns should be concentrated into a small volume of low-salt loading buffer. Unacceptable losses usually occur on concentration and dialysis of dilute solutions. Some of the buffer components such as non-ionic detergents may also concentrate with the protein and interfere with the electrophoresis. Biotinylated oligonucleotides can be used to concentrate the protein as outlined in the previous section. 111
R. H. Nicolas et al. Reverse-phase chromatography will remove the detergents and other buffer components, remove other protein contaminants, and concentrate the protein into a volatile buffer, Figure 3 shows an elution profile of protein from the previous CTCF affinity chromatograph loaded on to a Ci/Cx Pharmacia Pro-RPC column and eluted with an acctonitrile gradient in 0.08% trifluoroacetic acid (TFA). The sample was diluted with TFA and then loaded by three injections using a 2 ml loop. As can be seen, the vast majority of the optical density does not bind to the column. Most of the other major peaks do
Figure 3. (A) Elution profile of the Pro-RPC reverse-phase chromatography of CTCF. Flow rate, 0,7 ml/min; h 214 nm. Buffer A 0.08% TFA; buffer B 80% acetonitrile, 0.08% TFA. Three 2 ml loadings were made at 20, 14, and 7 min and the gradient started at time zero; 1 min (0.8 ml) fractions were collected. (B) SDS-PAGE analysis of reversephase chromatography fractions. Lanes 1-20 correspond to fractions 21-40; 20 ml of each fraction was loaded. Lane C is 20 ml of affinity-purified CTCF and the marker lanes M were loaded with 100 ng and 25 ng per band. The Excel gel was stained with silver by the Pharmacia standard protocol.
112
4: Purification and cloning not contain protein and are due to detergent and other buffer components used in the previous steps. The 130 kDa protein elutes at 35% acetonitrile in a volume of 0.7-1.4 ml. This protein is then available for direct sequence analysis and chemical or enzymatic cleavage. Protocol 6.
Reverse-phase chromatography
Equipment and reagents • Apparatus: HPLC with two pumps, large (2 ml) loop, and gradient programmer, and a detector set at 214 nm (the Beckman System Gold was used in Figure 3) • Column: Pharmacia Pro-RPC . Solvent A: 0.08% (v/v) TFA (Pierce)a • Solvent B: -0.08% (v/v) TFA in 80% acetonitrile, 20% H2Oa
• Gradient programme: Time (min) % Solvent B 5 Start fraction collector 0 3 5 3-5
5-15
5-45 45 45-50 55-60
15-70 70 Stop fraction collector 70-100 100-5 5 5 Stop flow
60 70
Method 1. Connect the Pro-RPC column to the HPLC. The 5/2 (5 mm diameter x 2 cm) column is used at a flow rate of 0.7 ml/min. Up to 4 ml of detergent-containing buffers have been loaded on to this column with good results. The 10/10 (10 mm x 10 cm) column is used for 10-20 ml of sample and can be run at 2 ml/min. 2. Pre-wash the column alternately with 100% solvent B and 100% solvent A a few times until the baseline stabilizes, then return to the loading condition (5% solvent B). 3. Return the HPLC to manual control mode so that multiple loading can be carried out. 4. Remove one 2 ml protein sample from ice and hand-warm it to room temperature. Add 20 ul 10% (v/v) TFA to the sample, load it into the loop, and inject the column. 5. After 3 min, reload the loop with protein as in step 3 and inject the column once the absorbance has returned to zero. 6. Set up the gradient programme. Start the fraction collector, recorder, and gradient at the same time and collect 1 min fractions. 7. Dry down 40 ul of each sample between fractions 15 and 40 using vacuum centrifugation (Savant SpeedVac concentrator). Redissolve in SDS sample solvent and analyse by SDS-PAGE, silver staining the gel.b 8. The remainder of the sample should be rapidly frozen in solid CO2 and stored at -70°C.
113
R. H. Nicolas et al. Protocol 6.
Continued
9. At the end of the run, wash out the loop with solvent A then wash the column and HPLC with methanol. aThe solvents should be made up and purged with helium for 10 min and then the absorbance at 214 nm measured. Small aliquots of 10% TFA can be added to the A or B solvent with the lower absorbance until they balance. b Note some proteins do not stain well with silver. In these cases, gels may be electroblotted on to PVDF (polyvinylidene flouride) membranes such as Immobilon-P (Millipore) and stained with the gold stain Aurodye (Janssen) (1).
7. Production and isolation of peptides In order to clone the cDNA, one should aim to get several peptide sequences since not all oligonucleotide probes (based on peptide sequence) are suitable for screening libraries. Some reasons why an oligonucleotide may not be suitable are: (a) if they contain a high GC content (b) if they are very redundant (c) if they contain cross-hybridizing sequences (d) if they code for the N-terminal end of the protein and the 5' end of the gene is not represented in the library Also, with two or more sequences one has the option of using a polymerase chain reaction (PCR) approach to obtain a larger probe to screen the library (see Chapter 6). The rather sparing quantities of the pure protein that are usually produced mean that there is very little opportunity to optimize the production and purification of the peptides. A test protein (e.g. bovine serum albumin) can be used but the peptide cleavage pattern of each protein is unique so one usually has to just 'go for it'. We have used two methods for separating peptides after cleavage: microbore reverse-phase chromatography and polyacrylamide gel electrophoresis followed by protein blotting (14). Both these methods will give sufficient peptides for sequencing using a minimum of 100 pmol of protein. There will always be losses associated with fractionating the peptides following cleavage, and not all the peptide immobilized on the support in the sequencer is chemically available. With 100 pmol of protein we obtained 5-10 pmol initial yield of amino acids at the start of a sequencing run, and a sequence of up to 20 amino acids can be obtained, depending on the nature and purity of the peptides. To obtain reliable sequences it is essential that sufficient pure protein is accumulated before committing it to cleavage and a sequence run. The two choices that have to be made are the type of cleavage and the type of purification. Cleavage with CNBr is commonly used, because it is very specific for methionine which is a rare amino acid (-2%) in most proteins. 114
4: Purification and cloning This generates few but large peptides, which are best separated by SDSpolyacrylamide gel electrophoresis (SDS-PAGE). This method is especially useful for large proteins. Enzymatic digestions normally cut more frequently and this can make it more difficult to purify peptides in one reverse-phase chromatography step. However, we have used the enzyme Glu-C, which cleaves the carboxyl terminus of glutamic and aspartic acid, successfully to generate peptides from GATA1 and have purified the peptides by reversephase chromatography. Microsequencing is a field of its own and beyond the scope of this chapter. There are two good guides to microsequencing and related techniques (14, 15) and the second describes the use of microbore columns for chromatographies other than reverse-phase chromatography. The sequence analysis of CTCF and GATA1 was carried out on an Applied Biosystems gas-phase sequentor 120A with a 900A data-handling system. Applied Biosystems also provides useful application notes. A complementary approach is to use mass spectroscopy to obtain the masses of tryptic peptides of the SDS-PAGE purified protein (16, 17). The data can then be used to search theoretically derived databases derived from established sequence databases (18). This peptide mass fingerprinting approach has been refined to include short partial peptide sequences that can be obtained from tandem mass spectroscopy techniques. Thus after the reversephase purification of the protein described in Protocol 6 the protein fraction can be evaporated to dryness, redissolved, and digested with trypsin then analysed by mass spectrometry. If the protein is still not pure after the reverse-phase chromatography the protein can be run out on an SDS electrophoretic gel; Protocol 9 describes the procedure that can be used to obtain tryptic peptides from gel-purified protein for matrix-assisted laser desorptionmass spectrometry (MALD-MS) (19 ). This protocol could be used after the affinity chromatography step instead of the reverse-phase chromatography for the final purification but the protein would have to be concentrated prior to loading on to the electrophoretic gel. This is carried out using an Amicon Centricon concentrator or using a biotinylated oligonucleotide and streptavidin-coated magnetic beads (see above). Other modifications to this protocol include using silver-stained gels and in-gel trypsin digestions (20). Protocol 7. Preparation of peptides by CNBr cleavage and purification by reverse-phase chromatography Equipment and reagents • SpeedVac (Savant) • CNBr: 25 mg/ml in 70% v/v formic acid * • 8 M guanidine-HCI, 20 mM Hepes pH 7.9, 100 mM DTT • Microbore reverse-phase column: Brownlee C18 RP-300, 2.1 x 100 mm
• Solvent A: 0.08% TFA Solvent B: -0.08% TFA, 80% acetonitrile • HPLC syringe pump designed for microbore work, programmable • UV detector: h = 214 nm, or variable wavelength
115
R. H. Nicolas et al. Protocol 7.
Continued
Method 1. Concentrate purified protein from the preceding reverse-phase chromatography to 200 ul by evaporation using a SpeedVac (Savant).a Do not evaporate to dryness. 2. Add 0.4 ml formic acid (analytical grade), followed by 0.2 ml of 25 mg/ ml CNBr in 70% v/v formic acid. 3. Flush with nitrogen and incubate in the dark at 25°C for 6 h. 4. Add a further 0.2 ml CNBr solution and incubate overnight. 5. Dry down sample in a SpeedVac with NaOH in the trap. 6. Add 100 ul of HPLC grade H2O and dry down again. Continue to step 7 for reverse-phase chromatography or to Protocol 8 for SDS-PAGE separation of peptides. 7. Redissolve sample in 100 ul 8 M guanidine-HCI, 20 mM Hepes (pH 7.9), 100 mM DTT. 8. Centrifuge sample and load on to microbore reverse-phase column with a flow rate of 100 ul/min. Collect 1 min fractions or collect peaks manually. (Remember to determine the time delay from the detector to the fraction collector.) Use the following gradient programme: Time (min)
% Solvent B
0 0-5 5-55 55-60 70-75 90
5 Start 5 70 100 5 5 Stop
9. Freeze all peak fractions rapidly and store at -70°C. Losses tend to increase with storage, so if possible analyse the best peaks immediately. a
For enzyme cleavage, neutralize the protein sample from the preceding reverse-phase chromatography by adding Hepes to 20 mM. Evaporate off 50% of the solvent; this removes most of the acetonitrile. Check the pH and add enzyme. For these dilute solutions, use a ratio of 1 ug sequence-grade enzyme (Boehringer) to 10 ug protein. Both Glu-C and trypsin will work well in 10% acetonitrile. After digestion, reduce with 100 mM DTT and continue to step 8.
Protocol 8. Purification of peptides by SDS-PAGE and blotting on to PVDF membrane Equipment and reagents • SDS-polyacrylamide (Laemmli) gel: 0.75 mm thick, 15-20% polyacrylamide • 100 uM thioglycollic acid
• SDS gel loading buffer: 2% (w/v) SDS, 62.5 mM Tris-HCI pH 6.9, 10% (v/v) glycerol, 100 mM DTT
116
4: Purification and cloning • Transfer buffer: 10 mM CAPS (3-[cyclo• Transfer apparatus hexylamino]-1-propanesulphonic acid) pH . 0.1% coomassie blue R250 (PAGE blue 83, 11.0, 10% methanol BDH) * PVDF (polyvinylidene flouride) membranes * Destain solution: 50% (v/v) methanol, 10% (Applied Biosystems) (v/v) acetic acid • Whatman 3MM paper
Method 1. Make up a 0.75 mm thick SDS-polyacrylamide (Laemmli) gel with 15-20% polyacrylamide, depending on the sizes of the peptides in the mixture. Use highly purified acrylamide, ultra-clean apparatus, and HPLC-grade water for the buffers. Store the gel overnight. 2. Redissolve peptide sample in 20-40 ul SDS gel loading buffer and heat to 90°C for 5 min. 3. Load gel and run as normal with markers but include 100 uM thioglycollic acid in the top reservoir buffer. 4. At the end of the electrophoresis, place the gel in transfer buffer for 5 min. 5. At the same time wet three PVDF membranes in methanol then soak in transfer buffer. 6. Make up the transfer sandwich with Whatman 3MM paper (soaked in transfer buffer) at the anode side, followed by two membranes, the gel, a protecting back-membrane of PVDF, and more sheets of Whatman 3MM paper. 7. Place the sandwich in the apparatus and start the transfer. The time and current required depend on the size of the protein and design of the apparatus. The conditions should first be optimized for some test peptides in the same molecular weight range before committing the transcription factor peptide sample. 8. The backing membrane will have picked up some of the protein by passive blotting: stain with Aurodye for a permanent record. 9. Wash transfer membranes in HPLC water, then stain with 0.1% coomassie blue for 5 min and destain with 50% (v/v) methanol, 10% (v/v) acetic acid and, finally, with methanol. Allow to dry. The detection limit is about 200 ng of peptide. Since this is the lower limit for sequencing, there is no need for more sensitive staining. 10. Cut bands out and place in gas-phase sequencer for sequencing. If protein bands are detected on the second transfer membrane, load them also into the sequencer. Bands can be stored at -20°C, if necessary.
117
R. H. Nicolas et al.
8. Design of oligonucleotides for cDNA isolation Typically, the sequencing of peptides will give you several sequences, 10-30 residues in length, which can be used to design oligonucleotides for PCR or library screening. At some positions, there may be doubt as to the identity of the amino acid; e.g. histidine and serine are sometimes not detected and tryptophan may be missed unless suitable precautions are taken. Two approaches should be used to isolate a cDNA. The first is to use highly redundant oligonucleotides in the PCR reaction to amplify a short fragment of DNA which (after cloning) can be used to screen a cDNA library for the full-length cDNA. This approach was first used to isolate a cDNA encoding the CREB transcription factor (21). The oligonucleotide primers can be 20-30 base pairs in length and can be up to 106-fold degenerate to accommodate all the codon possibilities, although we would advise restricting degeneracy to less than 105. The template is cDNA, preferably random primed. The PCR methodology is described in more detail in Chapter 6. The second strategy is the use of labelled oligonucleotides to screen the libraries. The problem here is that, unlike the PCR technique, it is difficult to use fully degenerate probes. If the complexity of the probe is very high and only a small percentage of the oligonucleotides in the mixture is sufficiently homologous to the target sequence to hybridize, then the concentration of hybridizing probe is not sufficiently high to drive the annealing kinetics at a reasonable rate. Also, a large percentage of the radioactivity will be on incorrect oligonucleotides and this will contribute to high backgrounds on the filters. In practice, researchers have used either short, mixed oligonucleotides to reduce degeneracy or single longer probes, guessing the third base at each codon or using inosine. Lathe (22) has advocated the use of a longer single probe, the sequence of which is optimized using codon usage considerations. The reader is well advised to consult this paper, not only for probe design but also for hybridization and washing conditions. Briefly, in order to screen a cDNA library of average complexity, the probe should be designed such that it has sufficient specificity to detect its target, and there should only be a 0.1 frequency of chance binding to spurious sequences in the library. This can be achieved with a 36-mer oligonucleotide, choosing the third base from a codon usage table and avoiding sequences encoding leucine, arginine, and serine. The average probability of correct choice of the third position is then 0.55 and gives an average predicted probe-target homology of 85%. Such a 36-mer is the minimum probe length required. In practice, one is likely to design a larger probe since there may be amino acids within the peptide chosen that were not identified or were not unambiguously identified, and there is a high chance that the chosen peptide has a serine, leucine, or arginine. Improved homology can be achieved by introducing a moderate level of complexity in the probe (giving a mixture of less than 128 oligonucleotides) by using two preferred bases at a few positions. Also, since deoxyinosine can base-pair with A and C (23), where the 118
4: Purification and cloning third base is likely to be T or G, this base can be incorporated. Inosine can also be used for the three bases of an unknown amino acid in the peptide sequence. With such considerations in mind, the CTCF cDNA was isolated by designing several oligonucleotides which were end-labelled and first checked by probing a Northern blot. One of the probes detected a band of sufficiently long mRNA to encode the protein. The sequence of this oligonucleotide was: ATG M GAG/A E
GAG/A E GCC/T A
GGC/A G ATT I
GAG/A E GTG V
GCT A GAG/A E
GTG V GA E
This oligonucleotide was end-labelled with polynucleotide kinase to a specific activity of more than 108 c.p.m./mg (Protocol 10) and used to probe a cDNA library. The most convenient procedure for screening high-complexity libraries (~106 recombinant) is to plate out the phage at high density in large rectangular dishes and grow the phage until the plaques are less than 1 mm diameter. Duplicate filters are lifted and hybridized (24-48 h) in pairs, back to back, in sealed bags (Protocol 11) at a temperature 10-25°C below the expected Tm of the hybrid. This can be calculated from the formula: where Tm is the melting temperature in 6 X SSC, l is the length of the probe, and h is the percentage homology between probe and target. The filters are washed with SSC buffers at increasing temperatures, autoradiographing after each wash. Phage are extracted from positive plaques and rescreened through two more rounds. The cloned phages are then amplified and the DNA extracted. The inserts can be amplified and isolated by PCR and checked by Northern blot hybridization for correct size or tissue distribution, before subcloning and sequencing Protocol 9. Trypsin digestion of electrophoretically purified proteins for mass spectrometry Equipment and reagents • SpeedVac (Savant) • SDS-PAGE and electroblotting apparatus as in Protocol 8 . 0.1% Coomassie blue R-250, 50% methanol • 70%